

CITATION REPORT

List of articles citing

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

DOI: 10.1212/wnl.00000000000001729
Neurology, 2015, 85, 177-89.

Source: <https://exaly.com/paper-pdf/62062364/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2211	Ectopic germinoma involving multiple midline and paramedian structures outside the pineal gland or hypophyseal region of the brain prior to tumor development. 2015 , 358, 512-4		1
2210	NMO ab jetzt nur noch als Spektrumerkrankung. 2015 , 17, 30-30		
2209	Ist die Neuromyelitis Optica eine eigenständige Erkrankung?. 2015 , 16, 20-21		
2208	Next-generation sequencing identifies altered whole blood microRNAs in neuromyelitis optica spectrum disorder which may permit discrimination from multiple sclerosis. 2015 , 12, 196		21
2207	Late-onset neuromyelitis optica spectrum disorder in AQP4-seropositive patients in a Chinese population. 2015 , 15, 160		23
2206	Severely exacerbated neuromyelitis optica rat model with extensive astrocytopathy by high affinity anti-aquaporin-4 monoclonal antibody. 2015 , 3, 82		32
2205	MRI in the Evaluation of Acute Visual Syndromes. 2015 , 24, 309-24		6
2204	Improvement to baseline after plasma exchange in spinal attacks associated with neuromyelitis optica. 2015 , 1, 2055217315622794		
2203	B Cells in the Multiple Sclerosis Central Nervous System: Trafficking and Contribution to CNS-Compartmentalized Inflammation. 2015 , 6, 636		82
2202	The Urine Proteome Profile Is Different in Neuromyelitis Optica Compared to Multiple Sclerosis: A Clinical Proteome Study. 2015 , 10, e0139659		11
2201	Development of an Aquaporin-4 Orthogonal Array of Particle-Based ELISA for Neuromyelitis Optica Autoantibodies Detection. 2015 , 10, e0143679		4
2200	The Diagnosis and Treatment of Optic Neuritis. 2015 , 112, 616-25; quiz 626		48
2199	Diagnosis Approach of Optic Neuritis. 2015 , 06,		2
2198	Acute Bilateral Optic Neuritis in Active Ankylosing Spondylitis. 2015 , 128, 2821-2		1
2197	Fulminant demyelinating encephalomyelitis: Insights from antibody studies and neuropathology. 2015 , 2, e175		63
2196	Fulminant Demyelinating Diseases of the Central Nervous System. 2015 , 35, 656-66		16
2195	Pushing the boundaries of neuromyelitis optica: does antibody make the disease?. <i>Neurology</i> , 2015 , 85, 118-9	6.5	13

2194	Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. 2015 , 262, 2329-35	71
2193	A Clinical Approach to the Differential Diagnosis of Multiple Sclerosis. 2015 , 15, 57	22
2192	Primary spinal oligoastrocytoma mimicking longitudinally extensive transverse myelitis. 2015 , 4, 590-3	
2191	Progressive cerebral atrophy in neuromyelitis optica. 2015 , 21, 1872-5	5
2190	Neue Diagnosekriterien der Neuromyelitis-optica-Spektrumerkrankungen. 2015 , 16, 26-27	
2189	Acute and Chronic Management of Neuromyelitis Optica Spectrum Disorder. 2015 , 17, 48	38
2188	Antibodies as Mediators of Brain Pathology. 2015 , 36, 709-724	38
2187	Secondary progressive NMO, or concomitant NMO and a primary neurodegenerative disorder?. 2015 , 21, 1876-8	1
2186	Neuromyelitis optica spectrum disorder and varicella-zoster infection. 2015 , 358, 520-1	18
2185	Gamma-aminobutyric acid receptor agonists, aquaporin-4, and neuromyelitis optica: a potential link. 2015 , 85, 628-30	3
2184	Devic's disease before Devic: Bilateral optic neuritis and simultaneous myelitis in a young woman (1874). 2015 , 358, 419-21	6
2183	Multiple sclerosis in First Nations Canadians: A pilot comparison study. 2016 , 2, 2055217316666093	1
2182	Clinical Features of Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. 2016 , 129, 2079-84	11
2181	Persistent Hyperthermia in a Patient with Aquaporin-4-Antibody-Positive Neuromyelitis Optica Spectrum Disorder. 2016 , 12, 515-516	5
2180	[Extensive Myelitis as a Manifestation of Neuroborreliosis]. 2016 , 29, 564-566	2
2179	A large fraction of neocortical myelin ensheathes axons of local inhibitory neurons. 2016 , 5,	143
2178	Pregnancy Management in NMO: A Case of MOG- Antibody Positive NMO and Literature Review. 2016 , 7,	
2177	Acute Transverse Myelitis Associated with Salmonella Bacteremia: A Case Report. 2016 , 17, 929-933	5

2176	A 66-Year-Old Woman with a Progressive, Longitudinally Extensive, Tract Specific, Myelopathy. 2016 , 2016, 4125294	1
2175	Clinical Features and Visual Outcomes of Optic Neuritis in Chinese Children. 2016 , 2016, 9167361	5
2174	Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic Implications. 2016 , 2016, 5314541	71
2173	Magnetic resonance imaging differential diagnosis of brainstem lesions in children. 2016 , 8, 1-20	9
2172	Neuromyelitis Optica Spectrum Disorder with Tumefactive Demyelination mimicking Multiple Sclerosis: A Rare Case. 2016 , 7, 73	5
2171	The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives. 2016 , 17, 273	71
2170	Comparative Analysis for the Presence of IgG Anti-Aquaporin-1 in Patients with NMO-Spectrum Disorders. 2016 , 17,	8
2169	Efficacy of Polyvalent Human Immunoglobulins in an Animal Model of Neuromyelitis Optica Evoked by Intrathecal Anti-Aquaporin 4 Antibodies. 2016 , 17,	9
2168	Aquaporins in the Spinal Cord. 2016 , 17,	26
2167	An adult-onset multiphasic disseminated encephalomyelitis (MDEM) presenting favorable response to steroid therapy. 2016 , 56, 846-851	
2166	Retinal Morphology and Sensitivity Are Primarily Impaired in Eyes with Neuromyelitis Optica Spectrum Disorder (NMOSD). 2016 , 11, e0167473	5
2165	Quantitative Susceptibility Mapping Indicates a Disturbed Brain Iron Homeostasis in Neuromyelitis Optica - A Pilot Study. 2016 , 11, e0155027	6
2164	Occurrence of Asymptomatic Acute Neuromyelitis Optica Spectrum Disorder-Typical Brain Lesions during an Attack of Optic Neuritis or Myelitis. 2016 , 11, e0167783	10
2163	Cerebral Cortex Involvement in Neuromyelitis Optica Spectrum Disorder. 2016 , 12, 188-93	18
2162	MRI and neurophysiological measures to predict course, disability and treatment response in multiple sclerosis. 2016 , 29, 243-53	27
2161	Literature Commentary. 2016 , 36, 103-109	1
2160	Atypical inflammatory demyelinating syndromes of the CNS. 2016 , 15, 967-981	86
2159	Intravenous immunoglobulin in paediatric neurology: safety, adherence to guidelines, and long-term outcome. 2016 , 58, 1180-1192	24

2158	Spinal Movement Disorders in Neuromyelitis Optica: An Under-recognized Phenomenon. 2016 , 3, 596-602	12
2157	Central nervous system neuroinflammatory disorders in Asian/Pacific regions. 2016 , 29, 372-80	14
2156	Incidence of AQP4-IgG seropositive neuromyelitis optica spectrum disorders in the Netherlands: About one in a million. 2016 , 2, 2055217315625652	9
2155	Paediatric brainstem encephalitis associated with glial and neuronal autoantibodies. 2016 , 58, 836-41	25
2154	Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands. 2016 , 23, 580-7	86
2153	What Is the Optimal Sequence of Rescue Treatments for Attacks of Neuromyelitis Optica Spectrum Disorder?. 2016 , 79, 204-5	7
2152	Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. 2016 , 79, 775-783	173
2151	Pain in patients with transverse myelitis and its relationship to aquaporin 4 antibody status. 2016 , 368, 84-8	21
2150	Cervical spinal cord atrophy in NMOSD without a history of myelitis or MRI-visible lesions. 2016 , 3, e224	38
2149	Tumefactive brain lesion with rapid cavity formation associated with anti-aquaporin-4 antibody. 2016 , 3, e230	2
2148	A box of chocolates. 2016 , 3, e234	
2147	Cytokine and Chemokine Profiles in Patients with Neuromyelitis Optica Spectrum Disorder. 2016 , 23, 352-358	10
2146	Anti-KIR4.1 Antibodies in Chinese Patients with Central Nervous System Inflammatory Demyelinating Disorders. 2016 , 23, 295-300	2
2145	Neuromyelitis optica spectrum disorders. 2016 , 365-371	
2144	Anti-myelin Oligodendrocyte Glycoprotein Antibodies in a Patient with Recurrent Optic Neuritis Involving the Cerebral White Matter and Brainstem. 2016 , 55, 1351-4	3
2143	The risk of varicella zoster virus infection in multiple sclerosis patients treated with fingolimod. 2016 , 56, 270-2	2
2142	Intractable Hiccup in Demyelinating Disease with Anti-Myelin Oligodendrocyte Glycoprotein (MOG) Antibody. 2016 , 55, 2905-2906	7
2141	Patient-reported outcome measure for neuromyelitis optica: pretesting of preliminary instrument and protocol for further development in accordance with international guidelines. 2016 , 6, e011142	5

2140	Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. 2016 , 87, 1005-15	157
2139	Cerebrospinal fluid/serum immunoglobulin G quotient is predictive of unresponsiveness to intravenous methylprednisolone therapy for acute exacerbation of neuromyelitis optica spectrum disorder. 2016 , 7, 209-210	
2138	Neuromyelitis Optica Spectrum Disorder: Disease Course and Long-Term Visual Outcome. 2016 , 36, 356-362	10
2137	Relapsing optic neuritis and isolated transverse myelitis are the predominant clinical phenotypes for patients with antibodies to myelin oligodendrocyte glycoprotein in India. 2016 , 2, 2055217316675634	12
2136	No association of polymorphisms with neuromyelitis optica and multiple sclerosis. 2016 , 7, 76-83	4
2135	Cognitive and Behavioral Functioning in Childhood Acquired Demyelinating Syndromes. 2016 , 22, 1050-1060	7
2134	Decreased serum IL-27 and IL-35 levels are associated with disease severity in neuromyelitis optica spectrum disorders. 2016 , 293, 100-104	11
2133	Acquired Demyelinating Diseases. 2016 , 59-70	
2132	Anti-N-methyl-d-aspartate receptor encephalitis in a patient with neuromyelitis optica spectrum disorders. 2016 , 8, 74-7	11
2131	Quantifying visual pathway axonal and myelin loss in multiple sclerosis and neuromyelitis optica. 2016 , 11, 743-750	31
2130	Increased Signal Intensity in the Dentate Nucleus of Patients with Multiple Sclerosis in Comparison with Neuromyelitis Optica Spectrum Disorder after Multiple Doses of Gadolinium Contrast. 2016 , 75, 195-8	19
2129	Optic neuritis: a 5-year follow-up study of Chinese patients based on aquaporin-4 antibody status and ages. 2016 , 263, 1382-9	28
2128	Longstanding spastic paraparesis in a patient infected with hepatitis C virus and seropositive for aquaporin-4 antibody - Case report and review of the literature. 2016 , 8, 120-3	1
2127	Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus. 2016 , 3, e225	94
2126	Neuromyelitis optica does not impact periventricular venous density versus healthy controls: a 7.0 Tesla MRI clinical study. 2016 , 29, 535-41	8
2125	Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder. <i>Neurology</i> , 2016 , 86, 1772-9	6.5 57
2124	Evoked potentials are useful for diagnosis of neuromyelitis optica spectrum disorder. 2016 , 364, 97-101	10
2123	Pediatric familial neuromyelitis optica in two sisters with long term follow-up. 2016 , 29, 183-4	5

2122	Astrocytes in multiple sclerosis. 2016 , 22, 1114-24		75
2121	Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. 2016 , 263, 1349-60		93
2120	Anti-thyroid antibodies and thyroid function in neuromyelitis optica spectrum disorders. 2016 , 366, 3-7		20
2119	Spinal Cord in Multiple Sclerosis: Magnetic Resonance Imaging Features and Differential Diagnosis. 2016 , 37, 396-410		7
2118	Imaging in Pediatric Demyelinating and Inflammatory Diseases of Brain- Part 2. 2016 , 83, 965-82		1
2117	Optical coherence tomography and neurodegeneration: are eyes the windows to the brain?. 2016 , 16, 765-75		23
2116	Acute disseminated encephalomyelitis in 228 patients: A retrospective, multicenter US study. <i>Neurology</i> , 2016 , 86, 2085-93	6.5	70
2115	Overview of the immune system. 2016 , 133, 61-76		16
2114	Common and Rare Manifestations of Neuromyelitis Optica Spectrum Disorder. 2016 , 16, 42		17
2113	Neuromyelitis optica spectrum disorder (NMOSD): A new concept. 2016 , 172, 256-62		21
2112	Transverse Myelitis and Neuromyelitis Optica Spectrum Disorders. 2016 , 37, 384-95		4
2111	Neuromyelitis optica spectrum disorder coinciding with hematological immune disease: A case report. 2016 , 9, 101-3		2
2110	3D-DIR for early differential diagnostic and prognostic evaluation of NMO. 2016 , 12, 1464-1468		1
2109	Application of diffusional kurtosis imaging to detect occult brain damage in multiple sclerosis and neuromyelitis optica. 2016 , 29, 1536-1545		11
2108	Serum sPECAM-1 and sVCAM-1 levels are associated with conversion to multiple sclerosis in patients with optic neuritis. 2016 , 300, 11-14		4
2107	Restoring immune tolerance in neuromyelitis optica: Part I. 2016 , 3, e276		26
2106	Anti-myelin oligodendrocyte glycoprotein antibody neuritis optica following anti-NMDA receptor encephalitis. 2016 , 58, 953-4		6
2105	Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: A prospective cohort study. 2016 , 370, 224-228		42

2104	Serum concentration of CD40L is elevated in inflammatory demyelinating diseases. 2016 , 299, 66-69		8
2103	The Changing Landscape of Childhood Inflammatory Central Nervous System Disorders. 2016 , 179, 24-32.e2		2
2102	Low T3 syndrome in neuromyelitis optica spectrum disorder: Associations with disease activity and disability. 2016 , 370, 214-218		7
2101	How long does it take to diagnose patients with neuromyelitis optica (NMO) using the 2006 diagnostic criteria?. 2016 , 9, 14-6		4
2100	Glycyrrhizic acid prevents astrocyte death by neuromyelitis optica-specific IgG via inhibition of C1q binding. 2016 , 478, 553-8		7
2099	Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. 2016 , 3, e257		152
2098	Fulminant case of neuromyelitis optica spectrum disorder initiated with area postrema symptoms. 2016 , 4, 121-123		3
2097	Clinical characteristics of disabling attacks at onset in patients with neuromyelitis optica spectrum disorder. 2016 , 368, 209-13		6
2096	Characterization of the binding pattern of human aquaporin-4 autoantibodies in patients with neuromyelitis optica spectrum disorders. 2016 , 13, 176		13
2095	Pediatric optic neuritis. <i>Neurology</i> , 2016 , 87, S53-8	6.5	31
2094	Neuromyelitis optica spectrum disorders in children and adolescents. <i>Neurology</i> , 2016 , 87, S59-66	6.5	62
2093	Acute disseminated encephalomyelitis: Updates on an inflammatory CNS syndrome. <i>Neurology</i> , 2016 , 87, S38-45	6.5	244
2092	Differential diagnosis and evaluation in pediatric inflammatory demyelinating disorders. <i>Neurology</i> , 2016 , 87, S28-37	6.5	19
2091	Eleven episodes of recurrent optic neuritis of the same eye for 22 years eventually diagnosed as neuromyelitis optica spectrum disorder. 2016 , 10, 22-25		1
2090	Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders. 2016 , 9, 436-40		25
2089	Sudden hearing loss as the initial symptom in Japanese patients with multiple sclerosis and seropositive neuromyelitis optica spectrum disorders. 2016 , 298, 16-8		16
2088	Etiological, clinical, and radiological features of longitudinally extensive myelopathy in Chinese patients. 2016 , 32, 61-6		5
2087	MRI phase changes in multiple sclerosis vs neuromyelitis optica lesions at 7T. 2016 , 3, e259		28

2086	Multiple Sclerosis and Demyelinating Diseases. 2016 , 475-511		1
2085	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. 2016 , 13, 279		255
2084	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. 2016 , 13, 280		468
2083	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. 2016 , 13, 282		158
2082	Caractéristiques cliniques des neuropathies optiques associées à la présence d'anticorps anti-MOG. 2016 , 37, A200-A201		
2081	Cytomegalovirus-associated encephalomyelitis in an immunocompetent adult: a two-stage attack of direct viral and delayed immune-mediated invasions. case report. 2016 , 16, 223		13
2080	Progressive solitary sclerosis: Gradual motor impairment from a single CNS demyelinating lesion. <i>Neurology</i> , 2016 , 87, 1713-1719	6.5	47
2079	Multiple Sclerosis. 2016 , 36, 350-6		10
2078	Recovery from optic neuritis attack in neuromyelitis optica spectrum disorder and multiple sclerosis. 2016 , 367, 375-9		8
2077	Astrocyte signaling and synaptic homeostasis: II: Astrocyte-neuron interactions and clinical correlations. <i>Neurology</i> , 2016 , 87, 726-35	6.5	6
2076	Other noninfectious inflammatory disorders. 2016 , 135, 425-446		5
2075	Role of regulatory b cells in neuroimmunologic disorders. 2016 , 94, 693-701		33
2074	Neuromyelitis Optica (Devic's Syndrome): an Appraisal. 2016 , 18, 54		11
2073	Multiple Sclerosis and Neurodegenerative Diseases. 2016 , 63-84		3
2072	Immunology of neuromyelitis optica during pregnancy. 2016 , 3, e288		32
2071	Diagnostic Utility of Systematic Aquaporin-4 Antibodies Determination in the First Event of Immune-Mediated Optic Neuritis. 2016 , 76, 227-233		3
2070	Optic Nerve. 2017 , 242, 369-386		
2069	Clinical Reasoning: Bacterial meningitis causing a neuromyelitis optica flare. <i>Neurology</i> , 2016 , 87, e215-e218		5

2068	Late AQP4-IgG seroconversion and shrinking of brainstem MRI lesions in a patient with overlapping CIS/NMOSD. 2016 , 263, 2549-2551		1
2067	Diagnosis and clinical features of common optic neuropathies. 2016 , 15, 1355-1367		42
2066	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome. 2016 , 13, 281		148
2065	Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder. 2016 , 3, e286		66
2064	Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest. <i>Neurology</i> , 2016 , 87, 2463-2470	6.5	40
2063	Inpatient Multidisciplinary Rehabilitation Intervention Outcomes for Neuromyelitis Optica Spectrum Disorder: A Retrospective Observational Study. 2016 , 1, 20160007		1
2062	Clear detection of lower medullary lesions by three-dimensional double inversion recovery imaging in a patient with neuromyelitis optica spectrum disorder. 2016 , 7, 355-356		
2061	Fulminant neuromyelitis optica in a Finnish woman - a case report. 2016 , 4, 782-5		1
2060	The role of anti-aquaporin 4 antibody in the conversion of acute brainstem syndrome to neuromyelitis optica. 2016 , 16, 203		11
2059	Longitudinal Study of Retinal Nerve Fiber Layer Thickness and Macular Volume in Patients With Neuromyelitis Optica Spectrum Disorder. 2016 , 36, 363-368		20
2058	Fifteen Years of Publication: Then and Now. 2016 , 16, 27-31		
2057	Severe Relapse After Cessation of Immunosuppressive Therapy in a Patient With Neuromyelitis Optica Spectrum Disorder. 2016 , 21, 97-98		2
2056	Finding NMO: The Evolving Diagnostic Criteria of Neuromyelitis Optica. 2016 , 36, 238-45		17
2055	Discriminating long myelitis of neuromyelitis optica from sarcoidosis. 2016 , 79, 437-47		102
2054	Acute Disseminated Encephalomyelitis After Influenza Vaccination: A Case Report. 2016 , 36, e1-6		31
2053	Neuromyelitis optica spectrum disorder associated with osmotic demyelination syndrome. 2016 , 37, 1009-11		2
2052	Paediatric Multiple Sclerosis: Update on Diagnostic Criteria, Imaging, Histopathology and Treatment Choices. 2016 , 16, 68		12
2051	NMOSD with an unusual cerebral radiologic manifestation. 2016 , 7, 74-5		

2050	Demyelinating diseases in Asia. 2016 , 29, 222-8		28
2049	Neuromyelitis optica and pregnancy. 2016 , 116, 431-438		7
2048	Primary Sjögren Syndrome in a Child with a Neuromyelitis Optica Spectrum Disorder. 2016 , 43, 1260-1		7
2047	NMO-Spektrum-Erkrankungen. 2016 , 18, 39-51		
2046	Increased levels of CSF CD59 in neuromyelitis optica and multiple sclerosis. 2016 , 453, 131-3		8
2045	Bulbar myelitis [As an initial presentation of NMO associated with SLE. 2016 , 6, 21-23		
2044	Immunoadsorption in patients with neuromyelitis optica spectrum disorder. 2016 , 9, 281-6		25
2043	Antibodies in acquired demyelinating disorders in children. 2016 , 1,		3
2042	Inflammatory demyelination without astrocyte loss in MOG antibody-positive NMOSD. <i>Neurology</i> , 2016 , 87, 229-31	6.5	43
2041	Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. 2016 , 263, 1727-35		35
2040	Normal volumes and microstructural integrity of deep gray matter structures in AQP4+ NMOSD. 2016 , 3, e229		38
2039	Longitudinally extensive transverse myelitis: A retrospective analysis of sixty-four patients at tertiary care center of North-West India. 2016 , 148, 5-12		16
2038	Myopathy associated with neuromyelitis optica spectrum disorders. 2016 , 126, 863-6		9
2037	MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. 2016 , 15, 292-303		486
2036	A Urinary Metabolic Signature for Multiple Sclerosis and Neuromyelitis Optica. 2016 , 15, 659-66		36
2035	Seronegative neuromyelitis optica presenting with life-threatening respiratory failure. 2016 , 39, 734-736		2
2034	Neuromyelitis optica presenting as intractable vomiting and hyperCKaemia. 2016 , 263, 171-3		4
2033	Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease. 2016 , 87, 897-905		78

2032	Increased occurrence of anti-AQP4 seropositivity and unique HLA Class II associations with neuromyelitis optica (NMO), among Muslim Arabs in Israel. 2016 , 293, 65-70	22
2031	Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study. 2016 , 263, 575-82	39
2030	Natalizumab in relapsing-remitting multiple sclerosis. 2016 , 16, 471-81	3
2029	Brain parenchymal damage in neuromyelitis optica spectrum disorder - A multimodal MRI study. 2016 , 26, 4413-4422	38
2028	Painful tonic spasms and brainstem involvement in a patient with neuromyelitis optica spectrum disorder. 2016 , 50, 55-8	8
2027	Consensus recommendations for the diagnosis and treatment of multiple sclerosis in Kuwait. 2016 , 143, 51-64	3
2026	Cognition, mood, and purpose in life in neuromyelitis optica spectrum disorder. 2016 , 362, 85-90	12
2025	International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. <i>Neurology</i> , 2016 , 86, 491-2	6.5 51
2024	Therapeutic options in neuromyelitis optica spectrum disorders. 2016 , 16, 319-29	20
2023	Demyelinating disease: NMO spectrum disorders: clinical or molecular classification?. 2016 , 12, 129-30	8
2022	Differentiation of neuromyelitis optica spectrum disorders from ultra-longitudinally extensive transverse myelitis in a cohort of Chinese patients. 2016 , 291, 96-100	3
2021	Neuromyelitis optica: Contribution of therapeutic responses markers monitoring in patients given rituximab. 2016 , 172, 220-4	3
2020	Caractéristiques IRM des anomalies encéphaliques atypiques typiques du spectre NMO. 2016 , 7, 59-63	
2019	Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis. 2016 , 3, e204	39
2018	Th17 cells in neuromyelitis optica spectrum disorder: a review. 2016 , 126, 1051-60	25
2017	Early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical recommendations. 2016 , 12, 137-56	83
2016	Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report. <i>Neurology</i> , 2016 , 86, 245-52	6.5 75
2015	Rapid exacerbation of neuromyelitis optica after rituximab treatment. 2016 , 26, 168-70	8

2014	Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis. 2016 , 37, 394-401	209
2013	Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders. 2016 , 13, 70-83	68
2012	Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. 2016 , 263, 140-9	40
2011	Seronegative neuromyelitis optica spectrum disorder patients diagnosed using new diagnostic criteria. 2016 , 22, 1371-5	9
2010	Brainstem and limbic encephalitis with paraneoplastic neuromyelitis optica. 2016 , 23, 159-161	11
2009	A novel automated segmentation method for retinal layers in OCT images proves retinal degeneration after optic neuritis. 2016 , 100, 484-90	9
2008	Microarray Analysis of lncRNA and mRNA Expression Profiles in Patients with Neuromyelitis Optica. 2017 , 54, 2201-2208	16
2007	Effects of early using azathioprine in the acute phase in neuromyelitis optica spectrum disorder. 2017 , 127, 508-515	1
2006	Biotinidase deficiency mimicking neuromyelitis optica beginning at the age of 4: A treatable disease. 2017 , 23, 119-122	17
2005	MRI Patterns of Isolated Lesions in the Medulla Oblongata. 2017 , 27, 135-143	3
2004	Early and extensive spinal white matter involvement in neuromyelitis optica. 2017 , 27, 249-265	22
2003	Association of Extension of Cervical Cord Lesion and Area Postrema Syndrome With Neuromyelitis Optica Spectrum Disorder. 2017 , 74, 359-361	28
2002	Concurrent Dawson's Fingers and Area Postrema Lesion in a Mixed Neuroimmune Disorder. 2017 , 44, 452-454	
2001	MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. 2017 , 4, e322	222
2000	The clinical characteristics of AQP4 antibody positive NMO/SD in a large cohort of Chinese Han patients. 2017 , 302, 49-55	22
1999	A case of very long longitudinally extensive transverse myelitis (LETM) with necrotizing Vasculitis. 2017 , 373, 152-154	3
1998	There is less MRI brain lesions and no characteristic MRI Brain findings in IIDDs patients with positive AQP4 serology among Malaysians. 2017 , 12, 34-38	2
1997	Deletional tolerance prevents AQP4-directed autoimmunity in mice. 2017 , 47, 458-469	17

1996	Severe structural and functional visual system damage leads to profound loss of vision-related quality of life in patients with neuromyelitis optica spectrum disorders. 2017 , 11, 45-50		62
1995	Child Neurology: Neuromyelitis optica spectrum disorders. <i>Neurology</i> , 2017 , 88, e10-e13	6.5	7
1994	Screening for onconeural antibodies in neuromyelitis optica spectrum disorders. 2017 , 17, 5		5
1993	Etiologic spectrum and functional outcome of the acute inflammatory myelitis. 2017 , 117, 507-513		6
1992	Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease. 2017 , 88, 132-136		108
1991	Clinical characteristics of autoimmune optic neuritis. 2017 , 8, 8-16		9
1990	LETM presented with causalgia and ensued by sudden death. 2017 , 17, 13		
1989	Pediatric Autoimmune Epileptic Encephalopathies. 2017 , 32, 418-428		9
1988	Assessment and Diagnosis of Relapsing Multiple Sclerosis. 2017 , 41-66		
1987	Short segment myelitis as a first manifestation of neuromyelitis optica spectrum disorders. 2017 , 23, 413-419		30
1986	Microstructural visual system changes in AQP4-antibody-seropositive NMOSD. 2017 , 4, e334		84
1985	Fast multiple sclerosis progression in North Africans: Both genetics and environment matter. <i>Neurology</i> , 2017 , 88, 1218-1225	6.5	16
1984	Neuromyelitis Optica Spectrum Disorders. 2017 , 27, 251-265		40
1983	Neuromyelitis optica spectrum disorder diagnostic criteria: Sensitivity and specificity are both important. 2017 , 23, 182-184		9
1982	Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders. 2017 , 23, 1902-1908		17
1981	A treatable cause of myelopathy and vision loss mimicking neuromyelitis optica spectrum disorder: late-onset biotinidase deficiency. 2017 , 32, 675-678		23
1980	Headache in Neuromyelitis Optica. 2017 , 21, 20		13
1979	Clinical outcomes and predictive factors related to good outcomes in plasma exchange in severe attack of NMOSD and long extensive transverse myelitis: Case series and review of the literature. 2017 , 13, 93-97		32

1978 Neuromielite ottica acuta (malattia di Devic). **2017**, 17, 1-13

1977 Normal-appearing white matter demyelination in neuromyelitis optica spectrum disorder. **2017**, 24, 652-658 18

1976 Neutrophil perversion in demyelinating autoimmune diseases: Mechanisms to medicine. **2017**, 16, 294-307 26

1975 Neuromyelitis optica presenting as acute bilateral ptosis. **2017**, 17, 57-59

1974 Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders. **2017**, 88, 218-225 40

1973 Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea. **2017**, 23, 1748-1756 34

1972 Pruritus may be a common symptom related to neuromyelitis optica spectrum disorders. **2017**, 13, 1-3 10

1971 Anti-NMDAR encephalitis followed by seropositive neuromyelitis optica spectrum disorder: A case report and literature review. **2017**, 155, 75-82 18

1970 Lesions of the posterior limb of the internal capsule in neuromyelitis optica spectrum disorder. **2017**, 39, 448-452 1

1969 Neurodegeneration in multiple sclerosis and neuromyelitis optica. **2017**, 88, 137-145 141

1968 Catastrophic relapses following initiation of dimethyl fumarate in two patients with neuromyelitis optica spectrum disorder. **2017**, 23, 1297-1300 34

1967 Expansion of IL-6 Th17-like cells expressing TLRs correlates with microbial translocation and neurological disabilities in NMOSD patients. **2017**, 307, 82-90 9

1966 Pediatric Optic Neuritis. **2017**, 24, 122-128 7

1965 Distinct clinical characteristics of atypical optic neuritis with seronegative aquaporin-4 antibody among Chinese patients. **2017**, 101, 1720-1724 6

1964 Central and peripheral nervous system immune-mediated demyelinating disease after allogeneic hematopoietic stem cell transplantation. **2017**, 307, 74-81 12

1963 Boundary between multiple sclerosis and neuromyelitis optica. **2017**, 8, 54-57

1962 An extensive spinal cord lesion: tumour or inflammation?. **2017**, 102, 754

1961 Neuro-Ophthalmology. **2017**,

1960	Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder. 2017 , 7, 831	24
1959	NMO-Spektrum-Erkrankungen. 2017 , 44, 180-193	1
1958	Neuromyelitis Optica: Deciphering a Complex Immune-Mediated Astrocytopathy. 2017 , 37, 291-299	18
1957	Association of CD58 gene polymorphisms with NMO spectrum disorders in a Han Chinese population. 2017 , 309, 23-30	12
1956	Contribution of blood vessels to retinal nerve fiber layer thickness in NMOSD. 2017 , 4, e338	15
1955	Effectiveness and safety of immunosuppressive therapy in neuromyelitis optica spectrum disorder during pregnancy. 2017 , 377, 72-76	13
1954	Recurrent Optic Neuritis Associated With MOG Antibody Seropositivity. 2017 , 22, 101-102	10
1953	Foveal thinning in neuromyelitis optica: A sign of retinal astrocytopathy?. 2017 , 4, e347	25
1952	Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder. 2017 , 4, e343	36
1951	NMOSD triggered by yellow fever vaccination - An unusual clinical presentation with segmental painful erythema. 2017 , 11, 43-44	11
1950	Cognitive dysfunction in adult patients with neuromyelitis optica: a systematic review and meta-analysis. 2017 , 264, 1549-1558	15
1949	An update on the use of cerebrospinal fluid analysis as a diagnostic tool in multiple sclerosis. 2017 , 17, 31-46	29
1948	High serum creatinine is associated with reduction of vision impaired in patients with NMOSD. 2017 , 310, 32-37	2
1947	Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis optica: an over 2-year follow-up study. 2017 , 117, 695-702	33
1946	Aquaporin-4 positive neuromyelitis optica spectrum disorders secondary to thrombopenic purpura: A case report. 2017 , 96, e5792	2
1945	MRI in the assessment and monitoring of multiple sclerosis: an update on best practice. 2017 , 10, 247-261	58
1944	Neuromyelitis optica spectrum disorder in the elderly associated with bronchiolitis obliterans organizing pneumonia. 2017 , 7, 404-406	2
1943	Case 19. 2017 , 105-111	

1942	Optic neuritis: the eye as a window to the brain. 2017 , 30, 61-66	28
1941	Citation classics in central nervous system inflammatory demyelinating disease. 2017 , 7, e00700	5
1940	Aquaporin-4 antibody positive neuromyelitis optica spectrum disorder associated with esophageal cancer. 2017 , 309, 38-40	11
1939	Cognitive impairment in Chinese IIDDs revealed by MoCA and P300. 2017 , 16, 1-7	1
1938	Detection of Thyroid Abnormalities in Aquaporin-4 Antibody-Seropositive Optic Neuritis Patients. 2017 , 37, 24-29	
1937	Aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder with recurrent short partial transverse myelitis and favorable prognosis: Two new cases. 2017 , 23, 1950-1954	3
1936	Clinical commentary on 'Aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder with recurrent short partial transverse myelitis and favorable prognosis: Two new cases', by Wang et al. 2017 , 23, 1954-1955	
1935	Suspected bacterial meningomyelitis: The first presenting clinical feature of neuromyelitis optica spectrum disorder. 2017 , 309, 68-71	6
1934	Clinical pitfall: false-positive aquaporin-4 IgG leading to misdiagnosis of neuromyelitis optica spectrum disorder in patient with spinal arteriovenous fistula. 2017 , 3, 17030	3
1933	Spontaneous remission lasting more than a decade in untreated AQP4 antibody-positive NMOSD. 2017 , 4, e351	8
1932	Acute paraparesis and sensory loss following intravenous corticosteroid administration in a case of longitudinally extensive transverse myelitis caused by spinal dural arteriovenous fistula: case report and review of literature. 2017 , 3, 17025	7
1931	Incidence and prevalence of NMOSD in Australia and New Zealand. 2017 , 88, 632-638	72
1930	First Pediatric Patient With Neuromyelitis Optica and Sjögren Syndrome Successfully Treated With Tocilizumab. 2017 , 73, e5-e6	16
1929	NMO Spectrum Disorders. 2017 , 01, E36-E47	2
1928	Diffusion tensor imaging of normal-appearing white matter in patients with neuromyelitis optica spectrum disorder and multiple sclerosis. 2017 , 24, 966-973	21
1927	Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. 2017 , 88, 639-647	88
1926	Pediatric Neuromyelitis Optica Spectrum Disorder and Sjögren Syndrome: More Common Than Previously Thought?. 2017 , 44, 959-960	13
1925	Diffuse F-FDG uptake throughout the spinal cord in the acute phase of Neuromyelitis Optica Spectrum disorder. 2017 , 44, 1609-1610	5

1924	Late onset neuromyelitis optica mimicking an acute stroke in an elderly patient. 2017 , 309, 1-3		7
1923	Differential diagnosis of neuromyelitis optica spectrum disorders. 2017 , 10, 265-289		51
1922	Diagnostic algorithm for relapsing acquired demyelinating syndromes in children. <i>Neurology</i> , 2017 , 89, 269-278	6.5	117
1921	CD8-Positive T-Cell Leukoencephalitis With Astrocytopathy Clinically Presenting as Neuromyelitis Optica. 2017 , 76, 347-357		
1920	Neuromyelitis optica and neuromyelitis optica spectrum disorders. 2017 , 30, 208-215		29
1919	Convergence spasm due to aquaporin-positive neuromyelitis optica spectrum disorder. 2017 , 7, 7-8		6
1918	Neuromyelitis Optica: Immunopathogenesis, Clinical Manifestations, and Treatments. 2017 , 187-202		
1917	Myelin oligodendrocyte glycoprotein antibodies: How clinically useful are they?. 2017 , 30, 295-301		69
1916	Brain and Spinal Cord MR Imaging Features in Multiple Sclerosis and Variants. 2017 , 27, 205-227		16
1915	Pediatric Multiple Sclerosis: Distinguishing Clinical and MR Imaging Features. 2017 , 27, 229-250		11
1914	Monophasic demyelination reduces brain growth in children. <i>Neurology</i> , 2017 , 88, 1744-1750	6.5	34
1913	Neuromyelitis Spectrum Disorders. 2017 , 92, 663-679		153
1912	Circulating regulatory B cell subsets in patients with neuromyelitis optica spectrum disorders. 2017 , 38, 1205-1212		11
1911	Practice current: How do you treat neuromyelitis optica?. 2017 , 7, 170-178		2
1910	Untersuchungen des visuellen Systems in der Neurologie: aktuelle Forschung und klinische Relevanz. 2017 , 44, 27-45		2
1909	Interleukin-6 analysis of 572 consecutive CSF samples from neurological disorders: A special focus on neuromyelitis optica. 2017 , 469, 144-149		25
1908	What's new in neuromyelitis optica? A short review for the clinical neurologist. 2017 , 264, 2330-2344		18
1907	Soluble CD40 ligand contributes to blood-brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder. 2017 , 305, 102-107		24

1906	Enhancing Brain Lesions during Acute Optic Neuritis and/or Longitudinally Extensive Transverse Myelitis May Portend a Higher Relapse Rate in Neuromyelitis Optica Spectrum Disorders. 2017 , 38, 949-953	5
1905	Ruxolitinib treatment in a patient with neuromyelitis optica: A case report. 2017 , 4, e328	6
1904	Deep gray matter atrophy in neuromyelitis optica spectrum disorder and multiple sclerosis. 2017 , 24, 437-445	33
1903	Pregnancy in neuromyelitis optica spectrum disorder: A multicenter study from South China. 2017 , 372, 152-156	19
1902	Longitudinally extensive transverse myelitis immune-mediated in aquaporin-4 antibody negative patients: Disease heterogeneity. 2017 , 373, 134-137	4
1901	The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature. 2017 , 264, 453-466	75
1900	Clinical analysis of neuromyelitis optica presenting as intractable nausea, vomiting and hiccups. 2017 , 127, 854-858	7
1899	Nausea and Vomiting. 2017 ,	3
1898	The characteristics of spinal imaging in different types of demyelinating diseases. 2017 , 372, 138-143	12
1897	Modulation of Neuroinflammation in the Central Nervous System: Role of Chemokines and Sphingolipids. 2017 , 34, 396-420	35
1896	Nausea and Vomiting Related to the Central Nervous System Diseases. 2017 , 109-118	2
1895	Efficiency of antibody therapy in demyelinating diseases. 2017 , 29, 327-335	14
1894	Intractable Nausea Due to the Area Postrema Syndrome of Neuromyelitis Optica: An Uncommon Cause of a Common Symptom. 2017 , 53, e73-e76	3
1893	Optic neuritis with radiological longitudinal spinal cord involvement and seronegative anti-aquaporin antibody: Evidence from a case study. 2017 , 18, 26-28	1
1892	Diagnosis and management of Neuromyelitis Optica Spectrum Disorder (NMOSD) in Iran: A consensus guideline and recommendations. 2017 , 18, 144-151	22
1891	Short term outcome of ADEM: Results from a retrospective cohort study from South India. 2017 , 18, 128-134	11
1890	Peduncular Hallucinoses and Autonomic Dysfunction in Anti-Aquaporin-4 Antibody Syndrome. 2017 , 30, 116-124	3
1889	A NMOSD case with multifocal nervous system involvement in a single attack. 2017 , 18, 82-84	

1888	High risk of postpartum relapses in neuromyelitis optica spectrum disorder. <i>Neurology</i> , 2017 , 89, 2238-2244	38
1887	Increased relapse rate during pregnancy and postpartum in neuromyelitis optica. <i>Neurology</i> , 2017 , 89, 2220-2221	6.5 3
1886	Neuromyelitis optica spectrum disorders: An experience from tertiary care hospital of North West India. 2017 , 8, 192-196	1
1885	[Neuromyelitis optica with anti-MOG antibodies: A case report]. 2017 , 40, e303-e305	
1884	A population-based prospective study of optic neuritis. 2017 , 23, 1893-1901	51
1883	Epidemiology of neuromyelitis optica in Latin America. 2017 , 3, 2055217317730098	14
1882	Post herpes zoster infection neuromyelitis optica spectrum disorder. 2017 , 18, 93-94	13
1881	Cerebrospinal fluid analysis and the determination of oligoclonal bands. 2017 , 38, 217-224	19
1880	Diagnostics of the neuromyelitis optica spectrum disorders (NMOSD). 2017 , 38, 231-236	12
1879	Cognitive impairment in neuromyelitis optica spectrum disorders: What do we know?. 2017 , 18, 225-229	14
1878	Association of TNFSF4 Polymorphisms with Neuromyelitis Optica Spectrum Disorders in a Chinese Population. 2017 , 63, 396-402	8
1877	[Anti-Myelin Oligodendrocyte Glycoprotein Antibodies in Paediatric Patients with Optic Neuritis]. 2017 , 234, 1243-1249	0
1876	MS in self-identified Hispanic/Latino individuals living in the US. 2017 , 3, 2055217317725103	6
1875	Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study. 2017 , 264, 2420-2430	88
1874	Neuromyelitis optica broke my heart too. 2017 , 82, 489-490	2
1873	The Spectrum of Inflammatory Acquired Demyelinating Syndromes in Children. 2017 , 24, 189-200	15
1872	Cortical blindness and not optic neuritis as a cause of vision loss in a Sjögren's syndrome (SS) patient with the neuromyelitis optica spectrum disorder (NMOSD): Challenges of ascribing demyelinating syndromes to SS: a case report. 2017 , 96, e7454	7
1871	Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. 2017 , 264, 2003-2009	98

1870	Time is vision in recurrent optic neuritis. 2017 , 1673, 95-101	4
1869	Muscle damage in patients with neuromyelitis optica spectrum disorder. 2017 , 4, e400	9
1868	Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France. 2017 , 264, 2173-2175	54
1867	Autoimmune aquaporin-4 induced damage beyond the central nervous system. 2017 , 18, 41-46	15
1866	Clinical Reasoning: A 50-year-old woman with SLE and a tumefactive lesion. <i>Neurology</i> , 2017 , 89, e140-e145	145
1865	STAT4 Polymorphisms are Associated with Neuromyelitis Optica Spectrum Disorders. 2017 , 19, 493-500	6
1864	Neuromyelitis Optica. 2017 , 43, 579-591	33
1863	Multimodal magnetic resonance imaging in relation to cognitive impairment in neuromyelitis optica spectrum disorder. 2017 , 7, 9180	14
1862	[An asynchronous bilateral optic neuropathy with positive MOG antibodies]. 2017 , 40, e211-e213	
1861	Methotrexate-associated lymphoproliferative disorder in a patient with neuromyelitis optica spectrum disorder: An implication for pathogenesis mediated by Epstein-Barr virus. 2017 , 379, 219-221	3
1860	Neuromyelitis optica spectrum disorders: Emerging therapies. 2017 , 8, 107-116	5
1859	Anti-C1q autoantibodies in patients with neuromyelitis optica spectrum disorders. 2017 , 310, 150-157	4
1858	Acute-Onset Severe Occipital Neuralgia Associated With High Cervical Lesion in Patients With Neuromyelitis Optica Spectrum Disorder. 2017 , 57, 1145-1151	4
1857	Patient perspectives on neuromyelitis optica spectrum disorders: Data from the PatientsLikeMe online community. 2017 , 17, 116-122	24
1856	Cervical cord myelin water imaging shows degenerative changes over one year in multiple sclerosis but not neuromyelitis optica spectrum disorder. 2017 , 16, 17-22	17
1855	Mielopatie acute. 2017 , 17, 1-14	
1854	Gender differences among Chinese patients with neuromyelitis optica spectrum disorders. 2017 , 17, 5-8	8
1853	Clinical characteristics and long-term visual outcome of optic neuritis in neuromyelitis optica spectrum disorder: A comparison between Thai and American-Caucasian cohorts. 2017 , 17, 87-91	11

1852	First report of persistent dengue-1-associated autoimmune neurological disturbance: neuromyelitis optica spectrum disorder. 2017 , 23, 768-771		5
1851	MOG antibody-related disorders: common features and uncommon presentations. 2017 , 264, 1945-1955		75
1850	Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. <i>Neurology</i> , 2017 , 89, 900-908	6.5	197
1849	RETINAL VASCULITIS ASSOCIATED WITH NEUROMYELITIS OPTICA. 2017 , 11 Suppl 1, S211-S215		1
1848	Pediatric Optic Neuritis: What Is New. 2017 , 37 Suppl 1, S14-S22		12
1847	Postinfectious Anti-Myelin Oligodendrocyte Glycoprotein Antibody Positive Optic Neuritis and Myelitis. 2017 , 32, 996-999		16
1846	Neutrophil to lymphocyte ratio may be a helpful marker to evaluate disease activity in NMOSD. 2017 , 38, 1859-1863		11
1845	Hazards of Neurological Nomenclature: Observations From Neurodevelopmental and Neurodegenerative Disorders. 2017 , 74, 1165-1166		3
1844	Tumefactive demyelinating lesions of 15 patients: Clinico-radiological features, management and review of the literature. 2017 , 381, 32-38		26
1843	Biomarkers in the evolution of multiple sclerosis. 2017 , 7, 3-6		5
1842	Vitamin D in the prevention, prediction and treatment of neurodegenerative and neuroinflammatory diseases. 2017 , 8, 313-325		57
1841	Serum Neurofilament Light Chain in NMOSD and Related Disorders: Comparison According to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies Status. 2017 , 3, 2055217317743098		16
1840	Mystery Case: A 61-year-old woman with lower extremity paralysis and sensory loss. <i>Neurology</i> , 2017 , 89, e257-e263	6.5	3
1839	An update on multiple sclerosis in children: diagnosis, therapies, and prospects for the future. 2017 , 13, 975-989		8
1838	Extracellular miR-145, miR-223 and miR-326 expression signature allow for differential diagnosis of immune-mediated neuroinflammatory diseases. 2017 , 383, 188-198		22
1837	Neuromyelitis optica spectrum disorders and pregnancy: Interactions and management. 2017 , 23, 1808-1817		27
1836	Evaluation of the retinal nerve fiber layer in neuromyelitis optica spectrum disorders: A systematic review and meta-analysis. 2017 , 383, 108-113		11
1835	Time is vision: The importance of the early discovery and diagnosis of optic neuritis. 2017 , 23, 1806-1807		2

1834	A case of neuromyelitis optica spectrum disorder presenting with undiagnosed Sjogren's syndrome and a single, atypical tumefactive lesion: A clinical conundrum. 2017 , 383, 216-218	2
1833	Neuromyelitis Optica Spectrum Disorder with Brainstem Presentation. 2017 , 189-194	
1832	Neuromyelitis Optica Spectrum Disease with Transverse Myelitis Presentation. 2017 , 251-259	
1831	Clinical Reasoning: A patient with a history of encephalomyelitis and recurrent optic neuritis. <i>Neurology</i> , 2017 , 89, e231-e234	6.5 1
1830	Pediatric Demyelinating Diseases of the Central Nervous System and Their Mimics. 2017 ,	1
1829	[Optical coherence tomography in neuromyelitis optica spectrum disorders]. 2017 , 88, 1411-1420	3
1828	Neuromyelitis optica spectrum disorders in Iran. 2017 , 18, 209-212	35
1827	Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS. 2017 , 4, e363	29
1826	Painful tonic spasm in neuromyelitis optica spectrum disorders: Prevalence, clinical implications and treatment options. 2017 , 17, 99-102	17
1825	Safety and Efficacy of Bortezomib in Patients With Highly Relapsing Neuromyelitis Optica Spectrum Disorder. 2017 , 74, 1010-1012	43
1824	Can Wernekink commissure syndrome and wall-eyed bilateral internuclear ophthalmoplegia be ascribed to neuromyelitis optica spectrum disorder?. 2017 , 38, 2053-2055	2
1823	Analysis of brain and spinal cord lesions to occult brain damage in seropositive and seronegative neuromyelitis optica. 2017 , 94, 25-30	3
1822	Myelitis in systemic lupus erythematosus. 2017 , 44, 18-22	16
1821	Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases. 2017 , 88, 811-817	87
1820	Identification of the flotillin-1/2 heterocomplex as a target of autoantibodies in bona fide multiple sclerosis. 2017 , 14, 123	13
1819	Altered humoral immunity to mycobacterial antigens in Japanese patients affected by inflammatory demyelinating diseases of the central nervous system. 2017 , 7, 3179	12
1818	Magnetic Resonance Imaging and Clinical Features in Acute and Subacute Myelopathies. 2017 , 27, 417-433	21
1817	Combined brain and anterior visual pathways' MRIs assist in early identification of neuromyelitis optica spectrum disorder at onset of optic neuritis. 2017 , 117, 67-74	8

1816	Diffusion-weighted imaging helps differentiate multiple sclerosis and neuromyelitis optica-related acute optic neuritis. 2017 , 45, 1780-1785	13
1815	Intractable Hiccups in a Middle-Aged Female. 2017 , 7, 202-203	0
1814	Aquaporin-4 antibody in neuromyelitis optica: re-testing study in a large population from China. 2017 , 127, 790-799	2
1813	Isolated recurrent myelitis in a 7-year-old child with serum aquaporin-4 IgG antibodies. 2017 , 264, 179-181	0
1812	Gender effect on neuromyelitis optica spectrum disorder with aquaporin4-immunoglobulin G. 2017 , 23, 1104-1111	26
1811	Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases. 2017 , 14, 135-147	7
1810	Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder. 2017 , 24, 219-226	47
1809	Distinctive characteristics of early-onset and late-onset neuromyelitis optica spectrum disorders. 2017 , 127, 334-338	12
1808	Thickness of macular inner retinal layers and peripapillary retinal nerve fibre layer in neuromyelitis optica spectrum optic neuritis and isolated optic neuritis with one episode. 2017 , 95, 583-590	6
1807	The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates. 2017 , 23, 228-233	39
1806	Is pruritus an indicator of aquaporin-positive neuromyelitis optica?. 2017 , 23, 810-817	19
1805	Association of CD40 Gene Polymorphisms with Susceptibility to Neuromyelitis Optica Spectrum Disorders. 2017 , 54, 5236-5242	10
1804	Multifrequency magnetic resonance elastography of the brain reveals tissue degeneration in neuromyelitis optica spectrum disorder. 2017 , 27, 2206-2215	13
1803	Risk of venous thromboembolism in neuromyelitis optica patients hospitalized for acute relapse. 2017 , 23, 988-994	5
1802	Case Studies in Multiple Sclerosis. 2017 ,	
1801	Relationship Between Neuromyelitis Optica Spectrum Disorder and Sjögren's Syndrome: Central Nervous System Extraglandular Disease or Unrelated, Co-Occurring Autoimmunity?. 2017 , 69, 1069-1075	23
1800	Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: Their possible role on blood-brain barrier disruption. 2017 , 23, 1072-1084	35
1799	Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. 2017 , 23, 1377-1384	59

1798	Diagnosis of multiple sclerosis: progress and challenges. 2017 , 389, 1336-1346	260
1797	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up. 2017 , 372, 92-96	21
1796	Pseudotumoral brain lesions: MRI review. 2017 , 117, 17-26	2
1795	Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder. 2017 , 23, 946-955	26
1794	Anaplastic astrocytoma with aquaporin-4 positive in CSF: A case report. 2017 , 96, e9193	3
1793	Autonomic Dysregulation, Cognitive Impairment, and Symptoms of Psychosis as an Unusual Presentation in an Anti-Aquaporin 4-Positive Patient. 2017 , 9, 12-16	3
1792	Clinical presentation and prognosis in MOG-antibody disease: a UK study. 2017 , 140, 3128-3138	331
1791	MOG-antibody neuromyelitis optica spectrum disorder: is it a separate disease?. 2017 , 140, 3072-3075	7
1790	Autoimmune Encephalitis in Critical Care: Optimizing Immunosuppression. 2017 , 38, 807-820	2
1789	A case of neuromyelitis optica diagnosed with a chronic subdural hematoma. 2017 , 12, 126-129	3
1788	Optische Kohärenztomografie in der Neurologie [Methodik und Anwendung in Forschung und Klinik. 2017 , 48, 211-225	0
1787	Antibody response against HERV-W env surface peptides differentiates multiple sclerosis and neuromyelitis optica spectrum disorder. 2017 , 3, 2055217317742425	8
1786	How to use the new 2017 Japanese guidelines for multiple sclerosis and neuromyelitis optica. 2017 , 8, 351-360	4
1785	Differentiating Vogt-Koyanagi-Harada syndrome from recurrent optic neuritis: a case report and review of the literature concerning Hispanic patients. 2017 , 2,	1
1784	Schluckauf als Leitsymptom. 2017 , 28, 30-40	
1783	Unique central nervous system involvement and leukoencephalopathy-like magnetic resonance imaging findings in a patient with neuromyelitis optica spectrum disorder with Sjögren's syndrome. 2017 , 8, 255-257	1
1782	Gastroparesis as the Sole Presenting Feature of Neuromyelitis Optica. 2017 , 4, e109	2
1781	MOG-IgG associated optic neuritis is not multiple sclerosis. 2017 , 75, 687-691	7

1780	Complexity and wide range of neuromyelitis optica spectrum disorders: more than typical manifestations. 2017 , 13, 2653-2660	14
1779	A Case of Primary Sjögren's Syndrome Presenting as Mass-Like Encephalitis, With Progression to Neuromyelitis Optica Spectrum Disorder. 2017 , 32, 353-357	3
1778	Diagnostiques différentiels de la sclérose en plaques. 2017 , 113-143	
1777	Large-Scale in-House Cell-Based Assay for Evaluating the Serostatus in Patients with Neuromyelitis Optica Spectrum Disorder Based on New Diagnostic Criteria. 2017 , 13, 175-180	20
1776	Pattern Recognition of the Multiple Sclerosis Syndrome. 2017 , 7,	15
1775	Methodological Challenges in Protein Microarray and Immunohistochemistry for the Discovery of Novel Autoantibodies in Paediatric Acute Disseminated Encephalomyelitis. 2017 , 18,	4
1774	Reactivity to Novel Autoantigens in Patients with Coexisting Central Nervous System Demyelinating Disease and Autoimmune Thyroid Disease. 2017 , 8, 514	3
1773	Mechanisms of Autoantibody-Induced Pathology. 2017 , 8, 603	218
1772	The Role of Brain-Reactive Autoantibodies in Brain Pathology and Cognitive Impairment. 2017 , 8, 1101	32
1771	Immunopathogenesis in Myasthenia Gravis and Neuromyelitis Optica. 2017 , 8, 1785	23
1770	Different Phenotypes at Onset in Neuromyelitis Optica Spectrum Disorder Patients with Aquaporin-4 Autoimmunity. 2017 , 8, 62	13
1769	Increased Circulating T Follicular Helper Cells Are Inhibited by Rituximab in Neuromyelitis Optica Spectrum Disorder. 2017 , 8, 104	11
1768	Fulminant Acute Ascending Hemorrhagic Myelitis Treated with Eculizumab. 2017 , 8, 345	2
1767	The Contribution of Optical Coherence Tomography in Neuromyelitis Optica Spectrum Disorders. 2017 , 8, 493	9
1766	Isolated Horizontal Gaze Palsy: Observations and Explanations. 2017 , 8, 611	3
1765	Upregulation of Bcl-2 and Its Promoter Signals in CD4+ T Cells during Neuromyelitis Optica Remission. 2017 , 11, 11	5
1764	Signes et symptômes de la sclérose en plaques. 2017 , 3-78	
1763	Neuromyelitis Optica in a Nepalese Man. 2017 , 2017, 8596781	

1762	The Prevalence of Anti-Aquaporin 4 Antibody in Patients with Idiopathic Inflammatory Demyelinating Diseases Presented to a Tertiary Hospital in Malaysia: Presentation and Prognosis. 2017 , 2017, 1359761		5
1761	Optic Nerve: Optic Neuritis?. 2017 ,		
1760	Successful treatment for psychomotor agitation in neuromyelitis optica spectrum disorder with trazodone-risperidone combination: a case report. 2017 , 13, 775-777		1
1759	Retinal Nerve Fiber Layer May Be Better Preserved in MOG-IgG versus AQP4-IgG Optic Neuritis: A Cohort Study. 2017 , 12, e0170847		38
1758	Comparison of cognitive and brain grey matter volume profiles between multiple sclerosis and neuromyelitis optica spectrum disorder. 2017 , 12, e0184012		5
1757	A case of neuromyelitis optica spectrum disorder (NMOSD) with Sjögren's syndrome manifested only brain involvement by preceding parotitis. 2017 , 57, 77-81		2
1756	Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan. <i>Neurology</i> , 2017 , 89, 1995-2001	6.5	55
1755	Increased frequency of IL-6-producing non-classical monocytes in neuromyelitis optica spectrum disorder. 2017 , 14, 191		10
1754	Relationship between Azathioprine metabolites and therapeutic efficacy in Chinese patients with neuromyelitis optica spectrum disorders. 2017 , 17, 130		5
1753	Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination. 2017 , 14, 208		66
1752	Kognitive Defizite bei chronisch-entzündlichen ZNS-Erkrankungen. 2017 , 28, 40-48		
1751	The early diagnosis and treatments in multiple sclerosis. 2017 , 32, 151		
1750	Characteristics and predictors of progression in an Egyptian multiple sclerosis cohort: a multicenter registry study. 2017 , 13, 1895-1903		14
1749	The Role of Peripheral CNS-Directed Antibodies in Promoting Inflammatory CNS Demyelination. 2017 , 7,		11
1748	Neuromyelitis optica: phenotypic characteristics in a Brazilian case series. 2017 , 75, 81-86		11
1747	Rituximab therapy in pemphigus and other autoantibody-mediated diseases. 2017 , 6, 83		17
1746	Neuromyelitis Optica Spectrum Disorder with Recurrent Intracranial Hemorrhage. 2017 , 56, 1729-1732		3
1745	Insights into Initial Demyelinating Episodes of Central Nervous System during Puerperium. 2017 , 130, 1791-1795		1

1744	Comprehensive analysis of patients with neuromyelitis optica spectrum disorder (NMOSD) combined with chronic hepatitis B (CHB) infection and seropositive for anti-aquaporin-4 antibody. 2018 , 18, 35-42	3
1743	Severe course of neuromyelitis optica in a female patient with chronic C hepatitis. 2018 , 52, 397-400	1
1742	Myointimal Hyperplasia in a Patient with Neuromyelitis Optica (Devic's Disease) after the Creation of an Arteriovenous Graft. 2017 , 9, 252-255	2
1741	Investigational drugs in development to prevent neuromyelitis optica relapses. 2018 , 27, 265-271	35
1740	Movement disorders in multiple sclerosis and neuromyelitis optica: A clinical marker of neurological disability. 2018 , 51, 73-78	5
1739	A comparison of pediatric and adult neuromyelitis optica spectrum disorders: A review of clinical manifestation, diagnosis, and treatment. 2018 , 388, 222-231	17
1738	Short transverse myelitis in Chinese patients with neuromyelitis optica spectrum disorders. 2018 , 21, 78-83	11
1737	Antibodies and the brain: anti-N-methyl-D-aspartate receptor antibody and the clinical effects in patients with systemic lupus erythematosus. 2018 , 31, 294-299	12
1736	Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder. 2018 , 317, 1-4	10
1735	Imaging Pediatric Multiple Sclerosis-Challenges and Recent Advances. 2018 , 49, 165-172	1
1734	Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes. 2018 , 60, 958-962	72
1733	Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy. 2018 , 9, 21-33	56
1732	The current role of MRI in differentiating multiple sclerosis from its imaging mimics. 2018 , 14, 199-213	95
1731	Central vein sign in multiple sclerosis: Ready for front and center?. <i>Neurology</i> , 2018 , 90, 631-632	6.5 3
1730	Value of the central vein sign at 3T to differentiate MS from seropositive NMOSD. <i>Neurology</i> , 2018 , 90, e1183-e1190	6.5 50
1729	Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4-IgG in Patients in the Optic Neuritis Treatment Trial. 2018 , 136, 419-422	54
1728	A practical approach to the diagnosis of spinal cord lesions. 2018 , 18, 187-200	19
1727	Neuromyelitis optical spectrum disorders presenting with isolated "inverted V" sign in area postrema. 2018 , 39, 1299-1301	2

1726	The clinical features of combined central and peripheral demyelination in Chinese patients. 2018 , 317, 32-36	13
1725	Default-mode network and deep gray-matter analysis in neuromyelitis optica patients. 2018 , 45, 256-260	1
1724	Neuromyelitis optica spectrum disorder mimicking extensive leukodystrophy. 2018 , 24, 1256-1258	3
1723	Extensive bilateral brain lesions in neuromyelitis optica spectrum disorders. 2018 , 24, 1262-1263	1
1722	Immunoabsorption plasmapheresis treatment for the recurrent exacerbation of neuromyelitis optica spectrum disorder with a fluctuating anti-aquaporin-4 antibody level. 2018 , 21, 378-382	7
1721	Contiguous and symmetrical disease expansion and massive necrosis of the cerebral white matter in a patient with neuromyelitis optica. 2018 , 24, 1258-1261	5
1720	Comparative study of quality of life, anxiety, depression, and fatigue among patients with neuromyelitis optica spectrum disorder and multiple sclerosis: The first report from Iran. 2018 , 22, 161-165	28
1719	Hyponatremia in neuromyelitis optica spectrum disorders: Literature review. 2018 , 138, 4-11	11
1718	Classification and diagnostic criteria for demyelinating diseases of the central nervous system: Where do we stand today?. 2018 , 174, 378-390	9
1717	Atypical inflammatory demyelinating lesions and atypical multiple sclerosis. 2018 , 174, 408-418	10
1716	An unusual case of anti-MOG CNS demyelination with concomitant mild anti-NMDAR encephalitis. 2018 , 320, 107-110	19
1715	Plasma Exchange for Neuromyelitis Optica Spectrum Disorders in Chinese Patients and Factors Predictive of Short-term Outcome. 2018 , 40, 603-612	20
1714	Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders. 2018 , 174, 255-264	33
1713	Neuropsychiatric Systemic Lupus Erythematosus. 2018 ,	
1712	Association of serum Cystatin C with neuromyelitis optica spectrum disorders. 2018 , 25, 999-1002	1
1711	Defining distinct features of anti-MOG antibody associated central nervous system demyelination. 2018 , 11, 1756286418762083	96
1710	Neuromyelitis optica and neuromyelitis optica like spectrum disorders: Is it not the time to change the criteria?. 2018 , 20, 153	
1709	Normal brain imaging accompanies neuroimmunologically justified, autoimmune encephalomyelitis. 2018 , 5, e456	4

1708	Early identification of anti-NMDA receptor encephalitis presenting cerebral lesions in unconventional locations on magnetic resonance imaging. 2018 , 320, 101-106	7
1707	Paediatric multiple sclerosis and other acute demyelinating diseases. 2018 , 31, 244-248	3
1706	Natural history of longitudinally extensive transverse myelitis in 35 Hispanic patients with systemic lupus erythematosus: good short-term functional outcome and paradoxical increase in long-term mortality. 2018 , 27, 1279-1286	7
1705	Frequency of Aquaporin-4 Immunoglobulin G in Longitudinally Extensive Transverse Myelitis With Antiphospholipid Antibodies. 2018 , 93, 1299-1304	17
1704	Imaging of Neuropsychiatric Systemic Lupus Erythematosus. 2018 , 113-127	
1703	MRI Features of Aquaporin-4 Antibody-Positive Longitudinally Extensive Transverse Myelitis: Insights into the Diagnosis of Neuromyelitis Optica Spectrum Disorders. 2018 , 39, 782-787	15
1702	Diagnosis and treatment of anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis. 2018 , 62, 101-108	22
1701	2017 McDonald MS diagnostic criteria: Evidence-based revisions. 2018 , 24, 92-95	20
1700	Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study. 2018 , 265, 917-925	30
1699	Oligoclonal bands and periventricular lesions in multiple sclerosis will not increase blood-brain barrier permeability. 2018 , 387, 129-133	9
1698	Clinical Features of Acute Flaccid Myelitis Temporally Associated With an Enterovirus D68 Outbreak: Results of a Nationwide Survey of Acute Flaccid Paralysis in Japan, August-December 2015. 2018 , 66, 653-664	71
1697	Spectrum of MRI brain lesion patterns in neuromyelitis optica spectrum disorder: a pictorial review. 2018 , 91, 20170690	10
1696	Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica. 2018 , 141, 1063-1074	53
1695	A Rare Presentation of Neuromyelitis Optica Spectrum Disorders. 2018 , 11, 1179547617752685	
1694	A severe, relapsing case of myelin oligodendrocyte glycoprotein IgG-associated CNS inflammation. 2018 , 8, 74-76	1
1693	Clinical features of demyelinating optic neuritis with seropositive myelin oligodendrocyte glycoprotein antibody in Chinese patients. 2018 , 102, 1372-1377	51
1692	Low body mass index can be associated with the risk and poor outcomes of neuromyelitis optica with aquaporin-4 immunoglobulin G in women. 2018 , 89, 1228-1230	6
1691	Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis. 2018 , 20, 144-152	52

1690	Neuromyelitis optica spectrum disorder associated with dengue virus infection. 2018 , 318, 53-55	13
1689	2017 Japanese guidelines for multiple sclerosis and neuromyelitis optica: Achievements and challenges. 2018 , 9, 4-6	
1688	Technological advances and changing indications for lumbar puncture in neurological disorders. 2018 , 17, 268-278	40
1687	The IL-10-producing regulatory B cells (B10 cells) and regulatory T cell subsets in neuromyelitis optica spectrum disorder. 2018 , 39, 543-549	14
1686	Incidence of neuromyelitis optica spectrum disorder in the Central Denmark Region. 2018 , 137, 582-588	14
1685	Paraneoplastic Neuromyelitis Optica Spectrum Disorder: A single center cohort description with two cases of histological validation. 2018 , 20, 37-42	18
1684	Eye movement abnormalities in AQP4-IgG positive neuromyelitis optica spectrum disorder. 2018 , 384, 91-95	4
1683	Chloride imbalance between serum and CSF in the acute phase of neuromyelitis optica. 2018 , 315, 45-49	8
1682	A case of paraneoplastic neuromyelitis optica associated with small cell lung carcinoma. 2018 , 316, 130-132	9
1681	Application of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorders in a cohort of Latin American patients. 2018 , 20, 109-114	18
1680	High resolution retinal scanning reveals regional structural differences between MS and NMOSD optic neuritis regardless of antibody status. 2018 , 384, 61-66	6
1679	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. 2018 , 17, 162-173	2419
1678	Diagnosis and management of neuromyelitis optica spectrum disorders - An update. 2018 , 17, 195-200	70
1677	Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder. 2018 , 385, 192-197	42
1676	Neuromyelitis Optica Spectrum Disorders: Spectrum of MR Imaging Findings and Their Differential Diagnosis. 2018 , 38, 169-193	63
1675	Association of Visual Impairment in Neuromyelitis Optica Spectrum Disorder With Visual Network Reorganization. 2018 , 75, 296-303	31
1674	Anti-Rituximab antibody in patients with NMOSDs treated with low dose Rituximab. 2018 , 316, 107-111	15
1673	Comparison of olfactory function between neuromyelitis optica and multiple sclerosis. 2018 , 128, 772-777	6

1672	Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. 2018 , 75, 478-487		202
1671	Elderly-Onset Neuromyelitis Optica Spectrum Disorder with Pre-Existing Prednisone Allergy. 2018 , 10, 25-28		5
1670	Cerebrospinal fluid mitochondrial DNA in neuromyelitis optica spectrum disorder. 2018 , 15, 125		8
1669	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. 2018 , 10, 30		29
1668	Fulminant rebound of relapsing-remitting multiple sclerosis after discontinuation of dimethyl fumarate: A case report. 2018 , 24, 1131-1133		7
1667	Neuromyelitis Optica and Herpes Simplex Virus 2: A Viral Trigger for Aquaporin-4 Autoimmunity?. 2018 , 23, 92-93		7
1666	Trident sign trumps Aquaporin-4-IgG ELISA in diagnostic value in a case of longitudinally extensive transverse myelitis. 2018 , 23, 7-8		12
1665	Pediatric Neuromyelitis Optica Spectrum Disorders. 2018 , 20, 19		24
1664	Peripheral blood monocyte count at onset may affect the prognosis in multiple sclerosis. 2018 , 319, 37-40		5
1663	Beneficial effect of plasma exchange in acute attack of neuromyelitis optica spectrum disorders. 2018 , 20, 115-121		24
1662	Frequent retinal ganglion cell damage after acute optic neuritis. 2018 , 22, 141-147		17
1661	Intracranial hemorrhagic lesions in neurosarcoidosis: The difference from neuromyelitis optica spectrum disorders. 2018 , 9, 60-62		0
1660	A woman with intractable nausea and vomiting. 2018 , 361, k1082		
1659	Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study. <i>Neurology</i> , 2018 , 90, e1858-e1869	6.5	268
1658	Time to separate MOG-Ab-associated disease from AQP4-Ab-positive neuromyelitis optica spectrum disorder. <i>Neurology</i> , 2018 , 90, 947-948	6.5	23
1657	Maladies du spectre NMO. 2018 , 9, 88-94		
1656	B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets. 2018 , 11, 1756286418761697		42
1655	Chloride imbalance is involved in the pathogenesis of optic neuritis in neuromyelitis optica. 2018 , 320, 98-100		6

1654	Autoimmune and immunogenetic profile of patients with optic neuritis in a population-based cohort. 2018 , 21, 97-102	3
1653	Myelin oligodendrocyte glycoprotein immunoglobulin G-associated disease: An overview. 2018 , 9, 48-55	11
1652	Parainfectious longitudinally extensive transverse myelitis associated with varicella-zoster virus. 2018 , 33, 342-343	
1651	Evaluation of 2016 MAGNIMS MRI criteria for dissemination in space in patients with a clinically isolated syndrome. 2018 , 24, 758-766	8
1650	Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: A predominantly population-based study. 2018 , 24, 331-339	29
1649	Anti-myelin oligodendrocyte glycoprotein antibodies: Magnetic resonance imaging findings in a case series and a literature review. 2018 , 31, 69-82	9
1648	CSF and clinical data are useful in differentiating CNS inflammatory demyelinating disease from CNS lymphoma. 2018 , 24, 1212-1223	22
1647	Mutation of the cellular adhesion molecule NECL2 is associated with neuromyelitis optica spectrum disorder. 2018 , 388, 133-138	2
1646	Prevalence of neuromyelitis optica spectrum disorder in the multi-ethnic Penang Island, Malaysia, and a review of worldwide prevalence. 2018 , 19, 20-24	40
1645	Central nervous system Aquaporin4 autoimmunity revealed by a single pseudotumoral encephalic lesion. 2018 , 33, 353-355	4
1644	Diagnostic Challenges in Pediatric Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. 2018 , 16, 185-191	
1643	Autoimmune Encephalitis in Children. 2018 , 16, 192-201	1
1642	Understanding the Antibody Repertoire in Neuropsychiatric Systemic Lupus Erythematosus and Neuromyelitis Optica Spectrum Disorder: Do They Share Common Targets?. 2018 , 70, 277-286	34
1641	Infections in neuromyelitis optica spectrum disorder. 2018 , 47, 14-19	18
1640	Predictors of outcome in a large retrospective cohort of patients with transverse myelitis. 2018 , 24, 1743-1752	7
1639	Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. 2018 , 89, 346-351	139
1638	Differential brainstem atrophy patterns in multiple sclerosis and neuromyelitis optica spectrum disorders. 2018 , 47, 1601-1609	9
1637	Autologous haematopoietic stem cell transplantation for neurological diseases. 2018 , 89, 147-155	35

1636	MOG Spectrum Disorders and Role of MOG-Antibodies in Clinical Practice. 2018 , 49, 3-11		41
1635	Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders. 2018 , 24, 1737-1742		31
1634	A protean disease: The phenotypic range of neuromyelitis optica spectrum disorder. 2018 , 24, 688-689		1
1633	Bidirectional degeneration in the visual pathway in neuromyelitis optica spectrum disorder (NMOSD). 2018 , 24, 1585-1593		26
1632	Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies. 2018 , 24, 1753-1759		44
1631	The Interleukin (IL)-23/T helper (Th)17 Axis in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. 2018 , 8,		14
1630	Validation of the Modified Fatigue Impact Scale and the relationships among fatigue, pain and serum interleukin-6 levels in patients with neuromyelitis optica spectrum disorder. 2018 , 385, 64-68		7
1629	White Matter and Myelin Disorders. 2018 , 581-616		
1628	Evaluation of idiopathic transverse myelitis revealing specific myelopathy diagnoses. <i>Neurology</i> , 2018 , 90, e96-e102	6.5	57
1627	Common Clinical and Imaging Conditions Misdiagnosed as Multiple Sclerosis: A Current Approach to the Differential Diagnosis of Multiple Sclerosis. 2018 , 36, 69-117		20
1626	Ethnic Considerations and Multiple Sclerosis Disease Variability in the United States. 2018 , 36, 151-162		19
1625	Consistent increase in the prevalence and female ratio of multiple sclerosis over 15 years in northern Japan. 2018 , 25, 334-339		21
1624	Autoimmune Neurologic Disorders. 2018 , 131, 226-236		11
1623	Frequency of brain MRI abnormalities in neuromyelitis optica spectrum disorder at presentation: A cohort of Latin American patients. 2018 , 19, 73-78		17
1622	Th2 axis-related cytokines in patients with neuromyelitis optica spectrum disorders. 2018 , 24, 64-69		15
1621	Psychiatric comorbidities and suicidality among patients with neuromyelitis optica spectrum disorders in Argentina. 2018 , 19, 40-43		12
1620	Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. 2018 , 89, 127-137		274
1619	Serum anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder presenting as acute eosinophilic encephalomyelitis. 2018 , 48, 93-94		4

1618	A Young Woman With Sudden Urinary Retention and Sensory Deficits. 2018 , 70, 635-642	2
1617	Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease. 2018 , 75, 65-71	138
1616	Inflammatory demyelinating diseases of the central nervous system. 2017 , 145, 263-283	54
1615	Paraneoplastic neuromyelitis optica spectrum disorder: A case report and review of the literature. 2018 , 48, 7-10	16
1614	Endocrinopathies in paediatric-onset neuromyelitis optica spectrum disorder with aquaporin 4 (AQP4) antibody. 2018 , 24, 679-684	5
1613	Late presentation of NMOSD as rapidly progressive leukoencephalopathy with atypical clinical and radiological findings. 2018 , 24, 685-688	10
1612	Neuromyelitis optica in Sub-Saharan Africa: the first case report from Togo. 2018 , 28, 221-223	0
1611	Challenges in the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders: A Case Report With a Brief Review of Literature. 2018 , 6, 232470961880950	78
1610	Epidural Labor Analgesia for a Patient with Neuromyelitis Optica: A Case Report and Review of the Literature. 2018 , 2018, 2404756	
1609	Pediatric Optic Neuritis and Other Demyelinating Optic Neuropathies. 2018 , 58, 113-123	1
1608	Post-infectious transverse myelitis in an older adult: A rare complication of Klebsiella bacteremia. 2018 , 18, 1135-1136	
1607	Imaging of Childhood Inflammatory Brain Diseases. 2018 , 27, 409-431	0
1606	Pediatric neuro-ophthalmology: not simply neuro-ophthalmology for small adults. 2018 , 3, 15-15	
1605	A multi-facet comparative analysis of neuromyelitis optica spectrum disorders in patients with seropositive and seronegative AQP4-IgG. 2018 , 97, e13100	7
1604	Anti-aquaporin-4 Antibody Positive Optic Neuritis Following Scrub Typhus in an Elderly Female. 2018 , 23, 183-184	2
1603	Development of Neuromyelitis Optica Spectrum Disorder and Spinal Arachnoid Cysts in a Patient With Intractable Epilepsy. 2018 , 118, 119-123	
1602	SLE presenting as demyelinating autoimmune visual loss. 2018 , 2018,	
1601	Neuromyelitis optica spectrum disorder presenting as rhomboencephalitis. 2018 , 2018,	1

1600	Neuromyelitis optica spectrum disorder presenting in an octogenarian. 2018 , 2018,			1
1599	Neuromyelitis optica with unilateral diaphragmatic paralysis. 2018 , 2018,			1
1598	Neuromyelitis Optica Spectrum Disorders Associated To Posterior Reversible Encephalopathy Syndrome: Pathogenesis, Diagnosis, Treatment and Evolution: A Case Report and Literature Review. 2018 , 09,			
1597	Neuromyelitis optica and myelin oligodendrocyte glycoprotein. 2018 , 3, 22-22			1
1596	Ataxie aiguë récidivante. 2018 , 9, 277-281			
1595	CSF-S100B Is a Potential Candidate Biomarker for Neuromyelitis Optica Spectrum Disorders. 2018 , 2018, 5381239			7
1594	Area postrema syndrome as frequent feature of Bickerstaff brainstem encephalitis. 2018 , 5, 1534-1542			4
1593	[Optical Coherence Tomography in Disorders of the Central Nervous System]. 2018 , 235, 1242-1258			1
1592	Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark. <i>Neurology</i> , 2018 , 91, e2265-e2275	6.5		59
1591	Cerebrospinal Fluid Level of Soluble CD27 Is Associated with Disease Severity in Neuromyelitis Optica Spectrum Disorder. 2018 , 25, 185-192			3
1590	Increased expression of the membrane-bound CD40 ligand on peripheral CD4 T cells in the acute phase of AQP4-IgG-seropositive neuromyelitis optica spectrum disorders. 2018 , 325, 64-68			6
1589	Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis. 2018 , 9, 888			130
1588	Multiple sclerosis. 2018 , 4, 43			372
1587	Epidemiología de la neuromielitis óptica en Costa Rica: un análisis multicéntrico. 2018 , 10, 185-193			
1586	Optical coherence tomography in central nervous system demyelinating diseases related optic neuritis. 2018 , 11, 1649-1656			10
1585	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorders: Toward a New Spectrum of Inflammatory Demyelinating CNS Disorders?. 2018 , 9, 2753			31
1584	Central Nervous System Involvement in Common Variable Immunodeficiency: A Case of Acute Unilateral Optic Neuritis in a 26-Year-Old Italian Patient. 2018 , 9, 1031			3
1583	Updated diagnostic criteria for neuromyelitis optica spectrum disorder: Similar outcomes of previously separate cohorts. 2018 , 4, 2055217318815925			6

1582	Should Spinal MRI Be Routinely Performed in Patients With Clinically Isolated Optic Neuritis?. 2018 , 38, 502-510		1
1581	Anti-Myelin Oligodendrocyte Glycoprotein and Human Leukocyte Antigens as Markers in Pediatric and Adolescent Multiple Sclerosis: on Diagnosis, Clinical Phenotypes, and Therapeutic Responses. 2018 , 2018, 8487471		6
1580	Cytokines and Tissue Damage Biomarkers in First-Onset Neuromyelitis Optica Spectrum Disorders: Significance of Interleukin-6. 2018 , 25, 215-224		13
1579	Anti-Mycobacterial Antibodies in Paired Cerebrospinal Fluid and Serum Samples from Japanese Patients with Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorder. 2018 , 7,		14
1578	Two cases of late-onset neuromyelitis optica spectrum disorder initially presenting with isolated cerebral white matter lesions. 2018 , 13, 35-37		4
1577	Clinical Characteristics, Treatment Outcomes and Predictive Factors in Optic Neuritis. 2018 , 12, 247-255		9
1576	[Clinical analysis of opticospinal multiple sclerosis (OSMS) presentation detecting anti-myelin oligodendrocyte glycoprotein (MOG) antibody]. 2018 , 58, 737-744		2
1575	Longitudinally Extensive Transverse Myelitis Revealing Systemic Lupus Erythematosus: A Case Report and Literature Review. 2018 , 09,		1
1574	Detection of aquaporin-4 antibodies for patients with CNS inflammatory demyelinating diseases other than typical MS in Lithuania. 2018 , 8, e01129		4
1573	Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders. 2018 , 5, e498		50
1572	Reduced expression of the IL7Ra signaling pathway in Neuromyelitis optica. 2018 , 324, 81-89		2
1571	Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG-positive NMOSD. <i>Neurology</i> , 2018 , 91, e1642-e1651	6.5	84
1570	Low-Dose Mycophenolate Mofetil for Treatment of Neuromyelitis Optica Spectrum Disorders: A Prospective Multicenter Study in South China. 2018 , 9, 2066		22
1569	[MOG encephalomyelitis: international recommendations on diagnosis and antibody testing]. 2018 , 89, 1388-1399		19
1568	[Autoimmune reactions and paraneoplastic syndromes]. 2018 , 58, 1080-1090		
1567	Factors Related to Long Term Motor, Behavioral, and Scholastic Outcome in Children with Acute Disseminated Encephalomyelitis. 2018 , 89, 49-57		4
1566	Neuroimaging in Inflammatory and Infectious Diseases of the Spinal Cord. 2018 , 1-23		
1565	Recurrent optic neuritis - Different patterns in multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody disease. 2018 , 324, 115-118		8

1564	Diagnostic Approach to Chronic Meningitis. 2018 , 36, 831-849	3
1563	Importance of Regular and Maintenance Therapy Adherence in Neuromyelitis Optica (NMO): Lessons from a Repeating Relapse Case. 2018 , 19, 41-46	1
1562	Prevalence of anti-aquaporin 4 antibody in a diagnostic cohort of patients being investigated for possible neuromyelitis optica spectrum disorder in Western Australia. 2018 , 324, 76-80	3
1561	Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder. 2018 , 174, 675-679	5
1560	The first Japanese report on neuromyelitis optica rediscovered: acute bilateral blindness, tetraparesis and respiratory insufficiency in a 35-year-old man (1891). 2018 , 395, 121-125	4
1559	Objective assessment of a relative afferent pupillary defect by B-mode ultrasound. 2018 , 13, e0202774	4
1558	Neuromyelitis optica spectrum disorders with and without connective tissue disorders. 2018 , 18, 177	4
1557	Racial differences in neuromyelitis optica spectrum disorder. <i>Neurology</i> , 2018 , 91, e2089-e2099	6.5 79
1556	Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies. 2018 , 15, 302	47
1555	Detection Methods for Autoantibodies in Suspected Autoimmune Encephalitis. 2018 , 9, 841	34
1554	A young man with numbness in arms and legs: From the National Multiple Sclerosis Society Case Conference Proceedings. 2018 , 5, e509	0
1553	Syringomyelia-like syndrome in neuromyelitis optica spectrum disorder complicated with Sjogren's syndrome: a case report. 2018 , 18, 168	1
1552	Rebound After Fingolimod and a Single Daclizumab Injection in a Patient Retrospectively Diagnosed With NMO Spectrum Disorder-MRI Apparent Diffusion Coefficient Maps in Differential Diagnosis of Demyelinating CNS Disorders. 2018 , 9, 782	4
1551	Principles of OCTA and Applications in Clinical Neurology. 2018 , 18, 96	34
1550	Prevalence and risk factors of deep venous thrombosis in patients with longitudinally extensive transverse myelitis: one center data from China. 2018 , 18, 179	3
1549	Refining the Nosology of Antigen-Specific Diseases Within the Spectrum of Neuromyelitis Optica. 2018 , 25, A1-A2	1
1548	MR Imaging of the Spine: Urgent and Emergent Indications. 2018 , 39, 551-569	6
1547	A prospective case-control study comparing optical coherence tomography characteristics in neuromyelitis optica spectrum disorder- optic neuritis and idiopathic optic neuritis. 2018 , 18, 247	5

1546	Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders. 2018 , 4, 2055217318796684	
1545	Clinical and radiological characteristics of neuromyelitis optica spectrum disorder in the North Egyptian Nile Delta. 2018 , 324, 22-25	11
1544	Clinical utility of anti-MOG antibody testing in a Danish cohort. 2018 , 26, 61-67	7
1543	Present Drug Therapy of Demyelinating Disorders. 2018 , 13, 25-42	
1542	[Neuroimmunology and rheumatology: overlap and differential diagnoses]. 2018 , 89, 1095-1105	1
1541	Retrospective analysis of children with myelin oligodendrocyte glycoprotein antibody-related disorders. 2018 , 26, 1-7	17
1540	Glial Fibrillary Acidic Protein Antibody: Another Antibody in the Multiple Sclerosis Diagnostic Mix. 2018 , 38, 281-284	2
1539	Interleukin-6, S-Nitrosothiols, and Neurodegeneration in Different Central Nervous System Demyelinating Disorders: Is There a Relationship?. 2018 , 14, 327-332	8
1538	Intractable vomiting and the medulla: neuromyelitis optica spectrum disorder presenting as area postrema syndrome. 2018 , 94, 724	0
1537	Pediatric-onset multiple sclerosis in Egypt: a multi-center registry of 186 patients. 2018 , 14, 631-640	4
1536	Low vitamin D-25(OH) level in Indonesian multiple sclerosis and neuromyelitis optic patients. 2018 , 25, 329-333	12
1535	Diagonistic Apraxia: A Unique Case of Corpus Callosal Disconnection Syndrome and Neuromyelitis Optica Spectrum Disorder. 2018 , 9, 653	3
1534	NMOSD with anti-MOG antibodies following anti-TNF α therapy: A case report. 2018 , 26, 37-39	9
1533	Intractable nausea and vomiting as an uncommon presentation in an anti-aquaporin 4-positive patient. 2018 , 46, 3411-3416	1
1532	Neuromyelitis optica. 2018 , 08, 159-181	
1531	Cocaine as a potential trigger for Neuromyelitis Optica. 2018 , 390, 99-101	3
1530	Multiple sclerosis biomarkers: Helping the diagnosis?. 2018 , 174, 364-371	5
1529	Short-segment transverse myelitis lesions in a cohort of Latin American patients with neuromyelitis optica spectrum disorders. 2018 , 56, 949-954	5

1528	Update on pediatric-onset multiple sclerosis. 2018 , 174, 398-407	12
1527	Differentiating Neuromyelitis Optica-Related and Multiple Sclerosis-Related Acute Optic Neuritis Using Conventional Magnetic Resonance Imaging Combined With Readout-Segmented Echo-Planar Diffusion-Weighted Imaging. 2018 , 42, 502-509	12
1526	Multiple Sclerosis. 2018 , 38, 212-225	43
1525	Short-term effect of additional apheresis on visual acuity changes in patients with steroid-resistant optic neuritis in neuromyelitis optica spectrum disorders. 2018 , 62, 525-530	17
1524	Autoimmune hepatitis induced by a single injection of interferon- α in a patient with multiple sclerosis. 2018 , 265, 1469-1471	1
1523	Comparison of probabilistic tractography and tract-based spatial statistics for assessing optic radiation damage in patients with autoimmune inflammatory disorders of the central nervous system. 2018 , 19, 538-550	29
1522	Transient Pulmonary Interstitial Lesions in Aquaporin-4-positive Neuromyelitis Optica Spectrum Disorder. 2018 , 57, 2981-2986	4
1521	2017 McDonald diagnostic criteria: A review of the evidence. 2018 , 24, 48-54	28
1520	Neuroimaging in Pediatric Autoimmune Diseases. 2018 , 16, 171-184	1
1519	Hypothermia in Multiple Sclerosis: Beyond the Hypothalamus? A Case Report and Review of the Literature. 2018 , 2018, 2768493	1
1518	Multiple Sclerosis Patients with Markedly Low Intrathecal Antibody Response in Sri Lanka. 2018 , 2018, 5342936	4
1517	Different features between pediatric-onset and adult-onset patients who are seropositive for MOG-IgG: A multicenter study in South China. 2018 , 321, 83-91	26
1516	Multiple Sklerose und andere autoimmune ZNS-Erkrankungen. 2018 , 1-103	
1515	Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study. 2018 , 89, 1259-1265	56
1514	Pediatric acquired demyelinating syndromes: a nationwide validation study of the Danish National Patient Register. 2018 , 10, 391-399	18
1513	Multiple sclerosis and neuromyelitis optica spectrum disorders in Malaysia: A comparison in different ethnic groups. 2018 , 25, 300-308	10
1512	Glutamic Acid Decarboxylase Antibody in a Patient with Myelitis: A Retrospective Study. 2018 , 25, 68-72	4
1511	MOG-IgG-associated disease has a stereotypical clinical course, asymptomatic visual impairment and good treatment response. 2018 , 4, 2055217318787829	11

1510	Paraneoplastic Neuromyelitis Optica Associated with Lung Adenocarcinoma in a Young Woman. 2018 , 14, 246-247	10
1509	Neuromyelitis optica spectrum disorder and multiple sclerosis in a Sardinian family. 2018 , 25, 73-76	3
1508	An interesting PRESentation of NMO. 2018 , 25, 163-164	
1507	Specificities of Children with Multiple Sclerosis and Neuromyelitis Optica. 2018 , 18, 16-20	1
1506	Flaccid paralysis in neuromyelitis optica: An atypical presentation with possible involvement of the peripheral nervous system. 2018 , 25, 83-86	5
1505	Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. 2018 , 195, 8-15	171
1504	Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 cases. 2018 , 25, 95-98	24
1503	Incidence and Mimickers of Acute Idiopathic Optic Neuritis: Analysis of 291 Consecutive Patients from Southern Finland. 2018 , 25, 386-391	3
1502	Neuromyelitis optica spectrum disorder and menstruation. 2018 , 174, 716-721	1
1501	Progressive motor impairment from a critically located lesion in highly restricted CNS-demyelinating disease. 2018 , 24, 1445-1452	11
1500	Applicability of McDonald 2010 and Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) 2016 Magnetic Resonance Imaging Criteria for the Diagnosis of Multiple Sclerosis in Sri Lanka. 2018 , 14, 339-344	1
1499	New biological agents in the treatment of multiple sclerosis. 2018 , 119, 191-197	5
1498	MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder. 2018 , 25, 66-72	123
1497	Neuromyelitis Optica Spectrum Disorder Presenting with Pseudoathetosis. 2018 , 14, 123-125	1
1496	Orbital Ectopic Lymphoid Follicles with Germinal Centers in Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorders. 2017 , 8, 1947	2
1495	Elevated Plasma Chemokines for Eosinophils in Neuromyelitis Optica Spectrum Disorders during Remission. 2018 , 9, 44	11
1494	Cerebral Blood Flow Changes in Multiple Sclerosis and Neuromyelitis Optica and Their Correlations With Clinical Disability. 2018 , 9, 305	5
1493	Progressive Demyelination in the Presence of Serum Myelin Oligodendrocyte Glycoprotein-IgG: A Case Report. 2018 , 9, 340	4

1492	Ovarian Reserve in Women With Neuromyelitis Optica Spectrum Disorder. 2018 , 9, 446	6
1491	Influences of pregnancy on neuromyelitis optica spectrum disorders and multiple sclerosis. 2018 , 25, 61-65	15
1490	Autoimmune Neurologic Diseases in Children. 2018 , 38, 355-370	3
1489	An Overview of Autoimmune and Paraneoplastic Encephalitides. 2018 , 38, 330-343	15
1488	Autoimmune and Paraneoplastic Myelopathies. 2018 , 38, 278-289	15
1487	Recurrent Optic Neuritis as the Initial Symptom in Demyelinating Diseases. 2018 , 14, 351-358	3
1486	The application of RNFL thickness detection in early differential diagnosis among various types of idiopathic optic neuritis. 2018 , 55, 82-85	7
1485	Neuromyelitis Optica Spectrum Disorder in a Patient with Ankylosing Spondylitis. 2018 , 14, 102-103	4
1484	A Novel Autoantibody against Plexin D1 in Patients with Neuropathic Pain. 2018 , 84, 208-224	10
1483	Health utilities of patients with multiple sclerosis and neuromyelitis optica spectrum disorders in Thailand. 2018 , 24, 151-156	4
1482	Visual function and inner retinal structure correlations in aquaporin-4 antibody-positive optic neuritis. 2018 , 62, 598-604	2
1481	Lower frequency of antibodies to MOG in Brazilian patients with demyelinating diseases: An ethnicity influence?. 2018 , 25, 87-94	11
1480	T-cell activation marker sCD27 is associated with clinically definite multiple sclerosis in childhood-acquired demyelinating syndromes. 2018 , 24, 1715-1724	5
1479	Pediatric-onset multiple sclerosis in Brazilian patients: Clinical features, treatment response and comparison to pediatric neuromyelitis optica spectrum disorders. 2018 , 25, 138-142	6
1478	MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder. 2018 , 9, 217	118
1477	Overlapping Autoimmune Syndromes in Patients With Glial Fibrillary Acidic Protein Antibodies. 2018 , 9, 251	25
1476	Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report. 2018 , 18, 95	31
1475	Imaging Differences between Neuromyelitis Optica Spectrum Disorders and Multiple Sclerosis: A Multi-Institutional Study in Japan. 2018 , 39, 1239-1247	12

1474	Circumventricular organs of human brain visualized on post-contrast 3D fluid-attenuated inversion recovery imaging. 2018 , 60, 583-590	9
1473	MRI-Based Methods for Spinal Cord Atrophy Evaluation: A Comparison of Cervical Cord Cross-Sectional Area, Cervical Cord Volume, and Full Spinal Cord Volume in Patients with Aquaporin-4 Antibody Seropositive Neuromyelitis Optica Spectrum Disorders. 2018 , 39, 1362-1368	8
1472	MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. 2018 , 15, 134	354
1471	Vaccines and the association with relapses in patients with neuromyelitis optica spectrum disorder. 2018 , 23, 78-82	19
1470	Pediatric Multiple Sclerosis. 2018 , 277-294	
1469	Neuromyelitis Optica Spectrum Disorders. 2018 , 313-335	1
1468	Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis. 2018 , 25, 246-250	20
1467	Acute Disseminated Encephalomyelitis. 2018 , 295-312	1
1466	Optic Neuritis: Clinical Manifestations, Pathophysiology, and Management. 2018 , 337-353	
1465	Differences in clinical features between optic neuritis in neuromyelitis optica spectrum disorders and in multiple sclerosis. 2018 , 4, 2055217318791196	17
1464	Optical Coherence Tomography versus Visual Evoked Potentials for Detecting Visual Pathway Abnormalities in Patients with Neuromyelitis Optica Spectrum Disorder. 2018 , 14, 200-205	10
1463	Parainfectious longitudinally extensive transverse myelitis associated with varicella-zoster virus. 2018 , 33, 342-343	
1462	Three Japanese adult cases of brain lesions with anti-myelin oligodendrocyte glycoprotein antibodies lacking optic neuritis and myelitis. 2018 , 9, 162-168	1
1461	Optical coherence tomography in acute optic neuritis: A population-based study. 2018 , 138, 566-573	24
1460	Blood Brain Barrier Permeability Could Be a Biomarker to Predict Severity of Neuromyelitis Optica Spectrum Disorders: A Retrospective Analysis. 2018 , 9, 648	6
1459	Acute intractable vomiting: Do I belong somewhere else?. 2018 , 37, 365-369	1
1458	Obstetric outcomes in a Mexican cohort of patients with AQP4-antibody-seropositive neuromyelitis optica. 2018 , 25, 268-270	10
1457	Acute and Chronic Therapies in Pediatric Inflammatory Central Nervous System Diseases. 2018 , 16, 202-216	1

1456	Tryptophan immunoadsorption during pregnancy and breastfeeding in patients with acute relapse of multiple sclerosis and neuromyelitis optica. 2018 , 11, 1756286418774973	18
1455	[Diagnosis of multiple sclerosis: revision of the McDonald criteria 2017]. 2018 , 89, 1344-1354	8
1454	Prevalence and characteristics of transverse myelitis and neuromyelitis optica spectrum disorders in the United Arab Emirates: A multicenter, retrospective study. 2018 , 9, 155-161	19
1453	Mortality in neuromyelitis optica is strongly associated with African ancestry. 2018 , 5, e468	45
1452	CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications. 2018 , 89, 927-936	63
1451	Only Follow-Up of Memory B Cells Helps Monitor Rituximab Administration to Patients with Neuromyelitis Optica Spectrum Disorders. 2018 , 7, 373-383	19
1450	Differential diagnosis with other rapid progressive dementias in human prion diseases. 2018 , 153, 371-397	21
1449	Overview of therapeutic plasma exchange in pediatric neurology: a single-center experience. 2018 , 118, 451-458	10
1448	Neuromyelitis optica spectrum disorders: Features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes. 2018 , 174, 458-470	18
1447	Structural and visual functional deficits in a rat model of neuromyelitis optica spectrum disorders related optic neuritis. 2018 , 175, 124-132	11
1446	Pain and Psychosocial Symptoms in Newly Diagnosed Neuromyelitis Optica Spectrum Disorder (NMOSD). 168-170	
1445	Differing Structural and Functional Patterns of Optic Nerve Damage in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. 2019 , 126, 445-453	39
1444	Application of the 2017 McDonald diagnostic criteria for multiple sclerosis in Korean patients with clinically isolated syndrome. 2019 , 25, 1488-1495	21
1443	Clinical characteristics and prognosis of myelin oligodendrocyte glycoprotein antibody-seropositive paediatric optic neuritis in China. 2019 , 103, 831-836	18
1442	Treating neuromyelitis optica with azathioprine: 20-year clinical practice. 2019 , 25, 1150-1161	14
1441	Pure spinal multiple sclerosis: A possible novel entity within the multiple sclerosis disease spectrum. 2019 , 25, 1189-1195	3
1440	Cross-modal plasticity among sensory networks in neuromyelitis optica spectrum disorders. 2019 , 25, 968-979	8
1439	Clinical presentation of optic neuritis with autoantibodies anti-myelin oligodendrocyte glycoprotein. 2019 , 29, 257-261	7

1438	A nationwide epidemiological study on the prevalence of multiple sclerosis and neuromyelitis optica spectrum disorder with important multi-ethnic differences in Malaysia. 2019 , 25, 1452-1461	22
1437	Nystagmus and diplopia in a patient with positive aquaporin-4 antibody. 2019 , 54, e66-e69	2
1436	Peripapillary and parafoveal vascular network assessment by optical coherence tomography angiography in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. 2019 , 103, 789-796	42
1435	Helicobacter pylori infection and demyelinating disease of the central nervous system. 2019 , 329, 14-19	17
1434	Primary optic neuropathy in Behçet's syndrome. 2019 , 25, 1132-1140	2
1433	Changing patterns of multiple sclerosis in Korea: Toward a more baseline MRI lesions and intrathecal humoral immune responses. 2019 , 35, 209-214	0
1432	Increased serum IL-36 and IL-36 levels in patients with neuromyelitis optica spectrum disorders: association with disease activity. 2019 , 19, 185	5
1431	Next-generation sequencing identifies contribution of both class I and II HLA genes on susceptibility of multiple sclerosis in Japanese. 2019 , 16, 162	14
1430	Ensayo pictórico: Diagnóstico diferencial radiológico en Esclerosis Múltiple. 2019 , 25, 5-18	
1429	AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD) coexisting with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis: A case report and literature review. 2019 , 35, 185-192	7
1428	Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: A systematic review and network meta-analysis. 2019 , 35, 246-252	31
1427	Different magnetic resonance imaging features between MOG antibody- and AQP4 antibody-mediated disease: A Chinese cohort study. 2019 , 405, 116430	12
1426	14th EUNOS Congress: PORTO, PORTUGAL, 16-19 JUNE 2019. 2019 , 43, 1-221	2
1425	Mysterious presentation of autoantibody in a neuromyelitis optica spectrum disorder patient. 2019 , 10, 186-189	1
1424	The Roles of Regulatory T Cells in Central Nervous System Autoimmunity. 2019 , 167-193	
1423	Neuroinflammation and Sjogren's Syndrome. 2019 , 699-709	
1422	Atypical Inflammatory Demyelinating Syndromes of the Central Nervous System. 2019 , 543-566	
1421	Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis. 2019 , 76, 1446-1456	59

1420	Utility of chemokines CCL2, CXCL8, 10 and 13 and interleukin 6 in the pediatric cohort for the recognition of neuroinflammation and in the context of traditional cerebrospinal fluid neuroinflammatory biomarkers. 2019 , 14, e0219987	10
1419	Validation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorders in a cohort of South Indian patients. 2019 , 35, 164-169	5
1418	Blood pressure and body fat percent in women with NMOSD. 2019 , 9, e01350	4
1417	Controversies in the management of neuromyelitis optica spectrum disorder. 2019 , 19, 1127-1133	7
1416	Neuroimaging in Inflammatory and Infectious Diseases of the Spinal Cord. 2019 , 1949-1971	
1415	Neuromyelitis Optica Spectrum Disorders (NMOSD). 2019 , 769-785	0
1414	A new M23-based ELISA assay for anti-aquaporin 4 autoantibodies: diagnostic accuracy and clinical correlation. 2019 , 10, 5	5
1413	Devic's index case: A critical reappraisal - AQP4-IgG-mediated neuromyelitis optica spectrum disorder, or rather MOG encephalomyelitis?. 2019 , 407, 116396	9
1412	In vivo structural and functional assessment of optic nerve damage in neuromyelitis optica spectrum disorders and multiple sclerosis. 2019 , 9, 10371	19
1411	A prospective, observational study on conversion of clinically isolated syndrome to multiple sclerosis during 4-year period (MS NEO study) in Taiwan. 2019 , 14, e0202453	4
1410	Pediatric acquired demyelinating syndrome (ADS) in inpatient hospital settings: The hospitalization rate, costs, and outcomes in the US. 2019 , 34, 150-157	2
1409	Neuromyelitis Optica Spectrum Disorders. 2019 , 187-195	
1408	Emergencies in Neurology. 2019 ,	
1407	Acute Non-traumatic Myelopathies. 2019 , 65-103	
1406	A unique case of multiphasic ADEM or what else?. 2019 , 35, 73-75	1
1405	Neuropathological features of non-motor symptoms in multiple sclerosis and neuromyelitis optica. 2019 , 10, 161-168	1
1404	Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study. 2019 , 16, 154	28
1403	Neuromyelitis optica spectrum disorder with radiological manifestation of multiple sclerosis in the first brain MRI: a case report. 2019 , 14, FNL15	

1402	Clinical characteristics of autoimmune disorders in the central nervous system associated with myasthenia gravis. 2019 , 266, 2743-2751	6
1401	Neurorheumatology. 2019 ,	1
1400	Validation of a symptom-based questionnaire for pediatric CNS demyelinating diseases. 2019 , 23, 157.e1-157.e7	
1399	Low Serum Interleukin-10 Is an Independent Predictive Factor for the Risk of Second Event in Clinically Isolated Syndromes. 2019 , 10, 604	5
1398	The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders. 2019 , 35, 1-4	5
1397	Neuromyelitis optica spectrum disorder: Patient experience and quality of life. 2019 , 6, e580	61
1396	Imaging of CNS Infections and Neuroimmunology. 2019 ,	0
1395	Late Onset of Neuromyelitis Optica Spectrum Disorders. 2019 , 8, 477-482	11
1394	Acute Disseminated Encephalomyelitis in Children: An Updated Review Based on Current Diagnostic Criteria. 2019 , 100, 26-34	50
1393	Paraneoplastic neurological syndromes. 2019 , 36, 279-292	10
1392	Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. 2019 , 16, 134	66
1391	Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD. 2019 , 6, e583	23
1390	Magnetic Resonance Imaging Patterns in Nontraumatic Pediatric Spinal Cord Myelopathy. 2019 , 9, 185-200	5
1389	Imaging markers of disability in aquaporin-4 immunoglobulin G seropositive neuromyelitis optica: a graph theory study. 2019 , 1, fcz026	10
1388	Editors' note: Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark. <i>Neurology</i> , 2019 , 93, 722.1-722	6.5
1387	Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders. 2019 , 36, 101430	14
1386	Long-term outcome and prognosis in patients with neuromyelitis optica spectrum disorder from Serbia. 2019 , 36, 101413	10
1385	Reduced Myelin Signal in Normal-appearing White Matter in Neuromyelitis Optica Measured by 7T Magnetic Resonance Imaging. 2019 , 9, 14378	12

1384	Demyelinating syndrome in systemic sclerosis and neuromyelitis optica. 2019 , 19, 234		7
1383	Plasma Homocysteine Level Is Associated with the Expanded Disability Status Scale in Neuromyelitis Optica Spectrum Disorder. 2019 , 26, 258-264		5
1382	[A case of suspected neuromyelitis optica spectrum disorder preceded by aseptic meningitis-like symptoms]. 2019 , 59, 736-739		2
1381	Brain Atrophy in Relapsing Optic Neuritis Is Associated With Crion Phenotype. 2019 , 10, 1157		3
1380	Probable neuromyelitis optica spectrum disorder presenting with recurrent cranial neuropathy. 2019 , 10, 259-263		
1379	B cells in autoimmune and neurodegenerative central nervous system diseases. 2019 , 20, 728-745		103
1378	Neuromyelitis optica spectrum disorder and systemic lupus erythematosus. 2019 , 28, 1722-1726		1
1377	Spinal cord syndromes in patients with systemic lupus erythematosus: differentiating lupus myelitis, neuromyelitis optica, and multiple sclerosis. 2019 , 28, 1656-1662		7
1376	Very late-onset recurrent myelitis in a patient diagnosed with antiphospholipid syndrome: A puzzle of autoimmunity. 2019 , 337, 577051		4
1375	A highly specific and sensitive nanoimmunosensor for the diagnosis of neuromyelitis optica spectrum disorders. 2019 , 9, 16136		4
1374	AQP4 Antibody Assay Sensitivity Comparison in the Era of the 2015 Diagnostic Criteria for NMOSD. 2019 , 10, 1028		30
1373	Pregnancy-Related Immune Changes and Demyelinating Diseases of the Central Nervous System. 2019 , 10, 1070		9
1372	Brain lesion distribution criteria distinguish demyelinating diseases in China. 2019 , 6, 2048-2053		8
1371	Complete horizontal gaze palsy due to bilateral paramedian pontine reticular formation involvement as a presentation of multiple sclerosis: a case report. 2019 , 19, 254		1
1370	Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases. <i>Neurology</i> , 2019 , 93, e1867-e1872	6.5	46
1369	Efficacy and Tolerability of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Neurologic Diseases. 2019 , 41, 2112-2136		12
1368	Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. <i>Neurology</i> , 2019 , 93, e1299-e1311	6.5	63
1367	Proportions of Th17 cells and Th17-related cytokines in neuromyelitis optica spectrum disorders patients: A meta-analysis. 2019 , 75, 105793		11

1366	The clinical spectrum and prognosis of idiopathic acute optic neuritis: A longitudinal study in Southern Finland. 2019 , 35, 215-220		2
1365	Neuromyelitis-optica-Spektrum-Erkrankung. 2019 , 2, 280-284		0
1364	Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination. 2019 , 7, 145		38
1363	Neuromyelitis optica spectrum disorders: still evolving and broadening. 2019 , 32, 385-394		82
1362	The spectrum of immune-mediated and inflammatory lesions of the brainstem: Clues to diagnosis. <i>Neurology</i> , 2019 , 93, 390-405	6.5	13
1361	The accuracy of flow cytometric cell-based assay to detect anti-myelin oligodendrocyte glycoprotein (MOG) antibodies determining the optimal method for positivity judgement. 2019 , 336, 577021		11
1360	Outer Retinal Dysfunction on Multifocal Electroretinography May Help Differentiating Multiple Sclerosis From Neuromyelitis Optica Spectrum Disorder. 2019 , 10, 928		7
1359	Early neuroaxonal injury is seen in the acute phase of pediatric optic neuritis. 2019 , 36, 101387		3
1358	The GTF2I rs117026326 polymorphism is associated with neuromyelitis optica spectrum disorder but not with multiple sclerosis in a Northern Han Chinese population. 2019 , 337, 577045		5
1357	Multidisciplinary rehabilitation for adults with neuromyelitis optica spectrum disorders: A pilot study. 2019 , 51, 692-697		4
1356	The imbalance between regulatory and memory B cells accompanied by an increased number of circulating T-follicular helper cells in MOG-antibody-associated demyelination. 2019 , 36, 101397		9
1355	Aquaporin-4-IgG positive neuromyelitis optica spectrum disorder and systemic autoimmune diseases overlap syndrome: a single-center experience. 2019 , 28, 1302-1311		9
1354	Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica. <i>Neurology</i> , 2019 , 93, e1732-e1741	6.5	36
1353	Unfavorable Structural and Functional Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis. 2019 , 39, 3-7		16
1352	Resting-state functional MRI demonstrates brain network reorganization in neuromyelitis optica spectrum disorder (NMOSD). 2019 , 14, e0211465		7
1351	Aquaporin-4 Water Channel in the Brain and Its Implication for Health and Disease. 2019 , 8,		72
1350	A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries. 2019 , 19, 5		12
1349	Diagnosing autoimmune encephalitis based on clinical features and autoantibody findings. 2019 , 15, 511-527		8

1348	Predictors of Evolution Into Multiple Sclerosis After a First Acute Demyelinating Syndrome in Children and Adolescents. 2018 , 9, 1156	8
1347	Low levels of vitamin D and the relationship between vitamin D and Th2 axis-related cytokines in neuromyelitis optica spectrum disorders. 2019 , 61, 22-27	7
1346	Foxp3+ regulatory T cells expression in neuromyelitis optica spectrum disorders. 2019 , 30, 114-118	10
1345	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. 2019 , 18, 185-197	74
1344	Neuromyelitis optica spectrum and myelin oligodendrocyte glycoprotein antibody-related disseminated encephalomyelitis. 2019 , 10, 9-17	2
1343	Coexistence of Neuromyelitis Optica and Amyotrophic Lateral Sclerosis: A Case Report. 2019 , 9, 37-40	2
1342	Neuromyelitis optica testing and treatment: Availability and affordability in 60 countries. 2019 , 33, 44-50	15
1341	Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis. 2019 , 33, 22-32	26
1340	Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?. 2019 , 6, e572	70
1339	Aquaporin 4 Suppresses Neural Hyperactivity and Synaptic Fatigue and Fine-Tunes Neurotransmission to Regulate Visual Function in the Mouse Retina. 2019 , 56, 8124-8135	7
1338	Incidence of pediatric neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease in Denmark 2008-2018: A nationwide, population-based cohort study. 2019 , 33, 162-167	17
1337	Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. 2019 , 142, 1858-1875	150
1336	Macular Star and Choroidal Tubercles: A Rare Cause of Opticospinal Syndrome. 2019 , 46, 625-627	
1335	Aquaporin-4 IgG antibody-related disorders in patients with juvenile systemic lupus erythematosus. 2019 , 28, 1243-1249	4
1334	Neuromyelitis Optica Spectrum Disorder and Anti-MOG Syndromes. 2019 , 7,	54
1333	Normal-Appearing Cerebellar Damage in Neuromyelitis Optica Spectrum Disorder. 2019 , 40, 1156-1161	2
1332	Critical review: Typical and atypical optic neuritis. 2019 , 64, 770-779	33
1331	Intractable Nausea and Vomiting: Gut Is Not Always the Answer. 2019 , 132, 1419-1420	1

1330	Area postrema syndrome as a debut of neuromyelitis optica spectrum disorders. 2019 , 7, 301-302		0
1329	TLR-2 and TLR-4 agonists favor expansion of CD4 T cell subsets implicated in the severity of neuromyelitis optica spectrum disorders. 2019 , 34, 66-76		9
1328	Concurrent aquaporin-4-positive NMOSD and neurosyphilis: A case report. 2019 , 34, 137-140		2
1327	Central Nervous System Involvement with Chronic Lymphocytic Leukemia. 2019 , 46, 640-641		2
1326	Differential Diagnosis of Pediatric Multiple Sclerosis. 2019 , 6,		2
1325	Epidemiology of NMOSD in Sweden from 1987 to 2013: A nationwide population-based study. <i>Neurology</i> , 2019 , 93, e181-e189	6.5	32
1324	Neuromyelitis optica and pregnancy-puerperal cycle. 2019 , 34, 59-62		4
1323	Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. 2019 , 34, 171-354		45 ^o
1322	Bilateral oculomotor nerve palsy in a case of anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. 2019 , 66, 271-272		2
1321	Cognitive Impairment in Neuromyelitis Optica Spectrum Disorders: A Review of Clinical and Neuroradiological Features. 2019 , 10, 608		29
1320	Attack-related damage of thalamic nuclei in neuromyelitis optica spectrum disorders. 2019 , 90, 1156-1164		15
1319	Neuromyelitis Optica Spectrum Disorders (NMOSD). 2019 , 1-17		
1318	Recurrent rhombencephalomyelitis associated with allergen immunotherapy by mite antigen sublingual tablets. 2019 , 15, 100190		
1317	Paraneoplastic neuromyelitis optica spectrum disorder associated with breast cancer. 2019 , 14, 1039-1044		8
1316	Neuromyelitis optica spectrum disorder coincident with renal clear cell carcinoma: A case report. 2019 , 98, e14229		3
1315	Epidemiology of neuromyelitis optica spectrum disorder in Denmark (1998-2008, 2007-2014). 2019 , 9, e01338		9
1314	Clinical Features of Diffuse Leptomeningeal Glioneuronal Tumor with Rapid Blindness Misdiagnosed as NMOSD and Literature Review. 2019 , 1, 434-441		1
1313	Distinct serum and cerebrospinal fluid cytokine and chemokine profiles in autoantibody-associated demyelinating diseases. 2019 , 5, 2055217319848463		5

1312	The Argentinean multiple sclerosis registry (RelevarEM): Methodological aspects and directions. 2019 , 32, 133-137	16
1311	Myelin in the Central Nervous System: Structure, Function, and Pathology. 2019 , 99, 1381-1431	125
1310	A descriptive study of clinical and radiological profile of longitudinal extensive myelitis in a tertiary hospital in Rajasthan, India. 2019 , 181, 33-40	2
1309	Neuromyelitis optica spectrum disorder with lung adenocarcinoma and intraductal papillary mucinous neoplasm. 2019 , 32, 77-80	5
1308	Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production. 2019 , 142, 1598-1615	36
1307	Seizure and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Encephalomyelitis in a Retrospective Cohort of Chinese Patients. 2019 , 10, 415	13
1306	Spectrally fat-suppressed coronal 2D TSE sequences may be more sensitive than 2D STIR for the detection of hyperintense optic nerve lesions. 2019 , 29, 6266-6274	2
1305	A comparison between spinal cord infarction and neuromyelitis optica spectrum disorders: Clinical and MRI studies. 2019 , 9, 7435	11
1304	Neuromyelitis optica spectrum disorder in three generations of a Chinese family. 2019 , 32, 94-96	1
1303	Magnetic resonance imaging in myelopathy: a pictorial review. 2019 , 57, 56-68	6
1302	Callosal lesions on magnetic resonance imaging with multiple sclerosis, neuromyelitis optica spectrum disorder and acute disseminated encephalomyelitis. 2019 , 32, 41-45	9
1301	Clinical Characteristics of Patients With Neuromyelitis Optica Spectrum Disorders With Early Onset. 2019 , 34, 487-490	10
1300	Pathologic and MRI analysis in acute atypical inflammatory demyelinating lesions. 2019 , 266, 1743-1755	5
1299	Epilepsy in Multiple Sclerosis and Other Acquired Demyelinating Diseases. 2019 , 749-756	
1298	Concurrence of NMOSD and ALS in a patient with hexanucleotide repeat expansions of C9orf72. 2019 , 20, 449-452	1
1297	Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. 2019 , 381, 614-625	314
1296	"Better explanations" in multiple sclerosis diagnostic workup: A 3-year longitudinal study. <i>Neurology</i> , 2019 , 92, e2527-e2537	6.5 22
1295	Myelin Oligodendrocyte Glycoprotein-IgG Contributes to Oligodendrocytopathy in the Presence of Complement, Distinct from Astrocytopathy Induced by AQP4-IgG. 2019 , 35, 853-866	6

1294	Neuromyelitis optica spectrum disorder and adenocarcinoma of ovary: a novel association. 2019 , 12,	2
1293	Role of Glutamatergic Excitotoxicity in Neuromyelitis Optica Spectrum Disorders. 2019 , 13, 142	9
1292	Positive anti-MOG antibodies in a patient with Sjögren's syndrome and transverse myelitis. 2019 , 6, 102-104	4
1291	Neuromyelitis optica spectrum disorder occurred after interferon alpha therapy in malignant melanoma. 2019 , 32, 33-36	1
1290	Comparison of sleep complaints and quality of life between patients with neuromyelitis optica spectrum disorder (NMOSD) and healthy controls. 2019 , 32, 81-87	10
1289	Pediatric Multiple Sclerosis: A Review. 2019 , 66, 209-229	7
1288	A Case Where Selective Plasma Exchange for Neuromyelitis Optica Was Effective. 2019 , 23, 299-300	
1287	Disease-modifying therapies should be stopped in NMOSD patients in remission - No. 2019 , 25, 1218-1220	4
1286	Disease-modifying therapies should be stopped in NMOSD patients in remission - Yes. 2019 , 25, 1217-1218	5
1285	Bilateral extensive lesions of the brain in a patient with neuromyelitis optica manifested with seizure and cognitive impairments. 2019 , 175, 272-274	0
1284	Seronegative neuromyelitis optica spectrum disorder: severe polysymptomatic presentation with successful treatment response. 2019 , 12,	1
1283	Diagnostic Value of Oligoclonal Bands in Children: A Nationwide Population-Based Cohort Study. 2019 , 97, 56-63	5
1282	Nontarget metabolomics profiling of neuromyelitis optica spectrum disorder. 2019 , 33, e4533	3
1281	Interleukin-36 alpha levels are elevated in the serum and cerebrospinal fluid of patients with neuromyelitis optica spectrum disorder and correlate with disease activity. 2019 , 224, 397-401	4
1280	Effectiveness of rituximab in neuromyelitis optica: a meta-analysis. 2019 , 19, 36	59
1279	Neuromyelitis optica spectrum disorder in pediatrics. Case report. 2019 , 5, 11-18	
1278	Evidence of Müller Glial Dysfunction in Patients with Aquaporin-4 Immunoglobulin G-Positive Neuromyelitis Optica Spectrum Disorder. 2019 , 126, 801-810	26
1277	Autoantibodies against Neurologic Antigens in Nonneurologic Autoimmunity. 2019 , 202, 2210-2219	12

1276	Myelinoclastic diffuse sclerosis (Schilder's disease) is immunologically distinct from multiple sclerosis: results from retrospective analysis of 92 lumbar punctures. 2019 , 16, 51	11
1275	Comparison of Ocular Motor Findings Between Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis Involving the Brainstem and Cerebellum. 2019 , 18, 511-518	3
1274	Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study. 2019 , 40, 1383-1391	4
1273	Immune-mediated conditions affecting the brain, eye and ear (BEE syndromes). 2019 , 90, 882-894	17
1272	Serum Creatine Kinase in Patients with Neuromyelitis Optica Spectrum Disorder. 2019 , 330, 87-89	4
1271	[A case of neuromyelitis optica spectrum disorders, with slowly progressive bulbar palsy, mimicking a motor neuron disease]. 2019 , 59, 139-143	
1270	Unusual Cause of Intractable Vomiting in a Young Girl. 2019 , 86, 386	
1269	Clinical characteristics of patients with paraneoplastic myelopathy. 2019 , 330, 136-142	11
1268	Magnetic resonance imaging diagnosis of demyelinating diseases: An update. 2019 , 10, 32-48	5
1267	Brain MRI Findings in Pediatric-Onset Neuromyelitis Optica Spectrum Disorder: Challenges in Differentiation from Acute Disseminated Encephalomyelitis. 2019 , 40, 726-731	7
1266	Neuromyelitis optic with positive Anti-AQP4 and Anti-SSA/Ro antibody. 2019 , 11, 7958	
1265	Neuromyelitis optica spectrum disorders. 2019 , 19, 169-176	83
1264	Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial. 2019 , 116, 8463-8470	59
1263	Case report: an area postrema syndrome revealing a neuromyelitis optica spectrum disorder associated with central nervous system tuberculosis in a young Togolese (black African) woman. 2019 , 19, 58	6
1262	The association between dietary sugar intake and neuromyelitis optica spectrum disorder: A case-control study. 2019 , 31, 112-117	3
1261	Quantitative 7T MRI does not detect occult brain damage in neuromyelitis optica. 2019 , 6, e541	13
1260	Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. 2019 , 142, 1310-1323	75
1259	The Big Yawning: Pathological Yawning as a Symptom of Neuromyelitis Optica Spectrum Disorders. 2019 , 2019, 9691863	

1258	Co-existing of Neuromyelitis Optica and Fulminant Type 1 Diabetes. 2019 , 58, 1913-1916	
1257	A Longitudinally Extensive Spinal Cord Lesion Restricted to Gray Matter in an Adolescent Male. 2019 , 10, 270	2
1256	Cerebral cortex impairment in neuromyelitis optica spectrum disorder: A case report and literature review. 2019 , 32, 9-12	7
1255	Neuromyelitis optica spectrum disorder in a tertiary hospital in the Philippines: a case series. 2019 , 31, 124-130	3
1254	The expansion of circulating IL-6 and IL-17-secreting follicular helper T cells is associated with neurological disabilities in neuromyelitis optica spectrum disorders. 2019 , 330, 12-18	10
1253	Clinical, neuroimaging and therapeutic response in AQP4-positive NMO patients from India. 2019 , 30, 85-93	12
1252	Moyamoya disease presenting as thalamic infarction in a patient with neuromyelitis optica spectrum disorder. 2019 , 25, 412-414	1
1251	Intra-family phenotype variations in familial neuromyelitis optica spectrum disorders. 2019 , 30, 57-62	5
1250	A case of neuromyelitis optica spectrum disorder following seasonal influenza vaccination. 2019 , 30, 110-113	6
1249	Radiomics in multiple sclerosis and neuromyelitis optica spectrum disorder. 2019 , 29, 4670-4677	17
1248	Increased cerebrospinal fluid neurofilament light chain in central nervous system inflammatory demyelinating disease. 2019 , 30, 123-128	12
1247	Spontaneous Improvement of Visual Acuity in a 13-Year-Old Boy with Neuromyelitis Optica Spectrum Disorder. 2019 , 43, 114-119	
1246	Gut microbiota-dependent CCR9+CD4+ T cells are altered in secondary progressive multiple sclerosis. 2019 , 142, 916-931	32
1245	Clinical course of neuromyelitis optica spectrum disorder in a moroccan cohort. 2019 , 30, 141-148	7
1244	Sex Hormones and Optic Nerve Disorders: A Review. 2019 , 13, 57	26
1243	Plasma exchange: an effective add-on treatment of optic neuritis in neuromyelitis optica spectrum disorders. 2019 , 39, 2477-2483	15
1242	So Dramatic They Could Never Be Overlooked: History of Pediatric Neuromyelitis Optica. 2019 , 96, 3-6	
1241	Aquaporin-4 antibody positive short transverse myelitis associated with breast cancer. 2019 , 30, 119-122	7

1240	Association of Optic Neuritis with Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis in Korea. 2019 , 33, 82-90		10
1239	Dietary total antioxidant capacity and neuromyelitis optica spectrum disorder susceptibility. 2019 , 50, 653-663		3
1238	Reader response: Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark. <i>Neurology</i> , 2019 , 93, 722-723	6.5	0
1237	Editors' note: Ordinal vs dichotomous analyses of modified Rankin Scale, 5-year outcome, and cost of stroke. <i>Neurology</i> , 2019 , 93, 724.1-724	6.5	
1236	Experience with tocilizumab in patients with neuromyelitis optica spectrum disorders. 2019 ,		6
1235	Understanding Childhood Neuroimmune Diseases of the Central Nervous System. 2019 , 7, 511		15
1234	Classifying the antibody-negative NMO syndromes: Clinical, imaging, and metabolomic modeling. 2019 , 6, e626		9
1233	Late-onset neuromyelitis optica spectrum disorder: The importance of autoantibody serostatus. 2019 , 6,		26
1232	Author response: Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark. <i>Neurology</i> , 2019 , 93, 723	6.5	
1231	Diagnosis of Multiple Sclerosis. 2019 ,		
1230	Reader response: Ordinal vs dichotomous analyses of modified Rankin Scale, 5-year outcome, and cost of stroke. <i>Neurology</i> , 2019 , 93, 724-725	6.5	0
1229	Author response: Ordinal vs dichotomous analyses of modified Rankin Scale, 5-year outcome, and cost of stroke. <i>Neurology</i> , 2019 , 93, 725	6.5	1
1228	A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder. 2019 , 98, e15944		23
1227	Association Between BDNF Val66Met Polymorphism and Optic Neuritis Damage in Neuromyelitis Optica Spectrum Disorder. 2019 , 13, 1236		2
1226	The latest diagnostic criteria and treatment options for neuromyelitis optica. 2019 , 32, 1-6		4
1225	Aquaporin-4 Serostatus and Visual Outcomes in Clinically Isolated Acute Optic Neuritis. 2019 , 39, 165-169		8
1224	Pattern Visually Evoked Potentials in Japanese Girl With Optic Neuritis and Seropositive to Anti-myelin Oligodendrocyte Glycoprotein (MOG) Antibody. 2019 , 10, 1339		2
1223	Neuromyelitis optica spectrum disorder with massive basal ganglia involvement: a case report. 2019 , 19, 351		2

1222	Complex intensive treatment shows promise against a complex aggressive disease. <i>Neurology</i> , 2019 , 93, 776-777	6.5
1221	Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. 2019 , 381, 2114-2124	212
1220	Low-Density Granulocytes Are a Novel Immunopathological Feature in Both Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. 2019 , 10, 2725	13
1219	Prognostic indicators of improvement with therapeutic plasma exchange in pediatric demyelination. <i>Neurology</i> , 2019 , 93, e2065-e2073	6.5 12
1218	Atypical Pediatric Demyelinating Diseases of the Central Nervous System. 2019 , 19, 95	9
1217	Triglyceride Level Is an Independent Risk Factor in First-Attacked Neuromyelitis Optica Spectrum Disorders Patients. 2019 , 10, 1230	12
1216	Predictive Value of Serum Antibodies and Point Mutations of AQP4, AQP1 and MOG in A Cohort of Spanish Patients with Neuromyelitis Optica Spectrum Disorders. 2019 , 20,	4
1215	The Balance in T Follicular Helper Cell Subsets Is Altered in Neuromyelitis Optica Spectrum Disorder Patients and Restored by Rituximab. 2019 , 10, 2686	15
1214	Comparison of psychiatric disturbances in patients with multiple sclerosis and neuromyelitis optica. 2019 , 98, e17184	8
1213	Top 100 Publications as Measured by Altmetrics in the Field of Central Nervous System Inflammatory Demyelinating Disease. 2019 , 2019, 3748091	4
1212	Encefalomiелitis aguda diseminada. Leucoencefalitis aguda hemorrágica. Otras enfermedades desmielinizantes. 2019 , 12, 4606-4615	1
1211	Free thyroxine level is associated with both relapse rate and poor neurofunction in first-attack Neuromyelitis Optica Spectrum Disorder (NMOSD) patients. 2019 , 19, 329	6
1210	The history of neuromyelitis optica. Part 2: 'Spinal amaurosis', or how it all began. 2019 , 16, 280	12
1209	Association of polymorphism and multiple sclerosis in Malaysia: a pilot study. 2019 , 10, 13	0
1208	What You Need to Know About AQP4, MOG, and NMOSD. 2019 , 39, 718-731	17
1207	Clinical and radiologic approach to 'typical' versus antibody-related optic neuritis. 2019 , 30, 412-417	6
1206	Place des échanges plasmatiques dans la sclérose en plaques et la neuromyérite optique. 2019 , 10, 250-259	
1205	Tumefactive Demyelination Associated with Bilateral Optic Neuritis in Neuromyelitis Optica Spectrum Disorders. 2019 , 10, 693-696	

1204	Treatment of neuromyelitis optica spectrum disorders. 2019 , 31, 250-255	20
1203	Neuromyelitis optica spectrum disorders with vertigo as the initial symptom: A case report. 2019 , 98, e16906	2
1202	Neuromyelitis Optica: Review and Utility of Testing Aquaporin-4 Antibody in Typical Optic Neuritis. 2018 , 7, 229-234	6
1201	Clinical Course and Treatment Response of Neuromyelitis Optica Spectrum Disease: An 8-Year Experience. 2019 , 8, 206-210	5
1200	Update on pediatric optic neuritis. 2019 , 30, 418-425	11
1199	Chiasmal and Retrochiasmal Disorders. 2019 , 59, 59-81	1
1198	Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017 - continuity and change. 2019 , 32, 327-337	17
1197	Do Myelin Oligodendrocyte Glycoprotein Antibodies Represent a Distinct Syndrome?. 2019 , 39, 416-423	5
1196	Demyelinating Optic Neuritis and its Subtypes. 2019 , 59, 23-37	2
1195	Minor hallucinations in Parkinson disease: A subtle symptom with major clinical implications. <i>Neurology</i> , 2019 , 93, 725	6.5
1194	The changing concepts in the neuropathology of acquired demyelinating central nervous system disorders. 2019 , 32, 313-319	25
1193	Neuromylite optique compliquèe d'un lupus systémique. 2019 , 40, A175-A176	
1192	Visual Loss. 2019 , 101-196	3
1191	Multiple sclerosis with atypical MRI presentation: Results of a nationwide multicenter study in 57 consecutive cases. 2019 , 28, 109-116	4
1190	The X factor. 2019 , 64, 876-883	
1189	Follow-up study on Chinese children with relapsing MOG-IgG-associated central nervous system demyelination. 2019 , 28, 4-10	20
1188	Outcomes from acute attacks of neuromyelitis optica spectrum disorder correlate with severity of attack, age and delay to treatment. 2019 , 28, 60-63	12
1187	Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions. 2019 , 28, 64-68	28

1186	Myelin oligodendrocyte glycoprotein antibodies in neurological disease. 2019 , 15, 89-102	231
1185	Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults. 2019 , 266, 806-815	27
1184	Novel uses of retinal imaging with optical coherence tomography in multiple sclerosis. 2019 , 19, 31-43	32
1183	Circulating AQP4-specific auto-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat. 2019 , 137, 467-485	39
1182	Altered volume and microstructural integrity of hippocampus in NMOSD. 2019 , 28, 132-137	6
1181	Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody. 2019 , 76, 301-309	141
1180	Neurological update: MOG antibody disease. 2019 , 266, 1280-1286	95
1179	Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity. 2019 , 25, 1926-1936	27
1178	Clinical characteristics of 153 Brazilian patients with neuromyelitis optica spectrum disorder (NMOSD). 2019 , 27, 392-396	14
1177	Quantitative radiomic biomarkers for discrimination between neuromyelitis optica spectrum disorder and multiple sclerosis. 2019 , 49, 1113-1121	12
1176	Paraneoplastic neuromyelitis optica associated with fever of unknown origin as an early manifestation: A case report. 2019 , 27, 200-202	2
1175	Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis. 2019 , 25, 1907-1914	25
1174	MRI findings in pediatric neuromyelitis optica spectrum disorder with MOG antibody: Four cases and review of the literature. 2019 , 41, 367-372	4
1173	Acute epileptic seizures in myelin oligodendrocyte glycoprotein encephalomyelitis and neuromyelitis optica spectrum disorder: A comparative cohort study. 2019 , 27, 281-288	13
1172	AQP4 antibody-positive NMO spectrum disorder associated with Takayasu arteritis. 2019 , 396, 130-132	0
1171	Area postrema syndrome: A short history of a pearl in demyelinating diseases. 2019 , 25, 325-329	9
1170	Autoimmune diseases associated with Neuromyelitis Optica Spectrum Disorders: A literature review. 2019 , 27, 350-363	55
1169	Simultaneous bilateral optic neuritis in China: clinical, serological and prognostic characteristics. 2019 , 97, e426-e434	2

1168	Neuromyelitis optica: an elusive cause of dysphagia. 2019 , 12,	2
1167	Neuromyelitis optica spectrum disorder with area postrema syndrome. 2019 , 9, 173-175	2
1166	Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder. 2019 , 32, 111-114	5
1165	First clinical inflammatory demyelinating events of the central nervous system in a population aged over 70 years: A multicentre study. 2019 , 28, 309-312	7
1164	2 Optic Neuritis. 2019 ,	
1163	Incidence and timing of recurrence of optic neuritis. 2019 , 257, 651-655	
1162	Optic Neuritis as the Presenting Feature of Neuromyelitis Optica (NMO): Diagnosis and Management. 2019 , 11-22	
1161	Brain and cord imaging features in neuromyelitis optica spectrum disorders. 2019 , 85, 371-384	42
1160	Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study. 2019 , 266, 642-650	16
1159	Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options. 2019 , 79, 125-142	36
1158	Clinical course, treatment responses and outcomes in Chinese paediatric neuromyelitis optica spectrum disorder. 2019 , 28, 213-220	17
1157	Blockade of IL-6 signaling in neuromyelitis optica. 2019 , 130, 104315	24
1156	Sex differences in autoimmune disorders of the central nervous system. 2019 , 41, 177-188	54
1155	Neuromyelitis optica spectrum disorders (NMO-SD) in a Sub-Saharan Africa country: A preliminary study of sixteen Senegalese cases. 2019 , 27, 179-183	7
1154	Clinical spectrum of inflammatory central nervous system demyelinating disorders associated with antibodies against myelin oligodendrocyte glycoprotein. 2019 , 130, 104319	14
1153	Disruption of blood-brain barrier integrity associated with brain lesions in Chinese neuromyelitis optica spectrum disorder patients. 2019 , 27, 254-259	2
1152	The coexistence of recurrent cerebral tumefactive demyelinating lesions with longitudinally extensive transverse myelitis and demyelinating neuropathy. 2019 , 27, 223-225	2
1151	Clinical Characteristics of Anti-aquaporin 4 Antibody Positive Optic Neuritis in Japan. 2019 , 43, 71-80	4

1150	Multiple Sclerosis and Autoimmune Neurology of the Central Nervous System. 2019 , 103, 325-336	12
1149	Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations. 2019 , 19, 187-195	54
1148	Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models. 2019 , 27, 412-418	57
1147	Magnetic resonance imaging in enterovirus-71, myelin oligodendrocyte glycoprotein antibody, aquaporin-4 antibody, and multiple sclerosis-associated myelitis in children. 2019 , 61, 1108-1116	13
1146	Determination of Anti-aquaporin 5 Autoantibodies by Immunofluorescence Cytochemistry. 2019 , 1901, 79-87	1
1145	The prevalence and prognostic value of myelin oligodendrocyte glycoprotein antibody in adult optic neuritis. 2019 , 396, 225-231	24
1144	Imaging Approach to Myelopathy: Acute, Subacute, and Chronic. 2019 , 57, 257-279	16
1143	Motor neuron involvement in anti-Ma2-associated paraneoplastic neurological syndrome. 2019 , 266, 398-410	22
1142	The clinical and prognostic value of antinuclear antibodies in NMO-IgG seropositive neuromyelitis optica spectrum disorder. 2019 , 328, 1-4	11
1141	Headache in the course of multiple sclerosis: a prospective study. 2019 , 126, 131-139	2
1140	Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder. 2019 , 130, 104347	21
1139	Concurrence of juvenile idiopathic arthritis and primary demyelinating disease in a young child. 2019 , 27, 20-22	2
1138	Neuromyelitis optica spectrum disorder associated with Zika virus infection. 2019 , 9, e1-e3	10
1137	Inflammatory demyelinating diseases of the central nervous system in Niger. 2019 , 175, 261-268	6
1136	Radiomics Analysis of DTI Data to Assess Vision Outcome After Intravenous Methylprednisolone Therapy in Neuromyelitis Optic Neuritis. 2019 , 49, 1365-1373	10
1135	Resolution of inflammation in neuromyelitis optica spectrum disorders. 2019 , 27, 34-41	18
1134	Acute Disseminated Encephalomyelitis as a Complication of Scrub Typhus in Children. 2019 , 14, 264-266	3
1133	Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59. 2019 , 25, 523-531	5

1132	Neuromyelitis Optica Spectrum Disorder in a Patient With Systemic Lupus Erythematosus. 2019 , 25, 38-40	
1131	Evaluation of brain lesion distribution criteria at disease onset in differentiating MS from NMOSD and MOG-IgG-associated encephalomyelitis. 2019 , 25, 585-590	22
1130	Serum anti-John Cunningham virus antibody seroprevalence and index among Japanese patients with neuromyelitis optica spectrum disorders. 2020 , 26, 128-129	1
1129	Early predictors of epilepsy and subsequent relapse in children with acute disseminated encephalomyelitis. 2020 , 26, 333-342	20
1128	The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. 2020 , 26, 806-814	64
1127	Functional brain connectivity abnormalities and cognitive deficits in neuromyelitis optica spectrum disorder. 2020 , 26, 795-805	8
1126	Magnetic resonance imaging in immune-mediated myelopathies. 2020 , 267, 1233-1244	0
1125	Area postrema syndrome: Another feature of anti-GFAP encephalomyelitis. 2020 , 26, 253-255	8
1124	Brain and spinal MRI features distinguishing MS from different AQP4 antibody serostatus NMOSD at disease onset in a cohort of Latin American patients. 2020 , 26, 945-954	8
1123	Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study. 2020 , 26, 936-944	17
1122	Autonomic dysfunction in people with neuromyelitis optica spectrum disorders. 2020 , 26, 688-695	7
1121	Predictive value of conventional MRI parameters in first spinal attacks of neuromyelitis optica spectrum disorder. 2020 , 26, 468-475	5
1120	Serial Anti-Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes. 2020 , 77, 82-93	84
1119	The "central vein sign" in patients with diagnostic "red flags" for multiple sclerosis: A prospective multicenter 3T study. 2020 , 26, 421-432	21
1118	CNS inflammatory demyelinating disorders: MS, NMOSD and MOG antibody associated disease. 2020 , 68, 321-330	17
1117	Functional Connectivity Alterations in Neuromyelitis Optica Spectrum Disorder : Correlation with Disease Duration and Cognitive Impairment. 2020 , 30, 559-568	3
1116	Neuro-ophthalmic Disorders. 2020 ,	
1115	Differential diagnosis of multiple sclerosis and other inflammatory CNS diseases. 2020 , 37, 101452	21

1114	MOG-IgG myelitis coexisting with systemic lupus erythematosus in the post-partum setting. 2020 , 26, 997-1000	5
1113	Neuromyelitis optica spectrum disorders in Arabian Gulf (NMOAG); establishment and initial characterization of a patient registry. 2020 , 38, 101448	4
1112	MOG-IgG-associated demyelination: focus on atypical features, brain histopathology and concomitant autoimmunity. 2020 , 267, 359-368	12
1111	Optic neuritis in the era of biomarkers. 2020 , 65, 12-17	31
1110	Subclinical neurodegeneration in multiple sclerosis and neuromyelitis optica spectrum disorder revealed by optical coherence tomography. 2020 , 26, 1197-1206	21
1109	Angiotensin AT2 receptor-induced interleukin-10 attenuates neuromyelitis optica spectrum disorder-like pathology. 2020 , 26, 1187-1196	6
1108	Spinal cord involvement by atrophy and associations with disability are different between multiple sclerosis and neuromyelitis optica spectrum disorder. 2020 , 27, 92-99	13
1107	Frequency of autoimmune disorders and autoantibodies in European patients with neuromyelitis optica spectrum disorders. 2020 , 120, 223-225	8
1106	Lower serum interleukin-22 and interleukin-35 levels are associated with disease status in neuromyelitis optica spectrum disorders. 2020 , 26, 251-259	2
1105	Review: Recent advances in the understanding of the pathophysiology of neuromyelitis optica spectrum disorder. 2020 , 46, 199-218	22
1104	Room tilt illusion and persistent hiccups as presenting symptoms of a left PICA stroke: a case report. 2020 , 41, 469-471	2
1103	Therapeutic plasma exchange for neuromyelitis optica spectrum disorder: A multicenter retrospective study by the ASFA neurologic diseases subcommittee. 2020 , 35, 25-32	10
1102	Current Concepts in Ophthalmology. 2020 ,	
1101	Antibody response against HERV-W in patients with MOG-IgG associated disorders, multiple sclerosis and NMOSD. 2020 , 338, 577110	14
1100	Serum FAM19A5 in neuromyelitis optica spectrum disorders: Can it be a new biomarker representing clinical status?. 2020 , 26, 1700-1707	5
1099	Soluble CD146, a cerebrospinal fluid marker for neuroinflammation, promotes blood-brain barrier dysfunction. 2020 , 10, 231-246	15
1098	Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases. 2020 , 87, 256-266	58
1097	Retrospective study of the adverse events of the treatment for an acute attack of neuromyelitis optica spectrum disorder. 2020 , 24, 453-460	5

1096	Clinical, imaging and follow-up study of optic neuritis associated with myelin oligodendrocyte glycoprotein antibody: a multicentre study of 62 adult patients. 2020 , 27, 384-391	14
1095	A population-based epidemiological study of neuromyelitis optica spectrum disorder in Hungary. 2020 , 27, 308-317	16
1094	Autoimmune and Autoantibody-Associated Encephalomyelopathies. 2020 , 1067-1114	
1093	Somnolence Preceded the Development of a Subthalamic Lesion in Neuromyelitis Optica Spectrum Disorder. 2020 , 59, 577-579	0
1092	Neuromyelitis optica spectrum disorders in South of Tunisia: A rare entity with low seroprevalence of anti-aquaporin 4 autoantibodies. 2020 , 176, 261-267	3
1091	Therapeutic Plasma Exchange in Neuromyelitis Optica Spectrum Disorders and Related Disorders in Resource-Limited Settings: Outcomes in a Multiethnic Single-Center Population. 2020 , 24, 312-323	4
1090	Experimental animal models of aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorders: progress and shortcomings. 2020 , 30, 13-25	17
1089	Refining cell-based assay to detect MOG-IgG in patients with central nervous system inflammatory diseases. 2020 , 40, 101939	15
1088	Clinical features and prognosis of late-onset neuromyelitis optica spectrum disorders in a Latin American cohort. 2020 , 267, 1260-1268	19
1087	Diagnosis and management of central nervous system Sjögren's syndrome. 2020 , 189-209	
1086	Deciphering anti-MOG IgG antibodies: Clinical and radiological spectrum, and comparison of antibody detection assays. 2020 , 410, 116673	9
1085	The differential expression of natural killer cells in NMOSD and MS. 2020 , 71, 9-14	6
1084	Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders. 2019 , 39, 101920	24
1083	Does area postrema syndrome occur in myelin oligodendrocyte glycoprotein-IgG-associated disorders (MOGAD)? <i>Neurology</i> , 2020 , 94, 85-88	6.5 15
1082	Sexual dysfunction in patients with neuromyelitis optica spectrum disorder. 2020 , 338, 577093	14
1081	A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: Intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous ivmp and PLEX. 2020 , 38, 101506	22
1080	Detection of autoantibodies in central nervous system inflammatory disorders: Clinical application of cell-based assays. 2020 , 38, 101858	3
1079	Urinalysis in patients with neuromyelitis optica spectrum disorder. 2020 , 27, 619-625	1

1078	Subcortical structural abnormalities in female neuromyelitis optica patients with neuropathic pain. 2020 , 37, 101432	4
1077	Initiation of rituximab therapy for new onset neuromyelitis optica spectrum disorder during pregnancy. 2020 , 37, 101442	5
1076	Population-based Incidence of Pediatric and Adult Optic Neuritis and the Risk of Multiple Sclerosis. 2020 , 127, 417-425	17
1075	IRAK1 polymorphisms are associated with susceptibility to neuromyelitis optica spectrum disorder. 2020 , 37, 101438	1
1074	Scientific impact of multiple sclerosis and neuromyelitis optica spectrum disorder research from Southeast Asia: A bibliometric analysis. 2020 , 38, 101862	12
1073	HLA-G Ins/Del polymorphism and +3142C/G SNP are not related to neuromyelitis optica spectrum disorder (NMOSD) development, disability status or anti-aquaporin 4 presence in Brazilian patients. 2020 , 339, 577112	
1072	Neuromyelitis Optica Spectrum Disorder and Anti-Aquaporin 4 Channel Immunoglobulin in an Australian Pediatric Demyelination Cohort. 2020 , 35, 291-296	2
1071	A study on patients with neuromyelitis optica spectrum disorder from Eastern India. 2020 , 35, 22-28	4
1070	Dysbiosis of gut microbiota in patients with neuromyelitis optica spectrum disorders: A cross sectional study. 2020 , 339, 577126	12
1069	MOG-antibody-associated disease is different from MS and NMOSD and should be classified as a distinct disease entity - Commentary. 2020 , 26, 276-278	5
1068	NLRP3 level in cerebrospinal fluid of patients with neuromyelitis optica spectrum disorders: Increased levels and association with disease severity. 2019 , 39, 101888	5
1067	A diffuse large B cell lymphoma with clinical, imaging, and serologic characteristics of neuromyelitis optica spectrum disorder. 2020 , 61, 999-1001	0
1066	Neuromyelitis optica in patients with increased interferon alpha concentrations. 2020 , 19, 31-33	8
1065	Seropositive neuromyelitis optica spectrum disorder in Emirati patients: A case series. 2020 , 72, 185-190	0
1064	Kappa free light chains index in the differential diagnosis of Multiple Sclerosis from Neuromyelitis optica spectrum disorders and other immune-mediated central nervous system disorders. 2020 , 339, 577122	11
1063	Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis. 2020 , 33, 47-54	43
1062	Validation of claims-based diagnoses of adult and pediatric neuromyelitis optica spectrum disorder and variations in diagnostic evaluation and treatment initiation. 2020 , 37, 101488	3
1061	Reduced sarcolemmal aquaporin 4 expression can support the differential diagnosis of neuromyelitis optica spectrum disorders. 2020 , 339, 577121	1

1060	Central nervous system-specific antinuclear antibodies in patients with multiple sclerosis. 2020 , 409, 116619	1
1059	Prevalence and incidence of neuromyelitis optica spectrum disorder and multiple sclerosis in Korea. 2020 , 26, 1837-1844	14
1058	Quantitative brain lesion distribution may distinguish MOG-ab and AQP4-ab neuromyelitis optica spectrum disorders. 2020 , 30, 1470-1479	5
1057	Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence. 2020 , 7,	23
1056	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. 2020 , 38, 101868	15
1055	Secondary hypersomnia as an initial manifestation of neuromyelitis optica spectrum disorders. 2020 , 38, 101869	7
1054	The clinical value of the albumin quotient in patients with neuromyelitis optica spectrum disorder. 2020 , 38, 101880	0
1053	Investigating animal models of optic neuropathy: An accurate method for optic nerve and chiasm dissection in mice. 2020 , 331, 108527	
1052	Striking neurologic 18F-FDG PET/CT pattern in Devic's disease (neuromyelitis optica spectrum disorder). 2020 , 47, 511-512	3
1051	Effects of immunotherapies and prognostic predictors in neuromyelitis optica spectrum disorder: a prospective cohort study. 2020 , 267, 913-924	18
1050	Experience of Using Adrenocorticotrophic Hormone in the Treatment of Patients With Acute Neuromyelitis Optica Who Failed Systemic Steroids: A Case Series. 2020 , 43, 7-14	1
1049	Tacrolimus is effective for neuromyelitis optica spectrum disorders with or without anti-AQP4 antibody. 2019 , 39, 101907	5
1048	Update on neuromyelitis optica spectrum disorder. 2020 , 31, 462-468	9
1047	Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. 2020 , 10, 16727	8
1046	AQP4 autoantibodies in patients with idiopathic normal pressure hydrocephalus. 2020 , 349, 577407	0
1045	Elevated serum interleukin-39 levels in patients with neuromyelitis optica spectrum disorders correlated with disease severity. 2020 , 46, 102430	1
1044	Risk of relapse in patients with neuromyelitis optica spectrum disorder: Recognition and preventive strategy. 2020 , 46, 102522	4
1043	Double positivity for anti-N-methyl-d-aspartate receptor and anti-aquaporin-4 antibodies in a patient presenting with hypersomnolence, personality change, and reduced spontaneity. 2020 , 11, 53-56	

1042	Brain structural and functional alterations in MOG antibody disease. 2021 , 27, 1350-1363	5
1041	Presence of anti-neuronal antibodies in children with neurological disorders beyond encephalitis. 2020 , 28, 159-166	1
1040	Differential diagnosis in acute inflammatory myelitis. 2020 , 46, 102481	1
1039	Efficacy and safety of azathioprine for neuromyelitis optica spectrum disorders: A meta-analysis of real-world studies. 2020 , 46, 102484	2
1038	A case of area postrema syndrome associated with sick sinus syndrome in an elderly patient with neuromyelitis optica spectrum disorder: Case report. 2020 , 8, 183-185	1
1037	Genetic factors for susceptibility to and manifestations of neuromyelitis optica. 2020 , 7, 2082-2093	7
1036	Screening neuromyelitis optica patients for COVID-19 infection. 2020 , 19, 102669	7
1035	Isolated opsoclonus heralding neuromyelitis optica spectrum disorder. 2020 , 348, 577394	2
1034	Neuromyelitis optica spectrum disorder in China: Quality of life and medical care experience. 2020 , 46, 102542	8
1033	Experimental mouse model of NMOSD produced by facilitated brain delivery of NMO-IgG by microbubble-enhanced low-frequency ultrasound in experimental allergic encephalomyelitis mice. 2020 , 46, 102473	3
1032	Neuromyelitis optica. 2020 , 6, 85	77
1031	Etiologies of Acute Optic Neuritis in Thailand: An Observational Study of 171 Patients. 2020 , 14, 2935-2942	1
1030	Sequential intermittent therapeutic plasma exchange: A possible induction and maintenance therapy in the management of adult patients with neuromyelitis optica spectrum disorder. 2021 , 25, 513-532	4
1029	Therapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysis. 2021 , 268, 4549-4562	8
1028	A CD33 frameshift variant is associated with neuromyelitis optica spectrum disorders. 2020 ,	1
1027	Clinical characteristics of very late-onset neuromyelitis optica spectrum disorder. 2020 , 46, 102515	5
1026	Two cases of NMOSD with MRI findings mimicking CADASIL. 2020 , 46, 102532	2
1025	Central Sleep Apnea Syndrome Can Complicate Neuromyelitis Optica Spectrum Disorder: A Case Report. 2020 , 8, 547474	2

1024	Cognitive impairment in NMOSD-More questions than answers. 2020 , 10, e01842	8
1023	Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder. 2021 , 268, 4522-4536	16
1022	NMOSD acute attack: Understanding, treatment and innovative treatment prospect. 2020 , 348, 577387	7
1021	Off-label use of tocilizumab in neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases: A case-series. 2020 , 46, 102483	12
1020	Acute optic nerve lesions in first-ever NMOSD-related optic neuritis using conventional brain MRI: A Latin American multicenter study. 2020 , 46, 102558	2
1019	Research and progress on biomarkers of neuromyelitis optica spectrum disorders. 2021 , 41, 417-424	4
1018	White Matter Lesions in Adults - a Differential Diagnostic Approach. 2020 , 192, 1154-1173	2
1017	Population-Based Incidence of Optic Neuritis in the Era of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies. 2020 , 220, 110-114	13
1016	The Importance of Thiopurine S-Methyltransferase Gene Analysis Before Azathioprine Therapy. 2020 , 43, 112-113	0
1015	Neuromyelitis optica practice and prescribing changes in the setting of Covid19: A survey of neurologists. 2020 , 346, 577320	2
1014	Neuromyelitis optica spectrum disorder coexisting with ankylosing spondylitis: A case report. 2020 , 40, 101979	2
1013	Increased cerebrospinal fluid YKL-40 levels are associated with disease severity of neuromyelitis optica spectrum disorders. 2020 , 45, 102395	1
1012	Visual system damage and network maladaptation are associated with cognitive performance in neuromyelitis optica spectrum disorders. 2020 , 45, 102406	6
1011	Different alteration patterns of sub-macular choroidal thicknesses in aquaporin-4 immunoglobulin G antibodies sero-positive neuromyelitis optica spectrum diseases and isolated optic neuritis. 2020 , 98, 808-815	2
1010	Peroxiredoxins are involved in the pathogenesis of multiple sclerosis and neuromyelitis optica spectrum disorder. 2020 , 202, 239-248	3
1009	Higher Disease and Pain Severity and Fatigue and Lower Balance Skills Are Associated with Higher Prevalence of Falling among Individuals with the Inflammatory Disease of Neuromyelitis Optica Spectrum Disorder (NMOSD). 2020 , 9,	2
1008	Incidence of neuromyelitis optica spectrum disorder (NMOSD) in China: A national population-based study. 2020 , 2, 100021	10
1007	Assessment of mental health, knowledge, and attitude of patients with multiple sclerosis and neuromyelitis optica spectrum disorder in response to 2019 novel coronavirus. 2021 , 42, 2891-2901	6

1006	Neural Antibody Testing in Patients with Suspected Autoimmune Encephalitis. 2020 , 66, 1496-1509	15
1005	Clinical predictive factors for diagnosis of MOG-IgG and AQP4-IgG related paediatric optic neuritis: a Chinese cohort study. 2020 ,	0
1004	Male patients with neuromyelitis optica spectrum disorders: different clinical characteristics and worse steroid treatment response. 2021 , 42, 3267-3274	1
1003	Safety and efficacy of mycophenolate mofetil in treating neuromyelitis optica spectrum disorders: a protocol for systematic review and meta-analysis. 2020 , 10, e040371	2
1002	Acute Myelitis, Recurrent Optic Neuritis, and Seizures Over 17 Years. 2020 , 11, 541146	1
1001	Pregnancy and Neuromyelitis Optica Spectrum Disorder - Reciprocal Effects and Practical Recommendations: A Systematic Review. 2020 , 11, 544434	5
1000	Sleep disorders in autoimmune encephalitis. 2020 , 19, 1010-1022	23
999	Factors Associated with Changes in Retinal Layers Following Acute Optic Neuritis: A Longitudinal Study Using Optical Coherence Tomography. 2020 , 9,	1
998	Satralizumab for the Treatment of Neuromyelitis Optica Spectrum Disorders. 2021 , 55, 1167-1171	4
997	Multifocal visual evoked potential evaluation for diagnosis of acute optic neuritis and for prediction of visual outcome and ganglion cell layer thinning following optic neuritis. 2021 , 27, 1717-1726	
996	Predictive Factors of Resistance to High-Dose Steroids Therapy in Acute Attacks of Neuromyelitis Optica Spectrum Disorder. 2020 , 11, 585471	4
995	E.U. paediatric MOG consortium consensus: Part 1 - Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. 2020 , 29, 2-13	26
994	Neuromyelitis optica spectrum disorder: Do patients positive and negative for anti-aquaporin-4 antibodies present distinct entities? A Colombian perspective. 2020 ,	
993	Síndrome de Sjögren neuropsiquiátrico. 2020 , 27, 125-139	
992	Application of the 2015 neuromyelitis optica spectrum disorders diagnostic criteria in a cohort of Chinese patients. 2020 , 46, 102459	1
991	Application of 2015 Seronegative Neuromyelitis Optica Spectrum Disorder Diagnostic Criteria for Patients With Myelin Oligodendrocyte Glycoprotein IgG-Associated Disorders. 2020 , 77, 1572-1575	6
990	Effect of NMO-IgG on the interleukin-6 cascade in astrocytes via activation of the JAK/STAT3 signaling pathway. 2020 , 258, 118217	6
989	High-throughput investigation of molecular and cellular biomarkers in NMOSD. 2020 , 7,	6

988	Autoimmune and demyelinating optic neuritis. 2020 , 95, 386-395	
987	Eculizumab in the treatment of neuromyelitis optica spectrum disorder. 2020 , 12, 1053-1066	4
986	Seasonal variation in relapse of neuromyelitis optica spectrum disorders: A retrospective study in China. 2020 , 347, 577351	3
985	Differences in Clinical Features of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis in White and Asian Race. 2020 , 219, 332-340	5
984	Spinal Cord Atrophy in Neuromyelitis Optica Spectrum Disorders Is Spatially Related to Cord Lesions and Disability. 2020 , 297, 154-163	3
983	Hematopoietic Stem Cell Transplantation in Neuromyelitis Optica-Spectrum Disorders (NMO-SD): State-of-the-Art and Future Perspectives. 2020 , 21,	9
982	Inebilizumab: First Approval. 2020 , 80, 1259-1264	26
981	Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice. 2020 , 45, 102428	20
980	Understanding Pediatric Neuroimmune Disorder Conflicts: A Neuroradiologic Approach in the Molecular Era. 2020 , 40, 1395-1411	2
979	Low high-density lipoprotein cholesterol and high triglycerides lipid profile in neuromyelitis optica spectrum disorder: Associations with disease activity and disability. 2020 , 40, 101981	4
978	Painful tonic spasm in Chinese patients with neuromyelitis optica spectrum disorder: Prevalence, subtype, and features. 2020 , 45, 102408	6
977	Emerging drugs for the treatment of neuromyelitis optica. 2020 , 25, 285-297	9
976	Treatment and outcome of aquaporin-4 antibody-positive NMOSD: A multinational pediatric study. 2020 , 7,	15
975	Bilateral middle cerebellar peduncle lesions: Neuroimaging features and differential diagnoses. 2020 , 10, e01778	4
974	Is Fertility Affected in Women of Childbearing Age with Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorder?. 2020 , 70, 1829-1835	2
973	Neuroimmunologic disorders in pregnancy. 2020 , 172, 105-123	
972	Recent developments in MOG-IgG associated neurological disorders. 2020 , 13, 1756286420945135	21
971	Cytomegalovirus Infection in an Adult Patient With Neuromyelitis Optica and Acute Hemorrhagic Rectal Ulcer: Case Report and Literature Review. 2020 , 11, 1634	1

970	Intracranial dural arteriovenous fistula mimicking neuromyelitis optica spectrum disorder: A case report. 2020 , 29, 105007	
969	Conversion of Optic Neuritis to Relapsing Remitting Multiple Sclerosis: A Retrospective Comorbidity Cohort Study. 2020 , 83, 287-292	1
968	Differential Effects of MS Therapeutics on B Cells-Implications for Their Use and Failure in AQP4-Positive NMOSD Patients. 2020 , 21,	4
967	Native American ancestry significantly contributes to neuromyelitis optica susceptibility in the admixed Mexican population. 2020 , 10, 13706	8
966	Paramagnetic Rim Lesions are Specific to Multiple Sclerosis: An International Multicenter 3T MRI Study. 2020 , 88, 1034-1042	28
965	Serum level of IL-17n patients with inflammatory demyelinating disease: Marked upregulation in the early acute phase of MOG antibody associated disease (MOGAD). 2020 , 348, 577361	5
964	Is neuromyelitis optica without AQP4-IgG a T-cell mediated disease? insights from checkpoint inhibitor immune-related adverse events. 2020 , 46, 102451	4
963	Pediatric Demyelinating Disease: Emerging Patterns from Multiple Sclerosis to Anti-Myelin Oligodendrocyte Glycoprotein-Associated Encephalomyelitis. 2020 , 10, 139-151	2
962	Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis. 2020 , 8, 339	21
961	A rare case of short-lasting unilateral neuralgiform headache with conjunctival injection and tearing with progression to neuromyelitis optica spectrum disorder. 2020 , 48, 300060520964349	0
960	Ventral posterior nucleus volume is associated with neuropathic pain intensity in neuromyelitis optica spectrum disorders. 2020 , 46, 102579	5
959	Rituximab efficacy at different initial and maintenance doses in neuromyelitis optica spectrum disorder: Experience from a national health institute in Mxico. 2020 , 419, 117204	3
958	Differences in Advanced Magnetic Resonance Imaging in MOG-IgG and AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorders: A Comparative Study. 2020 , 11, 499910	8
957	Mimics of Optic Neuritis in Neuromyelitis Optica Spectrum Disorder: A Case Report. 2021 , 45, 334-338	
956	Recurrent Hypothalamic Dysfunction in Seropositive Neuromyelitis Optica.. 2021 , 11, e911-e912	
955	Lupus and NMOSD: The Blending of Humoral Autoimmunity. 2020 , 2020, 8820071	1
954	Serum levels of cell adhesion molecules in patients with neuromyelitis optica spectrum disorder. 2020 , 7, 1854-1861	1
953	Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients. 2020 , 17, 261	32

952	Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients. 2020 , 17, 262	18
951	Purified IgG from aquaporin-4 neuromyelitis optica spectrum disorder patients alters blood-brain barrier permeability. 2020 , 15, e0238301	7
950	Management Strategies of Patients with Neuromyelitis Optica Spectrum Disorder During the COVID-19 Pandemic Era. 2020 , 16, 759-767	4
949	Connexins in neuromyelitis optica: a link between astrocytopathy and demyelination. 2020 , 143, 2721-2732	8
948	Regulatory B Cells and Its Role in Central Nervous System Inflammatory Demyelinating Diseases. 2020 , 11, 1884	18
947	Metabolomic Profiling in Neuromyelitis Optica Spectrum Disorder Biomarker Discovery. 2020 , 10,	5
946	Brain MRI characteristics in neuromyelitis optica spectrum disorders: A large multi-center retrospective study in China. 2020 , 46, 102475	5
945	Post-infectious neurological disorders. 2020 , 13, 1756286420952901	12
944	Free light chains kappa can differentiate between myelitis and noninflammatory myelopathy. 2020 , 7,	6
943	Incidence of interattack asymptomatic brain lesions in NMO spectrum disorder. <i>Neurology</i> , 2020 , 95, e3124-e3128	6.5 9
942	Cortical Thinning and Ventricle Enlargement in Neuromyelitis Optica Spectrum Disorders. 2020 , 11, 872	2
941	Rapid Administration of High-Dose Intravenous Methylprednisolone Improves Visual Outcomes After Optic Neuritis in Patients With AQP4-IgG-Positive NMOSD. 2020 , 11, 932	10
940	Transverse myelitis associated with primary biliary cirrhosis: clinical, laboratory, and neuroradiological features. 2020 , 1-8	1
939	Gender issues of antibody-mediated diseases in neurology: (NMOSD/autoimmune encephalitis/MG). 2020 , 13, 1756286420949808	7
938	'Twenty syndrome' in neuromyelitis optica spectrum disorder. 2020 , 13,	1
937	MOG-IgG1 and co-existence of neuronal autoantibodies. 2021 , 27, 1175-1186	6
936	Multiple Sclerosis as a Syndrome-Implications for Future Management. 2020 , 11, 784	1
935	The Expanding Clinical Spectrum of Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Associated Disease in Children and Adults. 2020 , 11, 960	5

934	Distinct microglial and macrophage distribution patterns in the concentric and lamellar lesions in Baló disease and neuromyelitis optica spectrum disorders. 2020 , 30, 1144-1157	7
933	Area Postrema Syndrome: A Rare Feature of Chronic Lymphocytic Inflammation With Pontine Perivascular Enhancement Responsive to Steroids. 2020 , 11, 730	1
932	Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders. 2020 , 10, 13890	20
931	Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. 2020 , 7,	40
930	Alterations of the gut ecological and functional microenvironment in different stages of multiple sclerosis. 2020 , 117, 22402-22412	49
929	Clinical-radiological approach to nontraumatic myelopathy. 2020 , 62, 464-480	
928	Low Contrast Visual Acuity Might Help to Detect Previous Optic Neuritis. 2020 , 11, 602193	4
927	Optical Coherence Tomography Angiography (OCTA) in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. 2020 , 11, 604049	7
926	Evidence of subclinical quantitative retinal layer abnormalities in AQP4-IgG seropositive NMOSD. 2021 , 27, 1738-1748	9
925	Worldwide Incidence and Prevalence of Neuromyelitis Optica: A Systematic Review. <i>Neurology</i> , 2021 , 96, 59-77	6.5 26
924	Central Nervous System Demyelination Associated With Immune Checkpoint Inhibitors: Review of the Literature. 2020 , 11, 538695	9
923	3D Compressed Convolutional Neural Network Differentiates Neuromyelitis Optica Spectrum Disorders From Multiple Sclerosis Using Automated White Matter Hyperintensities Segmentations. 2020 , 11, 612928	3
922	Short report: assessment of coping strategies in patients with neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis. 2020 , 1-11	2
921	Naive B cells in neuromyelitis optica spectrum disorders: impact of steroid use and relapses. 2020 , 2, fcaa197	3
920	Atypical Neuromyelitis Optica Spectrum Disorder With Diffuse Cerebral Abnormalities: A Case Report. 2020 , 12, 1179573520973819	
919	Prognostic Factors for Visual Outcomes Following the First Episode of NMOSD-Related Optic Neuritis in Affected Eyes. 2020 , 14, 4271-4278	5
918	Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies. 2020 , 11, 778	12
917	E.U. paediatric MOG consortium consensus: Part 3 - Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. 2020 , 29, 22-31	11

916	Neuromyelitis optica spectrum disorder complicated with Sjögren's syndrome: first pediatric case responsive to mycophenolate mofetil treatment. 2021 , 121, 1065-1067	
915	Imagerie des pathologies non traumatiques du cordon mœdullaire et des espaces pœimœdullaires. 2020 , 3, 319-336	
914	Recurrent optic neuritis in a patient with Sjogren syndrome and neuromyelitis optica spectrum disorder: A case report. 2020 , 99, e23029	2
913	Seasonal variation of onset in patients with anti-aquaporin-4 antibodies and anti-myelin oligodendrocyte glycoprotein antibody. 2020 , 349, 577431	5
912	Antibody Testing in Atypical Optic Neuritis. 2020 , 35, 287-295	3
911	Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO). 2020 , 10, e035397	5
910	Clinical manifestations and imaging features of white matter demyelination in older patients. 2020 , 48, 300060520966806	1
909	Area postrema syndrome: a neurological presentation of nausea, vomiting and hiccups. 2020 , 13,	3
908	AQP4-IgG and MOG-IgG Related Optic Neuritis-Prevalence, Optical Coherence Tomography Findings, and Visual Outcomes: A Systematic Review and Meta-Analysis. 2020 , 11, 540156	24
907	Acute Disseminated Encephalomyelitis: Current Perspectives. 2020 , 7,	9
906	Moving beyond anti-aquaporin-4 antibodies: emerging biomarkers in the spectrum of neuromyelitis optica. 2020 , 20, 601-618	2
905	AQP4-IgG may cause muscle damage in patients with neuromyelitis optica spectrum disorder. 2020 , 42, 102126	1
904	Neuromyelitis optica spectrum disorder and active tuberculosis. 2020 , 13,	4
903	Serum albumin level is associated with the severity of neurological dysfunction of NMOSD patients. 2020 , 43, 102130	1
902	Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events. 2020 , 77, 937-946	37
901	Clinical, Radiological, and Laboratory Features of Spinal Cord Involvement in Primary Sjögren's Syndrome. 2020 , 9,	2
900	[Anti-myelin oligodendrocyte glycoprotein antibody-positive neurologic disease, manifested as clinical course of classical Devic's disease: A case report]. 2020 , 60, 219-222	
899	A Case of Multiple Sclerosis-Like Relapsing Remitting Encephalomyelitis Following Allogeneic Hematopoietic Stem Cell Transplantation and a Review of the Published Literature. 2020 , 11, 668	6

898	Perivenous demyelination: Association with anti-myelin oligodendrocyte glycoprotein antibody. 2020 , 11, 22-27	
897	Myelin oligodendrocyte glycoprotein immunoglobulin G-associated disease. 2020 , 11, 28-33	2
896	Precision therapy for neuromyelitis optica spectrum disorder: A retrospective analysis of the use of class-switched memory B-cells for individualised rituximab dosing schedules. 2020 , 43, 102175	4
895	NMOSD or GFAP astrocytopathy? A case report. 2020 , 43, 102202	4
894	Clinical and MRI correlates of autonomic dysfunction in neuromyelitis optica spectrum disorder. 2020 , 43, 102215	1
893	Dorsal midbrain involvement in MRI as a core clinical manifestation for NMOSD diagnosis. 2020 , 43, 102150	1
892	Altered resting-state functional connectivity density in patients with neuromyelitis optica-spectrum disorders. 2020 , 43, 102187	3
891	Pre-pregnancy, obstetric and delivery status in women with neuromyelitis optica spectrum disorder. 2020 , 44, 102252	0
890	Familial neuromyelitis optica spectrum disorder in a pair of sisters. 2020 , 113, 743-746	0
889	Evaluation of types of psychological disorders in patients with neuromyelitis optica spectrum disorder (NMOSD). 2020 , 42, 102128	4
888	Brain MRI features of Chinese Han patients with MOG-antibody disease. 2020 , 43, 102167	2
887	The Potential Immunoregulatory Roles of Vitamin D in Neuromyelitis Optica Spectrum Disorder. 2020 , 43, 102156	7
886	Proteomic profiles of major serum proteins in seropositive NMO patients alter after Rituximab treatment. 2020 , 11, 93-103	1
885	Correlation between serum levels of endothelin-1 and disease severity in patients with neuromyelitis optica spectrum disorders. 2020 , 225, 151959	0
884	Clinical and radiological profile of neuromyelitis optica spectrum disorders in an Ecuadorian cohort. 2020 , 44, 102208	2
883	Are aquaporin antibody titers useful outcome measures for neuromyelitis optica spectrum disorders?. 2020 , 7,	1
882	Myelin oligodendrocyte glycoprotein-associated disorders are associated with HLA subtypes in a Chinese paediatric-onset cohort. 2020 , 91, 733-739	6
881	Autoimmune hemolytic anemia, demyelinating relapse, and AQP1 antibodies after alemtuzumab infusion. 2020 , 7,	2

880	Different Exosomal microRNA Profile in Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorders. 2020 , 11, 1064	4
879	Spinal Cord Involvement in MS and Other Demyelinating Diseases. 2020 , 8,	7
878	The 2015 IPND Criteria Increases the Yield in Diagnosis of Neuromyelitis Optica Spectrum Disorder in Thai Patients Compared to the 2006 Diagnostic Criteria. 2020 , 43, 102218	1
877	The possible beneficial effects of higher vitamin B6 intake from diet on cognitive function of patients with neuromyelitis optica spectrum disorder. 2020 , 42, 102132	2
876	Unilateral Optic Neuritis in Children: Experience of a Tertiary Centre. 2020 , 83, 251-258	0
875	Radiological characteristics of neuromyelitis optica spectrum disorder in Kuwait. 2020 , 196, 106047	1
874	Optic neuropathy: A 15-year retrospective observational study. 2020 , 44, 102337	1
873	Characterization of pain syndromes in patients with neuromyelitis optica. 2020 , 24, 1548-1568	5
872	Characteristic of gut microbiota in southeastern Chinese patients with neuromyelitis optica spectrum disorders. 2020 , 44, 102217	2
871	Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases. 2020 , 7, 992-1001	10
870	Current and emerging therapeutics for neuromyelitis optica spectrum disorder: Relevance to the COVID-19 pandemic. 2020 , 44, 102249	14
869	Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica. 2020 , 11, 2856	24
868	The relationship between aquaporin-4 antibody status and visual tract integrity in neuromyelitis optica spectrum disorders: A visual evoked potential study. 2020 , 44, 102265	1
867	A comparative study on clinical characterizations between acute myelitis onset of neuromyelitis optica spectrum disease and idiopathic transverse myelitis. 2020 , 42, 612-617	2
866	Clinical commentary on the broadening spectrum of myelin oligodendrocyte glycoprotein-associated disorder (MOGAD). 2020 , 26, 1443-1444	0
865	Visualizing the Central Nervous System: Imaging Tools for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. 2020 , 11, 450	15
864	Tumefactive Demyelinating Lesions in Children: A Rare Case of Conus Medullaris Involvement and Systematic Review of the Literature. 2020 , 35, 690-699	4
863	A comparative evaluation of different neuromyelitis optica spectrum disorder sets of criteria. 2020 , 27, 2250-2256	0

862	The CSF Levels of Neutrophil-Related Chemokines in Patients with Neuromyelitis Optica. 2020 , 7, 1245-1251	2
861	Value of Area Postrema Syndrome in Differentiating Adults With AQP4 vs. MOG Antibodies. 2020 , 11, 396	9
860	Epidemiology of Pediatric NMOSD in Germany and Austria. 2020 , 11, 415	3
859	Bone health in neuromyelitis optica: Bone mineral density and fractures. 2020 , 42, 102080	1
858	Monoclonal Antibody-Based Treatments for Neuromyelitis Optica Spectrum Disorders: From Bench to Bedside. 2020 , 36, 1213-1224	6
857	Biotinidase deficiency in differential diagnosis of neuromyelitis optica spectrum disorder. 2020 , 44, 102280	2
856	Magnetic-Resonance Diffusion-Tensor Tractography in the Diagnosis of Tumefactive Spinal-Cord Lesions in Neuromyelitis Optica. 2020 , 10,	
855	Case Series: Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G-Related Disease Spectrum. 2020 , 11, 89	9
854	Different roles of soluble CD40 ligand in central nervous system damage. 2020 , 42, 372-378	2
853	Serum Systemic Autoantibodies in Anti-N-Methyl-D-Aspartate Receptor Encephalitis. 2020 , 11, 117	1
852	Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. 2020 , 19, 298-306	109
851	Old and new breakthroughs in neuromyelitis optica. 2020 , 19, 280-281	7
850	Intractable Hiccups due to Isolated Parainfectious Myelitis. 2020 , 11, 202-204	
849	Serum Synuclein and IL-1 β are increased and correlated with measures of disease severity in children with epilepsy: potential prognostic biomarkers?. 2020 , 20, 85	10
848	Imaging of Neuromyelitis Optica Spectrum Disorders. 2020 , 41, 319-331	0
847	Next-Generation Neuroimmunology: New Technologies to Understand Central Nervous System Autoimmunity. 2020 , 41, 341-354	7
846	Neuromyelitis-optica-Spektrum-Erkrankungen Alte und neue Entwicklungen. 2020 , 3, 43-58	
845	Brain magnetic resonance imaging features in multiple sclerosis and neuromyelitis optica spectrum disorders patients with or without aquaporin-4 antibody in a Latin American population. 2020 , 42, 102049	2

844	Comparison of Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis. 2020 , 16, 124-130	10
843	Changes in mitochondrial function in patients with neuromyelitis optica; correlations with motor and cognitive disabilities. 2020 , 15, e0230691	3
842	CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD. 2020 , 91, 605-611	8
841	Smelling the danger. 2020 , 26, 1960-1961	
840	Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders. 2020 , 20, 1061-1072	9
839	Acute Disseminated Encephalomyelitis followed by Optic Neuritis: A Rare Syndrome of Uncertain Treatment and Prognosis. 2020 , 51, 286-291	4
838	Evaluation of efficacy and tolerability of first-line therapies in NMOSD. <i>Neurology</i> , 2020 , 94, e1645-e1656.5	33
837	A Case of Primary Central Nervous System Lymphoma Mimic Neuromyelitis Optica. 2020 , 11, 28-33	
836	Refractory case of myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis with lumbosacral radiculitis. 2020 , 11, 126-130	3
835	The Detection of Retina Microvascular Density in Subclinical Aquaporin-4 Antibody Seropositive Neuromyelitis Optica Spectrum Disorders. 2020 , 11, 35	13
834	Aquaporin-4 immunoglobulin-G-positive neuromyelitis optica spectrum disorder associated with small cell lung carcinoma. 2020 , 55, e129-e132	1
833	Optic neuritis at disease onset predicts poor visual outcome in neuromyelitis optica spectrum disorders. 2020 , 41, 102045	6
832	RETRACTED: Retinal microvasculature alterations in neuromyelitis optica spectrum disorders before optic neuritis. 2020 , 44, 102277	1
831	Comparative Analysis of T-Cell Responses to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in Inflammatory Demyelinating Central Nervous System Diseases. 2020 , 11, 1188	4
830	Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation. 2020 , 11, 537	12
829	Cerebellar Neurocytoma with Excellent Response to Radiotherapy. 2020 , 141, 327-330	0
828	Retrospective Observation of Low-Dose Rituximab Treatment in Chinese Patients With Neuromyelitis Optica Spectrum Disorders in a Real-World Setting. 2020 , 11, 642	5
827	Relapsing Demyelinating Syndromes in Children: A Practical Review of Neuroradiological Mimics. 2020 , 11, 627	3

826	Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK. 2020 , 91, 1126-1128	20
825	Altered fovea in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders. 2020 , 7,	21
824	Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. 2020 , 11, 501	93
823	Safety and efficacy of plasma exchange for the treatment of optic neuritis in neuromyelitis optica spectrum disorders: A protocol for systematic review and meta-analysis. 2020 , 99, e21067	1
822	Intravenous immunoglobulin for acute attacks in neuromyelitis optica spectrum disorders (NMOSD). 2020 , 44, 102325	14
821	The impact of COVID-19 on patients with neuromyelitis optica spectrum disorder; a pilot study. 2020 , 45, 102347	5
820	Familial clustering of neuromyelitis optica and multiple sclerosis: clues pointing towards shared risks?. 2020 , 44, 102371	1
819	Evaluation of emotional intelligence (EI) in neuromyelitis optica spectrum disorder (NMOSD) patients compared to healthy individuals. 2020 , 45, 102387	
818	A case of possible atypical demyelinating event of the central nervous system following COVID-19. 2020 , 44, 102324	51
817	Myelin oligodendrocyte glycoprotein antibody associated central nervous system demyelinating disease: a tertiary center experience from Turkey. 2020 , 44, 102376	3
816	Cell-based assays for the detection of MOG antibodies: a comparative study. 2020 , 267, 3555-3564	14
815	The Development of New Diagnostic Tests for Neurologic Disorders in the Commercial Laboratory Environment. 2020 , 40, 331-339	
814	Multiple sclerosis with intractable vomiting and atypical area postrema lesion. 2020 , 45, 102348	2
813	Tumour-like presentation of atypical posterior reversible encephalopathy syndrome with prominent brainstem involvement. 2020 , 13,	1
812	Urinary Symptoms and Bladder Dysfunction in Patients with Neuromyelitis Optica Spectrum Disorders: Evaluation with Urodynamics and Management. 2020 , 11, 245-249	2
811	Environmental and genetic risk factors in the development of neuromyelitis optica. 2020 , 15, 1-9	7
810	Neuromyelitis optica spectrum disorder (NMOSD) with hypothalamic involvement and central nervous system tuberculosis: A case report. 2020 , 193, 105751	2
809	Overlapping Clinical Syndromes in Patients with Glial Fibrillary Acidic Protein IgG. 2020 , 27, 69-74	3

808	Neuromyelitis optica spectrum disorder with severe orthostatic hypotension due to hypothalamic lesions. 2020 , 40, 101977	2
807	Clinical features of transverse myelitis associated with systemic lupus erythematosus. 2020 , 29, 389-397	10
806	Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations. 2020 , 16, 154-170	37
805	Atypical myelitis in patients with multiple sclerosis: Characterization and comparison with typical multiple sclerosis and neuromyelitis optica spectrum disorders. 2021 , 27, 232-238	3
804	Update on Pediatric Optic Neuritis. 2020 , 20, 4	6
803	Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts. 2020 , 41, 102005	6
802	Diagnostic procedures in suspected attacks in patients with neuromyelitis optica spectrum disorders: Results of an international survey. 2020 , 41, 102027	6
801	Differentiate aquaporin-4 antibody negative neuromyelitis optica spectrum disorders from multiple sclerosis by multimodal advanced MRI techniques. 2020 , 41, 102035	3
800	Typique, atypique, vous avez dit n'rite optique?. 2020 , 11, 77-83	
799	Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. 2020 , 19, 234-246	86
798	White Matter Diseases. 2020 ,	1
797	Diseases of the Brain, Head and Neck, Spine 2020-2023. 2020 ,	4
796	MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation. 2020 , 267, 1632-1642	17
795	Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders. <i>Neurology</i> , 2020 , 94, e407-e418	6.5 23
794	Questioning the existence of monophasic neuromyelitis optica spectrum disorder by defining a novel long-term relapse-free form from a large Chinese population. 2020 , 267, 1197-1205	11
793	Repeated follow-up of AQP4-IgG titer by cell-based assay in neuromyelitis optica spectrum disorders (NMOSD). 2020 , 410, 116671	23
792	Evaluation of ethnicity as a predictor of diagnostic phenotype and prognosis in neuromyelitis optica spectrum disorder in Toronto, Canada. 2020 , 40, 101950	6
791	MRI differences between MOG antibody disease and AQP4 NMOSD. 2020 , 26, 1854-1865	35

790	[A case of neuromyelitis optica spectrum disorder with persistent nausea and repeated syncope]. 2020 , 60, 142-145	3
789	Trans-orbital sonography versus visual evoked potentials in acute demyelinating optic neuritis. 2020 , 40, 101934	0
788	Can a diagnosis of multiple sclerosis be made without ruling out neuromyelitis optica spectrum disorder ?. 2020 , 40, 101949	0
787	Role of Diffusional Kurtosis Imaging in Differentiating Neuromyelitis Optica-Related and Multiple Sclerosis-Related Acute Optic Neuritis: Comparison With Diffusion-Weighted Imaging. 2020 , 44, 47-52	1
786	Serum AQP4-IgG level is associated with the phenotype of the first attack in neuromyelitis optica spectrum disorders. 2020 , 340, 577168	7
785	Associations between HLA and autoimmune neurological diseases with autoantibodies. 2020 , 11, 2	30
784	Multiple sclerosis and neuromyelitis optica spectrum disorders in Argentina: comparing baseline data from the Argentinean MS Registry (RelevarEM). 2020 , 41, 1513-1519	12
783	Decreased mRNA Expressions of CD40L in Patients with Neuromyelitis Optica Spectrum Disorder. 2020 , 70, 610-617	1
782	The clinical profile of NMOSD in Australia and New Zealand. 2020 , 267, 1431-1443	12
781	Short segment myelitis as the initial and only manifestation of aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorders. 2020 , 13, 1756286419898594	5
780	Autoantibody Diagnostics in Neuroimmunology: Experience From the 2018 Italian Neuroimmunology Association External Quality Assessment Program. 2019 , 10, 1385	13
779	Near-fatal primary manifestation of anti-aquaporin 4-positive neuromyelitis optica spectrum disorder survived without neurological sequelae: A case report. 2020 , 412, 116797	
778	Current Advances in Pediatric Onset Multiple Sclerosis. 2020 , 8,	8
777	Longitudinal ultra-high field MRI of brain lesions in neuromyelitis optica spectrum disorders. 2020 , 42, 102066	2
776	Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder. 2020 , 80, 719-727	30
775	Dietary influence on central nervous system myelin production, injury, and regeneration. 2020 , 1866, 165779	9
774	Fever, nausea and vomiting, and CSF pleocytosis must be meningoencephalitis, right? No, think again!. 2020 , 194, 105813	1
773	Feasibility & safety of plasma exchange in paediatric neuro-immunology: A single center experience. 2020 , 27, 94-97	1

772	Risk factors of attacks in neuromyelitis optica spectrum disorders. 2020 , 343, 577236	11
771	Diagnostic and therapeutic issues of inflammatory diseases of the elderly. 2020 , 176, 739-749	1
770	Neuromyelitis Optica Spectrum Disorder Complicated by Posterior Reversible Encephalopathy Syndrome as an Initial Manifestation. 2020 , 59, 1887-1890	0
769	Different clinical characteristics of longitudinally extensive transverse myelitis with and without connective tissue disorders: a single-center retrospective study. 2020 , 41, 2859-2866	1
768	Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies. 2020 , 17, 128	5
767	Optic chiasm measurements may be useful markers of anterior optic pathway degeneration in neuromyelitis optica spectrum disorders. 2020 , 30, 5048-5058	4
766	High association of MOG-IgG antibodies in children with bilateral optic neuritis. 2020 , 27, 86-93	9
765	S1 guidelines "lumbar puncture and cerebrospinal fluid analysis" (abridged and translated version). 2020 , 2, 8	5
764	HLA association in MOG-IgG- and AQP4-IgG-related disorders of the CNS in the Dutch population. 2020 , 7,	22
763	Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. 2020 , 19, 402-412	137
762	Is Asian type MS an MS phenotype, an NMO spectrum disorder, or a MOG-IgG related disease?. 2020 , 42, 102082	6
761	Bilateral retinal pathology following a first-ever clinical episode of autoimmune optic neuritis. 2020 , 7,	4
760	Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. 2020 , 19, 391-401	95
759	Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options. 2020 , 20, 509-516	8
758	Outcome of pregnancies after onset of the neuromyelitis optica spectrum disorder. 2020 , 27, 1546-1555	8
757	Epidemiology of neuromyelitis optica spectrum disorder in Tehran, Iran: the prevalence, baseline characteristics, and clinical aspects. 2020 , 41, 2647-2648	6
756	Late-onset neuromyelitis optica spectrum disorder mimicking stroke in an elderly Chinese man: Case report. 2020 , 1-3	1
755	Acute anosmia in neuromyelitis optica spectrum disorder. 2020 , 26, 1958-1960	1

754	Cortical topological network changes following optic neuritis. 2020 , 7,	8
753	Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders: A prospective study. 2020 , 7,	28
752	Difference in fatigue and pain between neuromyelitis optica spectrum disorder and multiple sclerosis. 2020 , 15, e0224419	7
751	Comparison of macular structural and vascular changes in neuromyelitis optica spectrum disorder and primary open angle glaucoma: a cross-sectional study. 2021 , 105, 354-360	3
750	Diagnostic value of bright spotty lesions on MRI after a first episode of acute myelopathy. 2021 , 48, 28-36	12
749	Neuromyelitis optica associated with yellow fever vaccination. 2021 , 121, 567-569	2
748	[Copresence of myasthenia gravis and neuromyelitis optica: 2 case reports]. 2021 , 36, 174-176	
747	Pathogenesis of tissue injury in the brain in patients with systemic lupus erythematosus. 2021 , 341-348	2
746	Hemorrhagic encephalitis in a patient with neuromyelitis optica: A case report. 2021 , 44, 429-432	1
745	Spinal cord and brain MRI should be routinely performed during follow-up in patients with NMOSD - Commentary. 2021 , 27, 16-18	1
744	Spinal cord and brain MRI should be routinely performed during follow-up in patients with NMOSD - Yes. 2021 , 27, 13-15	
743	New therapies for neuromyelitis optica spectrum disorder. 2021 , 20, 60-67	37
742	Identification and measurement of cervical spinal cord atrophy in neuromyelitis optica spectrum disorders (NMOSD) and correlation with clinical characteristics and cervical spinal cord MRI data. 2021 , 177, 85-92	3
741	An update on epidemiology, diagnosis & management of NMO-SD in the tertiary neurology department of Marrakech (Morocco). 2021 , 177, 80-84	2
740	Mapping white matter damage distribution in neuromyelitis optica spectrum disorders with a multimodal MRI approach. 2021 , 27, 841-854	8
739	Imaging in Pediatric Multiple Sclerosis : An Iconographic Review. 2021 , 31, 61-71	
738	Evaluation of brain and spinal cord lesion distribution criteria at disease onset in distinguishing NMOSD from MS and MOG antibody-associated disorder. 2021 , 27, 871-882	7
737	Area postrema syndrome as initial manifestation in neuromyelitis optica spectrum disorder patients: A retrospective study. 2021 , 177, 400-406	2

736	Acute and subacute myelopathy. 2021 , 177, 557-566	1
735	Role of B Cells in Multiple Sclerosis and Related Disorders. 2021 , 89, 13-23	38
734	Satralizumab in the treatment of neuromyelitis optica spectrum disorder. 2021 , 11, 49-59	8
733	Clinical spectrum, treatment and outcome of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease in children: a tertiary care experience. 2021 , 121, 231-239	2
732	Could Galectin-3 be a key player in the etiology of neuromyelitis optica spectrum disorder?. 2021 , 146, 110450	1
731	MRI signs of CNS demyelinating diseases. 2021 , 47, 102665	3
730	Neuromyelitis optica spectrum disorders. 2021 , 420, 117225	7
729	A case of anti-aquaporin-4 antibody-positive optic neuritis treated by selective immunoadsorption. 2021 , 60, 102969	2
728	Neuromyelitis optica spectrum disorder: pregnancy-related attack and predictive risk factors. 2020 ,	3
727	Anti-MOG antibody-associated disorders: differences in clinical profiles and prognosis in Japan and Germany. 2020 ,	8
726	Myelitis in inflammatory disorders associated with myelin oligodendrocyte glycoprotein antibody and aquaporin-4 antibody: A comparative study in Chinese Han patients. 2021 , 28, 1308-1315	4
725	CD8 T cell subpopulations and pro-inflammatory cytokines in neuromyelitis optica spectrum disorder. 2021 , 8, 43-53	4
724	Cerebrospinal fluid lactate level in aquaporin-4 antibody positive neuromyelitis optica spectrum disorders: a hint on differential diagnosis and possible immunopathogenesis. 2021 , 47, 102629	
723	Patients with a relapsing course of steroid-responsive encephalopathy associated with autoimmune thyroiditis exhibit persistent intrathecal CD4+ T-cell activation. 2021 , 28, 1284-1291	0
722	Efficacy of plasma exchange in acute attacks of neuromyelitis optica spectrum disorders: A systematic review and meta-analysis. 2020 , 350, 577449	7
721	Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder. 2021 , 39, 35-49	9
720	is elevated in neuromyelitis optica spectrum disorder in India and shares sequence similarity with AQP4. 2021 , 8,	8
719	Multicentric clinical and epidemiological comparison of neuromyelitis optica spectrum disorder with multiple sclerosis from India. 2021 , 47, 102616	2

718	Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders. 2021 , 35, 7-17	6
717	Etiological spectrum, clinico-radiological profile and treatment outcomes of longitudinally extensive transverse myelitis - A prospective study from Northwest India. 2021 , 351, 577456	2
716	High serum neurofilament levels among Chinese patients with aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorders. 2021 , 83, 108-111	4
715	Epidemiological findings of neuromyelitis optica spectrum disorders in a Venezuelan study. 2021 , 47, 102652	2
714	Clinical and Radiological Characteristics of Neuromyelitis Optica Spectrum Disorder: The Experience from Saudi Arabia. 2021 , 47, 102668	1
713	Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders. 2021 , 48, 102683	1
712	Frequency of comorbidities in Neuromyelitis Optica spectrum disorder. 2021 , 48, 102685	3
711	An Autopsy Confirmed Neuromyelitis Optica Spectrum Disorder with Extensive Brain White Matter Lesion and Optic Neuritis but Intact Spinal Cord, Clinically Mimicking a Secondary Progressive Multiple Sclerosis-like Course. 2021 ,	
710	[Transverse myelitis syndrom as a result of neuromyelitis optica spectrum disorders, systemic lupus erythematosus and myasthenia gravis combination]. 2020 , 120, 97-106	2
709	NMO-Spektrum-Erkrankungen (NMOSE). 2020 , 1125-1138	
708	Longitudinal treatment responsiveness on plasma neurofilament light chain and glial fibrillary acidic protein levels in neuromyelitis optica spectrum disorder. 2021 , 14, 17562864211054952	3
707	Immunmedierte Erkrankungen des Nervensystems. 2020 , 37-87	
706	[Anti-NMDAR encephalitis associated with relapsing optic neuritis]. 2020 , 120, 105-113	
705	Neuromyelitis optica spectrum disorders in the Arabian Gulf: challenges and growing experience. 2020 , 6, 2055217319850195	0
704	Various MRI Findings of Toxocara canis Myelitis. 2020 , 81, 135	
703	[Actual issues of serum aquaporin-4 autoantibodies evaluation in the diagnostics of neuromyelitis optica spectrum disorders]. 2020 , 120, 24-31	3
702	[Comorbidity of neuromyelitis optica spectrum disorder and systemic lupus erythematosus]. 2020 , 120, 102-108	1
701	The Efficacy and Safety of Rituximab for the Treatment of Pediatric Autoimmune Neuroinflammatory Disorders at a Single Center. 2020 , 28, 30-36	0

- 700 Magnetic resonance imaging of intraocular optic nerve disorders: review article. **2020**, 85, e67-e81 3
- 699 Multiple Sklerose: Klinik. **2020**, 1073-1083
- 698 Diseases of the spinal cord. **2020**, 6127-6134
- 697 Demyelinating disorders of the central nervous system. **2020**, 6026-6042
- 696 Jaw clonus in neuromyelitis optica spectrum disorder with subsequent osmotic demyelination syndrome. **2020**, 9, 1209-1211 0
- 695 Anti-MOG Diseases. **2020**, 95-108
- 694 Association between Appendectomy and Demyelinating Disorders in Subjects 40 Years and Older. **2020**, 68, 850-855
- 693 A concise historical perspective of the area postrema structure and function. **2020**, 78, 121-123 0
- 692 Isolated Area Postrema Syndrome Presenting as Intractable Nausea and Vomiting. **2020**, 12, e7058 1
- 691 Neuromyelitis Optica Spectrum Disorders in Migrants. **2022**, 201-212
- 690 New BBB Model Reveals That IL-6 Blockade Suppressed the BBB Disorder, Preventing Onset of NMOSD. **2021**, 8, 3
- 689 Serum Aquaporin 4-Immunoglobulin G Titer and Neuromyelitis Optica Spectrum Disorder Activity and Severity: A Systematic Review and Meta-Analysis. **2021**, 12, 746959 0
- 688 The Human Eye Transcriptome Atlas: A Searchable Comparative Transcriptome Database for Healthy and Diseased Human Eye Tissue. 0
- 687 Gray Matter-Restricted Whole Spinal Cord Involvement in a Young Woman with SARS-CoV-2 Infection. **2021**, 1
- 686 Features of the diagnosis and treatment of patients with AQP-4-positive neuromyelitis optica and MOG antibody disease. **2021**, 16, 21-33
- 685 An optimal 1H-MRS technique at 7T: Proof-of-principle in Chronic Multiple Sclerosis and Neuromyelitis Optica Brain Lesions and Normal Appearing Brain Tissue. 0
- 684 Diagnostic features of initial demyelinating events associated with serum MOG-IgG. **2020**, 344, 577260
- 683 Neuromyelitis optica spectrum standstill in rheumatic systemic autoimmune diseases. **2020**, 47, 1

- 682 Diagnosekriterien bei Multipler Sklerose: ein Update. **2020**, 20, 343-359
- 681 Pruritus in neuromyelitis optica spectrum disorders and multiple sclerosis. **2020**, 79, 108-112 1
- 680 Clinical-radiological approach to nontraumatic myelopathy. **2020**, 62, 464-480
- 679 Contrasting the brain imaging features of MOG-Antibody disease, with AQP4- Antibody NMOSD and Multiple Sclerosis. 0
- 678 Efficacy and safety of rituximab in patients with refractory neuromyelitis optica spectrum disorders: A prospective observation in Iranian cases. **2020**, 11, 155-162 2
- 677 Rituximab in Neuromyelitis Optica Spectrum Disorders: Our Experience. **2017**, 20, 229-232 5
- 676 Radius and Ulna Stress Fractures in a Patient with Neuromyelitis Optica: A Case Report. **2017**, 7, 7-10 1
- 675 The pathologic and diagnostic in magnetic resonance imaging of brain and cervical spine of patients with neuromyelitis optica spectrum disorder. **2018**, 17, 58-63 1
- 674 Disability and Therapeutic Response in Paediatric Neuromyelitis Optica Spectrum Disorder: A Case Series from Iran. **2019**, 13, 99-104 0
- 673 Clinical and radiologic manifestation B-cell mediated autoimmune diseases of central nervous system. **2020**, 9, 28-40 1
- 672 [Clinical features of children with acute disseminated encephalomyelitis and related recurrence factors]. **2019**, 21, 223-228 1
- 671 A case report on the delayed diagnosis of transverse myelitis in a 61-year-old male farmer. **2020**, 64, 131-138 0
- 670 [Recurrence factors for myelin oligodendrocyte glycoprotein antibody disease in children and the effect of recurrence prevention regimens]. **2021**, 23, 724-729
- 669 Consensus recommendation on the use of therapeutic plasma exchange for adult neurological diseases in Southeast Asia from the Southeast Asia therapeutic plasma exchange consortium.. **2021**, 13, 11795735211057314 0
- 668 Pathobiology, Diagnosis, and Current Biomarkers in Neuromyelitis Optica Spectrum Disorders.. **2022**, 7, 305-310 1
- 667 Correlation of the symbol digit modalities test with the quality of life and depression in Japanese patients with multiple sclerosis. **2021**, 57, 103427
- 666 The Role of Pediatric Rheumatologists in Autoimmune Brain Disease. **2022**, 48, 343-369
- 665 Late-onset neuromyelitis optica spectrum disorder: A case series from Iran. **2021**,

- 664 Clinically Isolated Brainstem Progressive Multifocal Leukoencephalopathy: Diagnostic Challenges.. **2022**, 23, e935019 0
- 663 Chiasmatic lesions on conventional magnetic resonance imaging during the first event of optic neuritis in patients with neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein-associated disease in a Latin American cohort. **2021**, 1
- 662 Neuromyelitis optica spectrum disorder: a challenge in daily practice. **2021**, 82, 1-3
- 661 Post-COVID-19 longitudinally extensive transverse myelitis: is it a new entity?. **2021**, 1 1
- 660 [Neuroradiology for the Ophthalmologist]. **2021**,
- 659 Area postrema syndrome in neuromyelitis optica spectrum disorder: diagnostic challenges and descriptive patterns. **2021**, 57, 0
- 658 The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?. **2022**, 58, 103399 1
- 657 Comprehensive Analysis of N-Methyladenosine (m⁶A) Methylation in Neuromyelitis Optica Spectrum Disorders.. **2021**, 12, 735454
- 656 Effective Rituximab Treatment in Patients with Neuromyelitis Optica Spectrum Disorders Compared with Azathioprine and Mycophenolate. **2021**, 1 1
- 655 Imaging features to distinguish AQP4-positive NMOSD and MS at disease onset: A retrospective analysis in a single-center cohort.. **2021**, 146, 110063
- 654 Treatment response, risk of relapse and clinical characteristics of Taiwanese patients with neuromyelitis optica spectrum disorder. **2021**, 1
- 653 Safety and efficacy of interleukin-6-receptor inhibitors in the treatment of neuromyelitis optica spectrum disorders: a meta-analysis. **2021**, 21, 458 1
- 652 Approach to Common Visual Complaints Presenting to the Outpatient Neurologist. **2021**, 41, 699-716
- 651 Neuroradiologie für den Augenarzt. **2021**, 11, 375-399
- 650 Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease. **2021**, 1 0
- 649 Vaccination in neuromyelitis optica spectrum disorders: Friend or enemy?. **2022**, 58, 103394 4
- 648 Neuromyelitis Optica Spectrum Disorder With Hyponatremia as an Initial Presentation: A Case Report. **2021**, 0
- 647 Newly diagnosed neuromyelitis optica spectrum disorders following vaccination: Case report and systematic review.. **2022**, 58, 103414 3

- 646 Response to treatment in NMOSD: the Australasian experience.. **2022**, 58, 103408
- 645 Population-based incidence and clinico-radiological characteristics of tumefactive demyelination in Olmsted County, Minnesota, United States. **2021**, ○
- 644 Positive antithyroid antibody predicts severity of neuromyelitis optica spectrum disorder in children.. **2021**, 57, 103425 ○
- 643 Randomized Controlled Trials for Neuromyelitis Optica Spectrum Disorder: A Review of Trial Architecture. **2021**,
- 642 Successful treatment with 5-day oral 1 g/day methylprednisolone of optic neuritis and myelitis in AQP4 positive Neuromyelitis Optica: A report of two cases. **2021**, 1, 100045
- 641 The clinical application of critical flicker fusion frequency in demyelinating optic neuritis. **2021**, 1, 100011
- 640 Radiological Evidence of Myelitis in Neuromyelitis Optica Spectrum Disorder: Bright Spotty Lesions.. **2021**, 69, 1623 ○
- 639 Multiple Sclerosis-Minimizing Errors in Radiological Diagnosis.. **2021**, 69, 1539-1546 ○
- 638 Adverse events of rituximab in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis.. **2021**, 14, 17562864211056710 2
- 637 Optikusneuritis. **2021**, 105-112
- 636 Visual Evoked Potentials in Neuromyelitis Optica Spectrum Disorders.. **2021**, 13, 11795735211057315 ○
- 635 The German Multiple Sclerosis and Pregnancy Registry: rationale, objective, design, and first results. **2021**, 14, 17562864211054956 2
- 634 [Recurrent myelitis in a case of IgG4-related respiratory disease]. **2021**, 61,
- 633 Dysregulated B cell differentiation towards antibody-secreting cells in neuromyelitis optica spectrum disorder.. **2022**, 19, 6 ○
- 632 Clinico-epidemiological profile and outcome of pediatric neuromyelitis optica spectrum disorder at an eastern Indian tertiary care center. **2022**,
- 631 Comparative Study of Brain fMRI of Olfactory Stimulation in Neuromyelitis Optica Spectrum Disease and Multiple Sclerosis.. **2021**, 15, 813157
- 630 Free-water diffusion tensor imaging detects occult periependymal abnormality in the AQP4-IgG-seropositive neuromyelitis optica spectrum disorder.. **2022**, 12, 512
- 629 Clinical significance of anti-SSA/Ro antibody in Neuromyelitis optica spectrum disorders.. **2022**, 58, 103494 1

- 628 A comparison between subjective and objective measurements of spasticity in neuromyelitis optica spectrum disorder patients.. **2022**, 58, 103517
- 627 Half-and-half syndrome as the first manifestation of AQP4-positive neuromyelitis optica spectrum disorder. **2022**, 100064
- 626 Auditory evoked potentials in children and adolescents with multiple sclerosis and neuromyelitis optica spectrum disorders.. **2021**, 153, 111013 ○
- 625 New-onset Neuromyelitis Optica Spectrum Disorder in a Patient with COVID-19 and Chronic Hepatitis B Co-infection. **2022**, 100063 ○
- 624 Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.. **2021**, 363, 577790 ○
- 623 Platelet-to-lymphocyte ratio differs between MS and NMOSD at disease onset and predict disability.. **2022**, 58, 103507 ○
- 622 Prodromal emesis in MOG-antibody associated disorder.. **2021**, 58, 103463
- 621 Sparser macula microvasculature in neuromyelitis optica spectrum disorder occurs independently of optic neuritis.. **2021**, 58, 103470 ○
- 620 Optical coherence tomography angiography (OCTA) in differential diagnosis of aquaporin-4 antibody seronegative NMOSD and multiple sclerosis.. **2022**, 58, 103503 ○
- 619 Seasonal variation in attacks of neuromyelitis optica spectrum disorders and multiple sclerosis: Evaluation of 794 attacks from a nationwide registry in Argentina.. **2021**, 58, 103466 ○
- 618 Endocannabinoid system and cannabis hyperemesis syndrome: a narrative update. **2022**, 34, 1-8 ○
- 617 Relayed nuclear Overhauser effect weighted (rNOEw) imaging identifies multiple sclerosis. **2021**, 32, 102867 1
- 616 MOG and Aquaporin-4 Antibody Frequency, Clinical and MRI Characteristics, and Disease Course Among Children Diagnosed with MS and Controls.
- 615 Structural and functional markers of optic nerve damage in myelin oligodendrocyte glycoprotein antibody-associated optic neuritis.. **2021**, 7, 20552173211063126 ○
- 614 Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders. **2021**, 7, 20552173211052656 1
- 613 Neuromyelitis Optica Spectrum Disorder Presenting with Intractable Hiccups and Vomiting in a 16-Year-Old Girl. **2021**, 80, 239-242
- 612 Antibodies to Neural Cell Surface Antigens. **2022**, 135-166 ○
- 611 Vision Prognosis and Associated Factors of Optic Neuritis in Dependence of Glial Autoimmune Antibodies.. **2022**, ○

610	Sociodemographic and Illness-Related Indicators to Predict the Status of Neuromyelitis Optica Spectrum Disorder (NMOSD) Five Years after Disease Onset.. 2022 , 11,	1
609	Myopathies inflammatoires : de la SEP ^ la NMO. 2022 ,	
608	Paraneoplastic Neuromyelitis Optica Spectrum Disorder Associated With Lung Adenocarcinoma: A Case Report.. 2021 , 8, 743798	0
607	Pregnancy-Related Attack in Neuromyelitis Optica Spectrum Disorder With AQP4-IgG: A Single-Center Study and Meta-Analysis.. 2021 , 12, 800666	0
606	Incidence of neuromyelitis optica spectrum disorders in China: a large cohort study using claim data.. 2022 , 12, e048942	0
605	Aquaporin-4-Positive Triple-Negative Breast Cancer Presenting with Paraneoplastic Neuromyelitis Optica Spectrum Disorder.. 2022 , 7, 11-16	
604	Optic Nerve Lesion Length at the Acute Phase of Optic Neuritis Is Predictive of Retinal Neuronal Loss.. 2022 , 9,	3
603	Social participation and quality of life among patients with neuromyelitis optica spectrum disorders: The mediating effects of depression.. 2021 , 57, 103445	0
602	Acute Disseminated Encephalomyelitis and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. 2022 , 290-314	
601	Genetic disorders affecting the optic nerve. 2022 , 355-375	
600	Late-onset Neuromyelitis Optica Spectrum Disorder with Anti-AQP4 and Anti-MOG Antibodies.. 2021 ,	2
599	Association of subcortical structural shapes with fatigue in neuromyelitis optica spectrum disorder.. 2022 , 12, 1579	0
598	Frequently Asked Questions on Autoimmune Encephalitis and Related Disorders. 2022 , 630-655	0
597	Neuromyelitis Optica Spectrum Disorders and Glial Fibrillary Acidic Protein Autoimmunity. 2022 , 315-341	
596	Sleep and Autoimmunity. 2022 , 563-587	
595	Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Disease: CHANCE Study.. <i>Neurology</i> , 2022 ,	6.5 1
594	Possibilities of therapy for neuromyelitis optica spectrum disorders. 2022 , 16, 49-58	
593	The Blood-CSF-Brain Route of Neurological Disease: The Indirect Pathway into the Brain.. 2021 ,	0

592	Clonally Expanded B Cells in Multiple Sclerosis Bind EBV EBNA1 and GlialCAM.. 2022 ,	51
591	Serum molecular biomarkers in neuromyelitis optica and multiple sclerosis.. 2022 , 59, 103527	0
590	A Multisite and Multimodal Comparative Study of Cerebellar Connectome Between Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders.	
589	General Approach to Diagnosis. 2022 , 19-41	
588	Anti-aquaporin-4 immunoglobulin G colorimetric detection by silver nanoparticles.. 2022 , 102531	0
587	To treat or not to treat? A case of remote asynchronous bilateral optic neuritis with aquaporin-4 IgG seropositivity. 2022 , 2, 100069	
586	A prospective study on tryptophan immunoabsorption in AQP4 antibody-positive neuromyelitis optica spectrum disorders.. 2022 ,	0
585	Expression and Clinical Correlation Analysis Between Repulsive Guidance Molecule a and Neuromyelitis Optica Spectrum Disorders.. 2022 , 13, 766099	0
584	Incidence and risk factors for venous thromboembolism during an acute attack in patients with neuromyelitis optica spectrum disorders.. 2022 , 58, 103513	1
583	Quality of life of patients with multiple sclerosis and neuromyelitis optica spectrum disorders: Cross-sectional and longitudinal analysis.. 2022 , 58, 103500	1
582	Reduced GABA levels in the medial prefrontal cortex are associated with cognitive impairment in patients with NMOSD.. 2022 , 58, 103496	2
581	Clinical analysis of myelin oligodendrocyte glycoprotein antibody-associated demyelination in children: A single-center cohort study in China.. 2022 , 58, 103526	1
580	The Human Eye Transcriptome Atlas: A searchable comparative transcriptome database for healthy and diseased human eye tissue.. 2022 , 110286	2
579	Pediatric neuromyelitis optica spectrum disorders in Portugal: A multicentre retrospective study.. 2022 , 59, 103531	
578	Health-related quality of life in neuromyelitis optica spectrum disorder patients in an Argentinean cohort.. 2022 , 59, 103647	
577	Effective connectivity within the corticothalamic circuit in the neuromyelitis optica patients: A comparative study using resting-state fMRI.. 2022 , 97, 25-31	
576	Irregular degree centrality in neuromyelitis optica spectrum disorder patients with optic neuritis: A resting-state functional magnetic resonance imaging study.. 2022 , 59, 103542	0
575	Lower motor neuron involvement in patients with neuromyelitis optica spectrum disorders.. 2022 , 59, 103544	

574	Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): A systematic review and meta-analysis.. 2022 , 364, 577812	0
573	Complete Relief of Painful Tonic Seizures in Neuromyelitis Optica Spectrum Disorder by Satralizumab Treatment.. 2022 ,	0
572	CLINICAL CASE OF NEUROMYELITIS OPTICA SPECTRUM DISORDERS IN YOUNG WOMAN TREATED WITH RITUXIMAB. 2022 , 75, 132-137	0
571	A comparative analysis of clinical and imaging features of aquaporin 4 (AQP4) antibody positive, myelin oligodendrocyte glycoprotein (MOG) antibody positive and double seronegative subtypes of neuro myelitis optica spectrum disorder (NMOSD). 2022 ,	1
570	Comparison of clinical and radiological features of aquaporin4 (AQP-4) antibody positive neuromyelitis optica spectrum disorder (NMOSD) and anti myelin oligodendrocyte glycoprotein (Anti-MOG) syndrome-our experience from Northwest India. 2022 ,	1
569	Radiological characteristics of Neuromyelitis Optica Spectrum Disorder in Egypt.	
568	Posttranslational modifications of proteins are key features in the identification of CSF biomarkers of multiple sclerosis.. 2022 , 19, 44	2
567	Serum metabolic profiles and metal levels of patients with multiple sclerosis and patients with neuromyelitis optica spectrum disorders - NMR spectroscopy and ICP-MS studies.. 2022 , 60, 103672	
566	Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder. 2022 , 40, 15-21	
565	Centrally-located transverse myelitis would facilitate the differentiation of NMOSD and MOG-AD from MS.. 2022 , 60, 103664	
564	Clinical characteristics, sero- prevalence, treatment and outcomes of AQP4 IgG associated neuromyelitis optic spectrum disorder (NMOSD) in Sri Lanka.. 2022 , 59, 103663	
563	Relapsing neuromyelitis optica spectrum disorder. 2021 , 10, 269	
562	Results of a Survey on Diagnostic Procedures and Treatment Choices for Neuromyelitis Optica Spectrum Disorder in Korea: Beyond the Context of Current Clinical Guidelines.. 2022 , 18, 207-213	
561	A fatal disease hidden behind a common symptom: Neuromyelitis optica spectrum disorder. 2022 , 13, 124	
560	Emerging drugs for the acute treatment of relapses in adult neuromyelitis optica spectrum disorder patients.. 2022 , 27, 91-98	1
559	[A case of neuromyelitis optica spectrum disorders associated with primary biliary cholangitis: a twelve year follow-up study].. 2022 ,	0
558	Clinico-epidemiologic characteristics of optic neuritis in a tertiary eye centre in Eastern India based on the status of serum aquaporin-4 antibody.. 2022 , 70, 490-496	
557	An Update on the Laboratory Diagnosis of Neuromyelitis Optica Spectrum Disorders.. 2022 , 18, 152-162	

556 Multiple Sklerose. **2022**, 157-179

555 A Single-Health System Case Series of New-Onset CNS Inflammatory Disorders Temporally Associated With mRNA-Based SARS-CoV-2 Vaccines.. **2022**, 13, 796882 2

554 Longitudinal extensive transverse myelitis: A presentation of IgG4-related disease.

553 A Case of Neuromyelitis Optica: Puerto Rican Woman with an Increased Time Lag to Diagnosis and a High Response to Eculizumab Therapy.. **2022**, 2022, 4311382

552 Cell-Free DNA Derived From Neutrophils Triggers Type 1 Interferon Signature in Neuromyelitis Optica Spectrum Disorder.. **2022**, 9, 1

551 A new form of axonal pathology in a spinal model of neuromyelitis optica.. **2022**, 2

550 Pathological observations of a long spinal cord lesion in a patient with multiple sclerosis.. **2022**,

549 Risk Factors and Nomogram for Predicting Relapse Risk in Pediatric Neuromyelitis Optica Spectrum Disorders.. **2022**, 13, 765839 0

548 Sick sinus syndrome as the initial manifestation of neuromyelitis optica spectrum disorder: a case report.. **2022**, 22, 56

547 A Case With New-onset Neuromyelitis Optica Spectrum Disorder Following COVID-19 mRNA BNT162b2 Vaccination.. **2022**, 1

546 Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder: A Retrospective, Cross-sectional Analysis.. **2022**, 9, 2

545 Disrupted structural network of inferomedial temporal regions in relapsing-remitting multiple sclerosis compared with neuromyelitis optica spectrum disorder.. **2022**, 12, 5152

544 Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder treated with satralizumab in SAKuraSky: A case series.. **2022**, 61, 103772 1

543 The Role of Autoantibody Testing in Modern Personalized Medicine.. **2022**, 1 0

542 Magnetic Resonance Imaging of Autoimmune Demyelinating Diseases as a Diagnostic Challenge for Radiologists: Report of Two Cases and Literature Review.. **2022**, 12,

541 Association between dietary inflammatory index and risk of demyelinating autoimmune diseases.. **2022**, 0

540 Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models.. **2022**, 13, 873576 0

539 Neuromyelitis optica spectrum disorders associated with systemic sclerosis: a case report and literature review.. **2022**, 1 0

538	Female sexual dysfunction in newly diagnosed egyptian patients with neuromyelitis optica spectrum disorder.. 2022 , 22, 117	
537	Oligoclonal bands: clinical utility and interpretation cues.. 2022 , 1-14	0
536	Radiologically isolated aquaporin-4 antibody neuromyelitis optica spectrum disorder.. 2022 , 28, 676-679	2
535	Longitudinally Extensive Transverse Myelitis: One Disease, Variable OutcomesA Case Series.	
534	Sexual Dysfunction in Women with Neuromyelitis Optica Spectrum Disorders and Multiple Sclerosis. 1	0
533	Radiologically isolated syndrome and the possibility of preclinical disease activity in aquaporin-4 antibody NMOSD.. 2022 , 28, 679-680	0
532	Relationship between the Clinical Characteristics in Patients with Neuromyelitis Optica Spectrum Disorders and Clinical Immune Indicators: A Retrospective Study.. 2022 , 12,	0
531	Neuromyelitis Optica Spectrum Disorder in Central America and the Caribbean: A Multinational Clinical Characterization Study.. 2022 , 14, 284-293	0
530	Editorial: Antibody-Mediated Autoimmune Diseases of the CNS: Challenges and Approaches to Diagnosis and Management.. 2022 , 13, 844155	
529	Serum and Cerebrospinal Fluid Biomarkers in Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Associated Disease.. 2022 , 13, 866824	1
528	Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study.. 2022 , 19, 62	4
527	Clinical and prognostic aspects of patients with the Neuromyelitis Optica Spectrum Disorder (NMOSD) from a cohort in Northeast Brazil.. 2022 , 22, 95	0
526	Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD.. 2022 , 1	2
525	Lower urinary tract dysfunction in uncommon neurological diseases: A report of the neurourology promotion committee of the International Continence Society. 2022 , 1, 100022	
524	Mesenchymal Stem Cell-Derived Extracellular Vesicles and Their Therapeutic Use in Central Nervous System Demyelinating Disorders.. 2022 , 23,	0
523	Neuromyelitis Optica Spectrum Disorders (NMOSD). 1	1
522	Clinical Features and Imaging Findings of Myelin Oligodendrocyte Glycoprotein-IgG-Associated Disorder (MOGAD).. 2022 , 14, 850743	0
521	Multimodal magnetic resonance imaging quantification of gray matter alterations in relapsing-remitting multiple sclerosis and neuromyelitis optica spectrum disorder.. 2022 ,	0

520	Rapid Discrimination of Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis Using Machine Learning on Infrared Spectra of Sera.. 2022 , 23,	0
519	Clinical characteristics and clinical course of myelin oligodendrocyte glycoprotein antibody-seropositive pediatric optic neuritis.. 2022 , 60, 103709	0
518	Health utilities and costs for neuromyelitis optica spectrum disorder.. 2022 , 17, 159	2
517	Prevalence of neuromyelitis optica spectrum disorder in antioquia between 2016 and 2018.. 2022 , 60, 103677	
516	Adverse Events in NMOSD Therapy.. 2022 , 23,	3
515	Structural visual metrics associate with moderate to vigorous physical activity in youth with pediatric onset neuroinflammatory disorders.. 2022 , 60, 103745	
514	Therapeutic plasma exchange for optic neuritis attacks in patients with neuromyelitis optica spectrum disorders.. 2022 ,	1
513	Experiences of social isolation among patients with neuromyelitis optica spectrum disorder in China: A qualitative study.. 2022 , 60, 103711	0
512	Caspr2 antibodies in herpes simplex encephalitis: an extension of the spectrum of virus induced autoimmunity? - A case report.. 2022 , 22, 131	0
511	Longitudinal evaluation of clinical characteristics of Chinese neuromyelitis optica spectrum disorder patients with different AQP4-IgG serostatus.. 2022 , 62, 103786	
510	A point-of-care diagnostic test for aquaporin-4 antibody seropositive neuromyelitis optica.. 2022 , 60, 103716	1
509	Neuromyelitis optica spectrum disorder in Western Mexico.. 2022 , 61, 103733	
508	Efficacy and safety of rehabilitation exercise in neuromyelitis optica spectrum disorder during the acute phase: A prospective cohort study.. 2022 , 61, 103726	0
507	Microstructural white matter abnormalities in multiple sclerosis and neuromyelitis optica spectrum disorders: Evaluation by advanced diffusion imaging.. 2022 , 436, 120205	0
506	Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders. 2022 , 9,	7
505	Opticoneuromyelitis associated with melanoma. Case report. 2021 , 23, 884-890	
504	Distinct Immunological Features of Inflammatory Demyelinating Diseases of the Central Nervous System. 2021 , 1-11	1
503	Prevalence and direct costs of patients with neuromyelitis optica: data from Campania region in southern Italy. 2021 , 1,	0

502	Altered Microstructure of Cerebral Gray Matter in Neuromyelitis Optica Spectrum Disorder-Optic Neuritis: A DKI Study.. 2021 , 15, 738913	
501	Functional impairment of CD19CD24CD38 B cells in neuromyelitis optica spectrum disorder is restored by B cell depletion therapy.. 2021 , 13, eabk2132	0
500	Can Immune Tolerance Be Re-established in Neuromyelitis Optica?. 2021 , 12, 783304	
499	Evaluating the Economic Burden of Relapses in Neuromyelitis Optica Spectrum Disorder: A Real-World Analysis Using German Claims Data.. 2021 , 11, 247	0
498	Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder. 2021 , 4, e2137833	3
497	Immunoabsorption and plasma exchange-Efficient treatment options for neurological autoimmune diseases.. 2021 ,	4
496	Pediatric Neuromyelitis Optica Spectrum Disorder: Case Series and Literature Review.. 2021 , 12,	0
495	Imaging aspect of neuromyelitis optica: a case report and review of the literature. 2021 , 5, 034-036	
494	Case Report: Clinical and Imaging Characteristics of a Patient with Anti-flotillin Autoantibodies: Neuromyelitis Optica or Multiple Sclerosis?. 2021 , 12, 808420	0
493	Association Analysis Between HLA-DQA1 Loci and Neuromyelitis Optica Spectrum Disorder in a Han Chinese Population. 2021 ,	
492	Lymphocyte Subsets Are Associated with Disease Status in Neuromyelitis Optica Spectrum Disorders.. 2021 , 1-10	0
491	Differences in the involved sites among different types of demyelinating optic neuritis in traditional MRI examination: A systematic review and meta-analysis. 2021 , 1, 100019	1
490	A Missed Case of Area Postrema Syndrome Presenting with Neuromyelitis Optica Spectrum Disorder.. 2022 , 23, e934649	
489	Atypical Multiple Sclerosis Presenting as Bilateral Optic Neuritis. 2021 , 20, 182-188	
488	A Comparison of IgG Index and Oligoclonal Band in the Cerebrospinal Fluid for Differentiating between RRMS and NMOSD.. 2021 , 12,	1
487	Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy Associated With Area Postrema Syndrome: A Case Report.. 2021 , 12, 803116	1
486	Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment.. 2021 , 36, 45	2
485	Quantitative Susceptibility Mapping-Derived Radiomic Features in Discriminating Multiple Sclerosis From Neuromyelitis Optica Spectrum Disorder.. 2021 , 15, 765634	0

484 Oligodendrocyte: Structure, Function and Pathology. **2022**, 45-73

483 [A case report of neuromyelitis optica spectrum disorder with lesions of the medulla oblongata].. **2022**, 122, 121-125

482 Long-Term Visual Prognosis in Patients With Aquaporin-4-Immunoglobulin G-Positive Neuromyelitis Optica Spectrum Disorder.. **2022**,

481 In utero exposure to maternal anti-aquaporin-4 antibodies alters brain vasculature and neural dynamics in male mouse offspring.. **2022**, 14, eabe9726

480 Spinal Dural Arteriovenous Fistula: A Mimic of Demyelinating Disease and Radiculopathy.. **2022**, 14, e24134

479 Fractional anisotropy helps to differentiate the optic nerve impairment between neuromyelitis optica spectrum disorders and multiple sclerosis.. **2022**, 1

478 Aquaporin-4 in Neuromyelitis Optica Spectrum Disorders: A Target of Autoimmunity in the Central Nervous System.. **2022**, 12,

477 The Contribution of Neuropathology to Multiple Sclerosis Research.. **2022**,

476 Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSD.. **2022**,

475 Efficacy and safety of azathioprine, mycophenolate mofetil and reduced dose of rituximab in neuromyelitis optica spectrum disorder.. **2022**,

474 Relatively Early and Late-Onset Neuromyelitis Optica Spectrum Disorder in Central China: Clinical Characteristics and Prognostic Features.. **2022**, 13, 859276

473 Pain Symptoms in Optic Neuritis.. **2022**, 3, 865032

472 CSF GFAP levels in double seronegative neuromyelitis optica spectrum disorder: no evidence of astrocyte damage.. **2022**, 19, 86

471 image_1.PDF. **2018**,

470 Table_1.DOCX. **2020**,

469 Data_Sheet_1.docx. **2019**,

468 Table_1.docx. **2019**,

467 Data_Sheet_1.PDF. **2020**,

466 Data_Sheet_2.PDF. 2020,

465 Image_1.TIF. 2020,

464 Image_10.TIF. 2020,

463 Image_2.TIF. 2020,

462 Image_3.TIF. 2020,

461 Image_4.TIF. 2020,

460 Image_5.TIF. 2020,

459 Image_6.TIF. 2020,

458 Image_7.TIF. 2020,

457 Image_8.TIF. 2020,

456 Image_9.TIF. 2020,

455 Table_1.docx. 2020,

454 Table_2.docx. 2020,

453 Table_1.DOCX. 2020,

452 Table_2.DOCX. 2020,

451 Image_1.jpg. 2019,

450 Image_2.jpg. 2019,

449 Image_3.jpg. 2019,

448 Table_1.docx. **2019**,

447 Table_2.docx. **2019**,

446 Table_3.docx. **2019**,

445 Table_4.docx. **2019**,

444 Table_5.docx. **2019**,

443 data_sheet_1.PDF. **2018**,

442 data_sheet_2.PDF. **2018**,

441 data_sheet_3.PDF. **2018**,

440 table_1.PDF. **2018**,

439 Presentation_1.PPTX. **2018**,

438 presentation_1.PDF. **2018**,

437 Data_Sheet_1.docx. **2019**,

436 Table_1.docx. **2019**,

435 Table_1.DOCX. **2018**,

434 Table_2.DOCX. **2018**,

433 Table_1.DOCX. **2020**,

432 Image_1.JPEG. **2020**,

431 Table_1.XLSX. **2019**,

430 Table_1.DOCX. **2020**,

429 Table_1.docx. **2018**,

428 Data_Sheet_1.doc. **2018**,

427 Data_Sheet_2.docx. **2018**,

426 Image_1.JPEG. **2018**,

425 Image_2.JPEG. **2018**,

424 Image_3.JPEG. **2018**,

423 Image_4.JPEG. **2018**,

422 Image_5.JPEG. **2018**,

421 Image_6.JPEG. **2018**,

420 Table_1.XLSX. **2020**,

419 Table_1.XLSX. **2020**,

418 Table_1.DOCX. **2019**,

417 Table_1.DOCX. **2020**,

416 Data_Sheet_1.docx. **2019**,

415 Increased Intracranial Pressure on a Patient with Neuromyelitis Optica Spectrum Disorder. **2021**, 12, S435-S438

414 INFLUENCE OF PREGNANCY ON NEUROMYELITIS OPTICA FROM AN OPHTHALMOLOGICAL POINT OF VIEW. A CASE REPORT.. **2022**, 78, 31-34

413 Immunopathogenesis of acute disseminated encephalomyelitis. **2022**, 249-263

- 412 [Seroconversion of anti-aquaporin-4 antibody in a patient with neuromyelitis optica spectrum disorder: a case report].. **2022**, ○
- 411 Optic Neuritis. **2022**, 4505-4533
- 410 Optic Neuritis in the Era of NMOSD and MOGAD: A Survey of Practice Patterns in Singapore.. **2022**, 11, 184-195 1
- 409 Human Umbilical Cord Mesenchymal Stem Cells to Treat Neuromyelitis Optica Spectrum Disorder (hUC-MSC-NMOSD): A Study Protocol for a Prospective, Multicenter, Randomized, Placebo-Controlled Clinical Trial.. **2022**, 13, 860083 1
- 408 Low Contrast Visual Evoked Potentials for Early Detection of Optic Neuritis.. **2022**, 13, 804395
- 407 Case Report: Interferon-Alpha-Induced Neuromyelitis Optica Spectrum Disorder.. **2022**, 13, 872684 ○
- 406 ABCB1 gene polymorphisms impact the effect of high-dose intravenous methylprednisolone therapy on optic neuritis associated with AQP4-IgG-positive neuromyelitis optica spectrum disorder.. **2022**,
- 405 Clinical Characteristics and Outcomes of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder With Brainstem Lesions as Heraldng Prodrome. **2022**, 13, ○
- 404 Late onset neuromyelitis optica spectrum disorders (LONMOSD) from a nationwide Portuguese study: anti-AQP4 positive, anti-MOG positive and seronegative subgroups. **2022**, 103845
- 403 N-Methyl-D-Aspartate (NMDA)-Type Glutamate Receptors and Demyelinating Disorders: A Neuroimmune Perspective.. **2022**,
- 402 Cell-based flow cytometry assay for simultaneous detection of multiple autoantibodies in a single serum sample.. **2022**, 114721
- 401 Factors Influencing Social Participation Among Persons With Neuromyelitis Optica Spectrum Disorders: A Cross-Sectional Study. **2022**, 13,
- 400 Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients' Perspective: An Observational Cross-Sectional Study.. **2022**,
- 399 Comparison of Long-Term Use of Low Dose Rituximab and Mycophenolate Mofetil in Chinese Patients With Neuromyelitis Optica Spectrum Disorder. **2022**, 13,
- 398 Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder. **2022**, 12, 743 ○
- 397 A Rare Case of Neuromyelitis Optica Spectrum Disorders With Unknown Fever and Subacute Cognitive Decline With Normal Images. **2022**,
- 396 Overlapping anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis with neuromyelitis optica spectrum disorders: a case report.. **2022**, 27, 66
- 395 Follow-up of retinal thickness and optic MRI after optic neuritis in anti-MOG antibody-associated disease and anti-AQP4 antibody-positive NMOSD.. **2022**, 437, 120269 ○

- 394 Is there a link between neuropathic pain and constipation in NMOSD and MOGAD? Results from an online patient survey and possible clinical implications.. **2022**, 63, 103825 ○
- 393 Development and validation of a simple and practical method for differentiating MS from other neuroinflammatory disorders based on lesion distribution on brain MRI.. **2022**, 101, 32-36 ○
- 392 Comparison of neutrophil-to-lymphocyte ratio between myelin oligodendrocyte glycoprotein antibody-associated disease and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders in adults.. **2022**, 101, 89-93 ○
- 391 Association of Pain with Plasma C5a in Patients with Neuromyelitis Optica Spectrum Disorders During Remission. Volume 18, 1039-1046 ○
- 390 The Efficacy and Safety of Mycophenolate Mofetil in Thai Neuromyelitis Optica Spectrum Disorder Patients. **2022**, 103882 ○
- 389 MR T2-relaxation time as an indirect measure of brain water content and disease activity in NMOSD.. **2022**,
- 388 The clinical spectrum of haemorrhagic CNS inflammatory demyelinating lesions.. **2022**, 13524585221094241
- 387 Severe disease exacerbation after mRNA COVID-19 vaccination unmasks suspected multiple sclerosis as neuromyelitis optica spectrum disorder: a case report.. **2022**, 22, 185 1
- 386 Clinical and Radiological Features of Myelin Oligodendrocyte Glycoprotein-Associated Myelitis in Adults.. **2022**, 18, 280-289
- 385 Anti-AQP4-IgG-positive neuromyelitis optica spectrum disorder presenting as aseptic meningitis following EpsteinBarr virus infection. **2022**, 2, 100103
- 384 A Case of Late-Onset Neuromyelitis Optica Spectrum Disorder Associated With Cryptogenic Organizing Pneumonia. **2022**, 15, 117954762211005 ○
- 383 Exploring the risk factors and prognosis of transverse myelitis in systemic lupus erythematosus. **2022**, 13, 204062232210973 ○
- 382 Sudomotor dysfunction in people with neuromyelitis optica spectrum disorders. ○
- 381 Le croiseur fait coulé. **2022**,
- 380 Neuromylite optique : d'Éugène Devic au concept de gliopathies auto-immunes. **2022**,
- 379 Bilateral parafalcine cortical and leptomenigeal impairment: A characteristic pattern of MOG antibody disease and AQP4 neuromyelitis optica spectrum disorders?. **2022**, 577898 ○
- 378 A quarter-century report on neuromyelitis optica spectrum disorder in Thailand: A single-center tertiary care cohort. **2022**, 63, 103907 ○
- 377 Immuno-pathogenesis of neuromyelitis optica and emerging therapies. ○

- 376 Naïve B cells followed by aquaporin-4 antibodies characterise the onset of neuromyelitis optica: evidence from stem cell transplantation. *jnnp-2022-328982* ○
- 375 Immunosuppressant and Neuromyelitis Optica Spectrum Disorder: Optimal Treatment Duration and Risk of Discontinuation. 1
- 374 Testing for Antibodies Against Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in the Diagnosis of Patients With Suspected Autoimmune Myelopathy. **2022**, 13, ○
- 373 Efficacy and safety of monoclonal antibodies in neuromyelitis optica spectrum disorders: A survival meta-analysis of randomized controlled trials. **2022**, 100064
- 372 Case Report: Neuromyelitis Optica Spectrum Disorder With Progressive Elevation of Cerebrospinal Fluid Cell Count and Protein Level Mimicking Infectious Meningomyelitis: A Diagnostic Challenge. **2022**, 13,
- 371 Neuromyelitis optica spectrum disorder: do patients positive and negative for anti-aquaporin-4 antibodies present distinct entities? A Colombian perspective. **2022**,
- 370 Clinical and Paraclinical Profile of Neuromyelitis Optic Spectrum Disorder in a Peruvian Cohort. **2022**, 103919
- 369 Seroprevalence of MOG and AQP4 antibodies and outcomes in an Indian cohort of Pediatric Acquired Demyelinating Syndromes.
- 368 MRI EVALUATION OF PERIVASCULAR SPACE ABNORMALITIES IN NEUROMYELITIS OPTICA. ○
- 367 Nitrous oxide and cervical myelopathy. **2022**, 51, 321-323 ○
- 366 Differenzialdiagnose der zervikalen Myelitis. **2022**, 22, 137-155
- 365 NMO-IgG induce interleukin-6 release via activation of the NF- κ B signaling pathway in astrocytes. **2022**, 1
- 364 Seizures and epilepsy in multiple sclerosis, aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease. ○
- 363 Autoimmune/Inflammatory syndrome induced by adjuvants (ASIA): Neuromyelitis optica spectrum disorder after BBIBP-Cor-V vaccine, case report. **2022**, 2, 100107
- 362 Changes Within H3K4me3-Marked Histone Reveal Molecular Background of Neutrophil Functional Plasticity. 13,
- 361 Protocol for the treatment of patients with a spectrum of opiomyelitis-associated diseases using bone marrow stromal cells in the State Institution "Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Sciences of Ukraine". **2022**, 75-79
- 360 Acute myocardial infarction risk in multiple sclerosis and neuromyelitis optica spectrum disorder: A nationwide cohort study in South Korea. 135245852210969 ○
- 359 A Comparison of Pediatric- and Adult-Onset Aquaporin-4 Immunoglobulin G Positive Neuromyelitis Optica Spectrum Disorder: A Review of Clinical and Radiographic Characteristics. 088307382211030

- 358 Transformer-Based Deep-Learning Algorithm for Discriminating Demyelinating Diseases of the Central Nervous System With Neuroimaging. 13,
- 357 Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. 13, 3
- 356 Tuberculous myelitis: a prospective follow-up study.
- 355 Antibody-Positive Neuromyelitis Optica Spectrum Disorder After Second COVID-19 Vaccination: a Case Report. 2022, 4, 1
- 354 Neuromyelitis Optica Spectrum Disorder and Autoimmune Rheumatological Diseases: A Report of Two Cases and Literature Review. 2022,
- 353 Frequency of Asymptomatic Optic Nerve Enhancement in a Large Retrospective Cohort of Patients With Aquaporin-4+ NMOSD. *Neurology*, 10.1212/WNL.0000000000200838 6.5 0
- 352 Sarcoidosis presenting as bilateral optic neuritis after ChAdOx1 nCoV-19 vaccination. 0
- 351 Cross-syndrome: myasthenia gravis and the demyelinating diseases of the central nervous system combination. Systematic literature review and case reports.
- 350 Altered non-coding RNA profiles and potential disease marker identification in peripheral blood mononuclear cells of patients with NMOSD. 2022, 109, 108899 0
- 349 Disease Course and Outcomes in Patients With the Limited Form of Neuromyelitis Optica Spectrum Disorders and Negative AQP4-IgG Serology at Disease Onset: A Prospective Cohort Study. 2022, 18, 453 0
- 348 Recurrent diencephalic involvement as the sole manifestation of anti-aquaporin 4 antibody-positive disorder in an adult patient. 2022, 2, 100114
- 347 Paraneoplastic AQP-4 IgG negative neuromyelitis optica spectrum disorder (NMOSD) associated with large-cell high-grade undifferentiated carcinoma of unknown primary site: A case report and review of paraneoplastic NMOSD. 2022, 2, 100110
- 346 Correlation between Amerindian ancestry and neuromyelitis optica spectrum disorders (NMSOD) among patients in Midwestern Brazil. 2022, 80, 497-504
- 345 Autoantibodies in central nervous system and neuromuscular autoimmune disorders: A narrative review. 2022, 6, 105-116
- 344 A Case Presenting with Neuromyelitis Optica Spectrum Disorder and Infectious Polyradiculitis Following BNT162b2 Vaccination and COVID-19. 2022, 10, 1028 1
- 343 Sera of Neuromyelitis Optica Patients Increase BID-Mediated Apoptosis in Astrocytes. 2022, 23, 7117 1
- 342 Multiple autoimmune disorders in a patient with neuromyelitis optica spectrum disorder presenting with rhabdomyolysis. 2022, 15, e249102
- 341 Rituximab abrogates aquaporin-4-specific germinal center activity in patients with neuromyelitis optica spectrum disorders. 2022, 119, 1

- 340 Longitudinally extensive transverse myelitis preceding primary central nervous system lymphoma: Spinal sentinel neuroinflammation. 1-4
- 339 Brain structural and functional connectivity alterations are associated with fatigue in neuromyelitis optica spectrum disorder. **2022**, 22, 0
- 338 Update on Optic Neuritis in Adults. **2022**,
- 337 Investigating paraneoplastic aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorder through a data-driven approach. 0
- 336 Current status and prospects of IL-6 targeting therapy. 1-18 1
- 335 Update on Pediatric Optic Neuritis. **2022**,
- 334 Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAKuraSky and SAKuraStar. **2022**, 104025 2
- 333 Autoimmunity to ion channels in neurological diseases Autoimmunity to aquaporin water channels.
- 332 Area postrema syndrome: An initial presentation of double Seropositive AQP4 and MOG Antibody: A case report. 10.1212/CPJ.0000000000200065
- 331 Plasma Complement 3 and Complement 4 Are Promising Biomarkers for Distinguishing NMOSD From MOGAD and Are Associated With the Blood-Brain-Barrier Disruption in NMOSD. 13, 0
- 330 Contemporary management challenges in seropositive NMOSD. 1
- 329 P2R Inhibitors Prevent Antibody-Mediated Complement Activation in an Animal Model of Neuromyelitis Optica. 1
- 328 Time-varying connectivity of the precuneus and its association with cognition and depressive symptoms in neuromyelitis optica: A pilot MRI study. 135245852211071 0
- 327 Alterations in White Matter Fiber Tracts Characterized by Automated Fiber-Tract Quantification and Their Correlations With Cognitive Impairment in Neuromyelitis Optica Spectrum Disorder Patients. 16, 0
- 326 NMOSD Diagnostic Dilemmas Leading towards Final Diagnosis. **2022**, 12, 885 0
- 325 The impact of anti-monoclonal antibody drugs on healthcare economics in the treatment of multiple sclerosis and neuromyelitis optica spectrum disorders. 0
- 324 Saudi consensus recommendations on the management of Multiple Sclerosis: MS management in children and adolescents. **2022**, 104061
- 323 Neuromyelitis Optica Spectrum Disorders in Black African: Experience of Togo (2015-2020).

- 322 Neuritis ptica pedi6rica: un desafio diagn6stico. **2022**, 31, 182-186
- 321 Neuromyelitis Optica Spectrum Disorder: From Basic Research to Clinical Perspectives. **2022**, 23, 7908 1
- 320 Comparison on the effect of seven drugs to prevent relapses of neuromyelitis optica spectrum disorders: A modeling analysis of literature aggregate data. **2022**, 110, 109004 1
- 319 COVID-19 infection and vaccination against COVID-19: Impact on managing demyelinating CNS disorders in Southern India- experience from a demyelinating disease registry.. **2022**, 66, 104033
- 318 Case report: A patient with meningoencephalitis followed by asymptomatic anti-myelin oligodendrocyte glycoprotein antibody-related disorder. **2022**, 10, 100007
- 317 The description of neuromyelitis optica spectrum disorder: Patient registry in Yangtze River Delta area of China. **2022**, 66, 104023
- 316 Fulminant neuromyelitis optica spectrum disorder (NMOSD) following COVID-19 vaccination: A need for reconsideration?. **2022**, 66, 104035 1
- 315 Multiple sclerosis and neuromyelitis optica spectrum disorders. **2023**, 575-608
- 314 Update in autoimmune and paraneoplastic myelopathies: Newly described antigen targets and antibody testing. 13, 0
- 313 The prevalence, incidence, and clinical assessment of neuromyelitis optica spectrum disorder in patients with demyelinating diseases. **2022**,
- 312 A rare neuromyelitis optica mimic: Primary CNS histiocytic sarcoma. **2022**, 28, 1651-1654
- 311 Clinical, Radiological and Etiological Spectrum of Acute Transverse Myelitis Cases: A Single Center Experience and Review of the Literature. 306-312
- 310 Comparison of clinical and radiological characteristics in autoimmune GFAP astrocytopathy, MOGAD and AQP4-IgG+ NMOSD mimicking intracranial infection as the initial manifestation. **2022**, 66, 104057 0
- 309 II. Neuromyelitis Optica Spectrum Disorder. **2021**, 110, 1568-1574
- 308 Differential diagnosis of demyelinating diseases: what's new?. **2022**, 80, 137-142
- 307 Update on glial antibody-mediated optic neuritis. **2022**, 66, 405-412
- 306 The role of complement and complement therapeutics in neuromyelitis optica spectrum disorders. **2022**, 18, 933-945
- 305 Risk of Parkinson disease in multiple sclerosis and neuromyelitis optica spectrum disorder: a nationwide cohort study in South Korea. jnp-2022-329389 0

- 304 Telitacicept following plasma exchange in the treatment of subjects with recurrent neuromyelitis optica spectrum disorders: A single-center, single-arm, open-label study. ○
- 303 It is imperative to reconsider the concept of seronegative NMOSD. **2022**, 28, 1654-1655
- 302 Autoimmune glial fibrillary acidic protein astrocytopathy presented as isolated area postrema syndrome: a case report. **2022**, 22, ○
- 301 Association between infections, the microbiome, vaccination, and neuromyelitis optica spectrum disorder. 135245852211132
- 300 Comparative analysis of clinical and imaging data of first-attack neuromyelitis optica spectrum disorders with and without connective tissue disease. 13, ○
- 299 Risk of stroke in multiple sclerosis and neuromyelitis optic spectrum disorder: a Nationwide cohort study in South Korea. jnnp-2022-329628 ○
- 298 Makayla, a 16-Year-Old Girl with Fever and Blurry Vision. **2022**, 655-670
- 297 Serological biomarkers in autoimmune GFAP astrocytopathy. 13,
- 296 Seroprevalence of anti-myelin oligodendrocyte glycoprotein antibodies in adults with myelitis. ○
- 295 The risk factors of neuropathic pain in neuromyelitis optica spectrum disorder: a retrospective case-cohort study. **2022**, 22,
- 294 Onset of various CNS inflammatory demyelination diseases following COVID-19 vaccinations. **2022**, 104141 ○
- 293 Neuromyelitis Optica Spectrum Disorder. **2022**, 387, 631-639 1
- 292 Machine learning classification of multiple sclerosis in children using optical coherence tomography. 135245852211126 ○
- 291 Analysis of Pregnancy-Related Attacks in Neuromyelitis Optica Spectrum Disorder. **2022**, 5, e2225438 ○
- 290 Sex bias in multiple sclerosis and neuromyelitis optica spectrum disorders: How it influences clinical course, MRI parameters and prognosis. 13, 1
- 289 Acute disseminated encephalomyelitis in an elderly patient following pneumococcal vaccination with extremely high cerebrospinal fluid interleukin-6. ○
- 288 Editorial: Advances in neuromyelitis optica spectrum disorders. 13,
- 287 Pediatric Acquired Demyelinating Disorders. **2022**, 28, 1104-1130

- 286 Relapsing antibody-negative patients with features of neuromyelitis optica spectrum disorders: Differences in N-acetylaspartate level in the cervical spinal cord indicate distinct underlying processes. 135245852211153
- 285 Pathogenic autoantibodies in multiple sclerosis [From a simple idea to a complex concept. 1
- 284 Comparing evolvement of visual field defect in neuromyelitis optica spectrum disorder-optic neuritis and idiopathic optic neuritis: a prospective study. **2022**, 22,
- 283 Adult-Onset Genetic Central Nervous System Disorders Masquerading as Acquired Neuroinflammatory Disorders. 0
- 282 Myelin Oligodendrocyte Glycoprotein-Associated Disorders. **2022**, 28, 1171-1193
- 281 Serum glial fibrillary acidic protein correlates with retinal structural damage in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. **2022**, 104100 0
- 280 Neuro-ophthalmologische Präsentation der Retrobulbärneuritis im Rahmen der Myelin-Oligodendrozyten-Glykoprotein-Antikörper-assoziierten Erkrankung.
- 279 Myelin oligodendrocyte glycoprotein-associated disease is associated with BANK1, RNASET2 and TNIP1 polymorphisms. **2022**, 577937 0
- 278 Magnetic Resonance Imaging for Spine Emergencies. **2022**, 30, 383-407
- 277 The difference of the retinal structural and microvascular characteristics in patients with MOGAD-ON and AQP4-ON. **2022**, 22, 0
- 276 Neuromyelitis Optica Spectrum Disorders. **2022**, 28, 1131-1170 0
- 275 Case 25-2022: A 25-Year-Old Woman with Headache and Blurred Vision. **2022**, 387, 641-650
- 274 Clinical features of organizing pneumonia in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. **2022**, 60, 684-693
- 273 Central nervous system (CNS) inflammatory demyelinating diseases (IDDs) associated with COVID-19: A case series and review. **2022**, 371, 577939 1
- 272 Clinical use of CSF neopterin levels in CNS demyelinating diseases. **2022**, 441, 120385
- 271 MR imaging in children with transverse myelitis and acquired demyelinating syndromes. **2022**, 67, 104068
- 270 Altered functional connectivity associated with cognitive impairment in neuromyelitis optica spectrum disorder. **2022**, 68, 104113
- 269 Risk factors associated with permanent disability in neuromyelitis optica spectrum disorders. **2022**, 68, 104114 0

- 268 MRI pattern in acute optic neuritis: Comparing multiple sclerosis, NMO and MOGAD. 197140092211243 ○
- 267 Immunobiology of neuromyelitis optica spectrum disorders. **2022**, 76, 102618 ○
- 266 Lymphomas mimicking neuroinflammatory diseases [A diagnostic conundrum worth revisiting. **2022**, 372, 577970 ○
- 265 Use of retinal optical coherence tomography to differentiate suspected neuromyelitis optica spectrum disorder from multiple sclerosis: A cross-sectional study. **2022**, 68, 104160 ○
- 264 Relapses after SARS-CoV-2 vaccination in patients with neuromyelitis optica spectrum disorder and multiple sclerosis. **2022**, 68, 104167 2
- 263 The role of basal ganglia network in neural plasticity in neuromyelitis optica spectrum disorder with myelitis. **2022**, 68, 104170 ○
- 262 Multiple Sclerosis and related disorders. **2022**, 177-200 ○
- 261 What's new in neuromyelitis optica spectrum disorder treatment?. **2022**, 12, 249 ○
- 260 What's new in neuromyelitis optica spectrum disorder treatment?. **2022**, 0 ○
- 259 Differential diagnosis of multiple sclerosis in children. **2022**, 122, 60 ○
- 258 Safety and efficacy of therapeutic plasma exchange in neuromyelitis optica: A retrospective study from South India. **2022**, 0 ○
- 257 Serum levels of interleukin-6 and Vitamin D at the onset of multiple sclerosis and neuromyelitis optica: A pilot study. **2022**, 27, 67 ○
- 256 Neurosarcoidosis presenting as longitudinally extensive myelitis: Diagnostic assessment, differential diagnosis, and therapeutic approach. **2022**, 13, 191-197 ○
- 255 Educational Case: Neuromyelitis optica. **2022**, 9, 100041 ○
- 254 Cerebrospinal Fluid Biomarkers for Monitoring Delayed Neurologic Sequelae after Carbon Monoxide Poisoning. **2022**, 70, 1668 ○
- 253 Sex and gender differences in autoimmune demyelinating CNS disorders: Multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD) and myelin-oligodendrocyte-glycoprotein antibody associated disorder (MOGAD). **2022**, 129-178 ○
- 252 Immunotherapy-responsive recurrent extensive white matter disease without neuronal or glial surface antibodies: A case report. **2022**, 2, 100142 ○
- 251 NMOSD typical brain lesions after COVID-19 mRNA vaccination. **2022**, 269, 5213-5215 ○

- 250 New Treatment Perspectives for Acute Relapses in Neuromyelitis Optica Spectrum Disorder. **2022,** ○
- 249 Multiple sclerosis. **2022,** 81, 173-183 ○
- 248 Current Advancement of Immunomodulatory Drugs as Potential Pharmacotherapies for Autoimmunity Based Neurological Diseases. **2022,** 15, 1077 ○
- 247 Optical Coherence Tomography in Chronic Relapsing Inflammatory Optic Neuropathy, Neuromyelitis Optica and Multiple Sclerosis: A Comparative Study. **2022,** 12, 1140 ○
- 246 Application of the International Interocular Difference Thresholds into Practice: Localising the Patient Experience. 1-8 ○
- 245 Enlarged perivascular spaces, neuroinflammation and neurological dysfunction in NMOSD patients. 13, ○
- 244 Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder. ○
- 243 The Prevalence, Demographics, Clinical Features, Neuroimaging, and Interethnic Differences of MOG Disease in Malaysia with Global Perspectives. **2022,** 104168 ○
- 242 Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment. **2022,** ○
- 241 Association of cerebrospinal inflammatory profile with radiological features in newly diagnosed treatment-naïve patients with multiple sclerosis. 13, ○
- 240 Concentrations of B cell-activating factor, aquaporin-4 antibody and brain-derived neurotrophic factor in neuromyelitis optica spectrum disorder. **2022,** ○
- 239 Indications and safety of rituximab in pediatric neurology: a ten-year retrospective study.. **2022,** ○
- 238 A real-world study of interleukin-6 receptor blockade in patients with neuromyelitis optica spectrum disorder. ○
- 237 Identifying different cognitive phenotypes and their relationship with disability in neuromyelitis optica spectrum disorder. 13, ○
- 236 Different visual evoked potentials in neuromyelitis optica spectrum disorder-related optic neuritis and idiopathic demyelinating optic neuritis: a prospective longitudinal analysis. **2022,** 22, ○
- 235 Pain in neuromyelitis optic spectrum disorder. **2022,** 104192 ○
- 234 Gut Microbiota Dynamics in Relation to Long-COVID-19 Syndrome: Role of Probiotics to Combat Psychiatric Complications. **2022,** 12, 912 1
- 233 The causal relationship between neuromyelitis optica spectrum disorder and other autoimmune diseases. 13, ○

232	Neuromyelitis optica spectrum disorder in Western China impacts employment and increases financial burden in women. 13,	0
231	Area Postrema Syndrome in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy. 2022 , 9, e200029	0
230	L'interfaccia clinica-laboratorio nella diagnosi delle malattie neurologiche su base autoimmune: focus sulla pandemia da COVID-19.	0
229	Disability outcomes in NMOSD and MOGAD patients: data from a nationwide registry in Argentina.	0
228	Diagnosis and classification of optic neuritis. 2022 ,	3
227	COVID-19 and the risk of CNS demyelinating diseases: A systematic review. 13,	0
226	The patient journey with NMOSD: From initial diagnosis to chronic condition. 13,	0
225	MOG and AQP4 Antibodies among Children with Multiple Sclerosis and Controls.	0
224	Factors correlated with neuropathic pain in patients with neuromyelitis optica spectrum disorder. 2022 , 104213	0
223	Rare variants and HLA haplotypes associated in patients with neuromyelitis optica spectrum disorders. 13,	0
222	Neuromyelitis optica spectrum disease coexisting with subacute combined degeneration: a case report. 2022 , 22,	0
221	Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging. 10.1212/WNL.0000000000201465	1
220	Sensitivity and specificity of visual evoked potentials for early diagnosis of demyelinating diseases. 2022 , 2, 193-198	0
219	Aquaporin 4-positive neuromyelitis optica spectrum disorder with meningoencephalitis-like onset: A case report. 13,	0
218	Dorsal medulla surface texture: Differentiating neuromyelitis optica spectrum disorder from multiple sclerosis.	0
217	Asymptomatic MRI lesions in pediatric-onset AQP4-IgG positive NMOSD. 2022 , 104215	0
216	AQP4-IgG-positive neuromyelitis optica spectrum disorder and temporally detected neoplasms: case report and systematic review. 2022 , 104212	0
215	Impaired response of blood neutrophils to cell-death stimulus differentiates AQP4-IgG-seropositive NMOSD from MOGAD. 2022 , 19,	0

214	Identification of specific causes of myelopathy in a large cohort of patients initially diagnosed with transverse myelitis. 2022 , 442, 120425	1
213	Incidence and Prevalence of Neuromyelitis Optica Spectrum Disorders in the Background of International Consensus Diagnostic Criteria A Systematic Review. 2022 , 70, 1771	0
212	Neurologic autoimmune diseases. 2022 , 887-975	0
211	An Analysis of Clinico-radiological Features and Outcome in Patients with Longitudinally Extensive Transverse Myelitis. 2022 , 70, 1925	0
210	Pediatric Neuromyelitis Optica is clinically distinct from ADEM: Case report of a 9year old girl. 2022 , 2, 100144	0
209	Peripapillary hyper-reflective ovoid mass-like structures (PHOMS) in AQP4-IgG-positive neuromyelitis optica spectrum disease (NMOSD) and MOG-IgG-associated disease (MOGAD).	0
208	Effects of pregnancy on neuromyelitis optica spectrum disorder and predictors of related attacks.	0
207	Structurefunction correlates of vision loss in neuromyelitis optica spectrum disorders. 2022 , 12,	0
206	Neuroimaging features in inflammatory myelopathies: A review. 13,	0
205	Microglial/macrophage activation in the cerebrospinal fluid of neuromyelitis optica spectrum disorders.	0
204	A novel aquaporin-4-associated optic neuritis rat model with severe pathological and functional manifestations. 2022 , 19,	0
203	Persistent MRI-negative lupus myelitis-disease presentation, immunological profile and outcome. 13,	0
202	Multiple Sclerosis Followed by Neuromyelitis Optica Spectrum Disorder. 2023 , 10, e200037	0
201	Current view on the diagnosis and treatment of neuromyelitis optica spectrum disorders exacerbations. 2022 , 14, 69-76	1
200	Primary angiitis of the central nervous system as a mimic of multiple sclerosis: A case report. 2022 , 577991	0
199	Serum Vitamin D Levels and Status in Thai Optic Neuritis Subjects: A Case-Control Study. Volume 16, 3381-3389	0
198	The utility of diffusion-weighted imaging in patients with spinal cord infarction: difference from the findings of neuromyelitis optica spectrum disorder. 2022 , 22,	0
197	Clinical Reasoning: A 6-Year-Old Girl With Right-Sided Pain and Weakness. 10.1212/WNL.000000000201481	0

- 196 Astrocytoma with myelin oligodendrocyte glycoprotein antibody associated encephalomyelitis: A case report. **2022**, 101, e31003 ○
- 195 A case report on recurrent area postrema syndrome in AQP4-IgG-positive NMOSD. **2022**, 2022, ○
- 194 Pathogenic and clinical implications of serum protein biomarkers in idiopathic transverse myelitis. ○
- 193 Brain age gap in neuromyelitis optica spectrum disorders and multiple sclerosis. jnnp-2022-329680 ○
- 192 Letter to the Editor: Is it time to expand the clinical spectrum of transient global amnesia?. **2022**, 442, 120449 ○
- 191 Predictors of overlapping autoimmune disease in Neuromyelitis Optica Spectrum disorder (NMOSD): A retrospective analysis in two inner-city hospitals.. **2022**, 443, 120460 ○
- 190 Aquaporin-4 IgG neuromyelitis optica spectrum disorder onset after Covid-19 vaccination: Systematic review. **2022**, 373, 577994 ○
- 189 MOG antibody prevalence in adult optic neuritis and clinical predictive factors for diagnosis: A Chinese cohort study. **2022**, 68, 104248 ○
- 188 Neuromyelitisoptica Spectrum Disease with Brown-Sqard Syndrome as the Initial Presentation: A Case Report and Literature Review. **2022**, 12, 10052-10058 ○
- 187 Demyelinating syndromes and movement disorders. **2023**, 567-584 ○
- 186 Impact of dysautonomic symptom burden on the quality of life in Neuromyelitis optica spectrum disorder patients. ○
- 185 Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review. ○
- 184 Retina thickness in clinically affected and unaffected eyes in patients with aquaporin-4 immunoglobulin G antibody seropositive neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. ○
- 183 Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD. 13, 1 ○
- 182 Transitioning immunotherapy in neuromyelitis optica spectrum disorder ¶when and how to switch. 1-12 ○
- 181 Immune-mediated diseases involving central and peripheral nervous systems. ○
- 180 Increased peripheral inflammatory responses in myelin oligodendrocyte glycoprotein associated disease and aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. 13, ○
- 179 Effects of long-term magnesium L-threonate supplementation on neuroinflammation and bloodBrain barrier integrity in mice with neuromyelitis optica spectrum disorder. ○

- 178 Nontraumatic Spinal Cord Injury: Epidemiology, Etiology and Management. **2022**, 12, 1872 ○
- 177 Granzyme B in circulating CD8+ T cells as a biomarker of immunotherapy effectiveness and disability in neuromyelitis optica spectrum disorders. 13, ○
- 176 Autoimmune Myelitis and Myocarditis in a Patient With Anti-Aquaporin-4, Antinuclear, and Antiphospholipid Autoantibodies: The Neuromyelitis Optica-Systemic Lupus Erythematosus (NMO-SLE) Overlap Syndrome. **2022**, ○
- 175 Pregnancy and neuromyelitis optica spectrum disorders: 2022 recommendations from the French Multiple Sclerosis Society. 135245852211309 ○
- 174 Health-related quality of life in Japanese patients with multiple sclerosis. ○
- 173 What is the potential of paramagnetic rim lesions as diagnostic indicators in multiple sclerosis?. 1-9 ○
- 172 Neuromyelitis Optica: Clinical Course and Potential Prognostic Indicators. **2022**, 104414 ○
- 171 Clinical characteristics and prognosis of pediatric myelin oligodendrocyte glycoprotein antibody-associated diseases in China. **2022**, 22, ○
- 170 A Quality Assessment of Aquaporin-4 & Myelin Oligodendrocyte Glycoprotein Antibody Testing. 1-27 ○
- 169 Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: Onset Following Acute COVID-19 Infection, a Case Series. ○
- 168 Non-immune system comorbidity in neuromyelitis optica spectrum disorders. **2023**, 107, 16-22 ○
- 167 Identification of double-stranded DNA in the cerebrospinal fluid of patients with acute neuromyelitis optica spectrum disorder. **2023**, 107, 129-132 ○
- 166 General anesthesia, using remimazolam, for the patient with myelin oligodendrocyte glycoprotein antibody associated disease (MOGAD): A case report. **2022**, 101, e31734 ○
- 165 Ependyma: a new target for autoantibodies in neuromyelitis optica?. **2022**, 4, ○
- 164 Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD. **2023**, 10, e200065 ○
- 163 Prevalence, incidence and clinical features of neuromyelitis optica spectrum disorders in northern Japan. jnnp-2022-330274 ○
- 162 Diagnostik der Neuromyelitis-optica-Spektrum-Erkrankung (NMOSD) und der MOG-Antikörper-assoziierten Erkrankung (MOGAD). **2022**, 239, 1315-1324 ○
- 161 An update on biologic treatments for neuromyelitis optica spectrum disorder. **2023**, 19, 111-121 ○

- 160 Separation Imaging for Diagnosis of Multiple Sclerosis versus Neuromyelitis Optica Spectrum Disorder. ○
- 159 Demyelinating diseases of the central nervous system registry for patients with traditional Chinese medicine: Rationale and design of a prospective, multicenter, observational study. 13, ○
- 158 More Efficient Complement Activation by AntiAquaporin-4 Compared With AntiMyelin Oligodendrocyte Glycoprotein Antibodies. **2023**, 10, e200059 ○
- 157 Optic neuromyelitis in relation with juvenile idiopathic arthritis: A case report. **2022**, ○
- 156 Serial analyses of clinical spectra and outcomes in Chinese women with pregnancy-induced optic neuritis. 9, ○
- 155 Acute Inflammatory Diseases of the Central Nervous System After SARS-CoV-2 Vaccination. **2023**, 10, e200063 1
- 154 Challenging Myelopathy Cases. ○
- 153 Neuromielite ottica acuta (malattia di Devic). **2022**, 22, 1-11 ○
- 152 A case report of neuromyelitis optica spectrum disorder induced by pembrolizumab treatment for lung adenocarcinoma: a clinical and immunohistochemical study. **2022**, 22, ○
- 151 Relevance of bright spotty lesions in neuromyelitis optica spectrum disorders (NMOSD): a case series. **2022**, 58, ○
- 150 Barriers to access and unmet needs to neuromyelitis optica spectrum disorders care in an Argentinean cohort. **2022**, 104485 ○
- 149 Frequency of NMOSD misdiagnosis in a cohort from Latin America: Impact and evaluation of different contributors. 135245852211362 ○
- 148 Treatment of neuromyelitis optica spectrum disorder: revisiting the complement system and other aspects of pathogenesis. ○
- 147 The different damage patterns of short-, middle- and long-range connections between patients with relapse-remitting multiple sclerosis and neuromyelitis optica spectrum disorder. 13, ○
- 146 The pathogenesis and treatment of posterior reversible encephalopathy syndrome after neuromyelitis optica spectrum disorder: a case report and literature review. **2022**, 22, ○
- 145 Estimated Prevalence of AQP4 positive Neuromyelitis Optica Spectrum Disorder and MOG Antibody Associated Disease in S̃ Paulo, Brazil. **2022**, 104488 ○
- 144 Pregnancy and antibody-mediated CNS disorders: What do we know and what should we know?. 13, ○
- 143 Efficacy and safety of mycophenolate mofetil for steroid reduction in neuromyelitis optica spectrum disorder: a prospective cohort study. ○

- 142 Therapeutic Response in Pediatric Neuromyelitis Optica Spectrum Disorder. 10.1212/WNL.00000000002016250
- 141 Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective study. *jnnp-2022-330237* ○
- 140 CNS inflammatory demyelinating events after COVID-19 vaccines: A case series and systematic review. 13, ○
- 139 Aligning payer and provider strategies with the latest evidence to optimize clinical outcomes for patients with neuromyelitis optica spectrum disorder. **2022**, 28, S3-S27 ○
- 138 Clinical Neuroimaging in Pediatric Dysimmune Disorders of the Central Nervous System. **2022**, ○
- 137 Prognosis of Neuromyelitis Optica Spectrum Disorders: Differences Between Han Chinese and Tibetans, a retrospective cohort study. ○
- 136 Long-term Efficacy of Satralizumab in AQP4-IgG β eropositive Neuromyelitis Optica Spectrum Disorder From SAKuraSky and SAKuraStar. **2023**, 10, e200071 ○
- 135 A novel association of osmotic demyelination in Sjögren's syndrome prompts revisiting role of aquaporins in CNS demyelinating diseases: A literature review. **2022**, 104466 ○
- 134 Age of onset correlates with clinical characteristics and prognostic outcomes in neuromyelitis optica spectrum disorder. 13, ○
- 133 Consensus opinion on the management of patients with neuromyelitis optica spectrum diseases: issues of terminology and therapy. **2022**, 14, 139-148 1
- 132 Enlarged choroid plexus related to cortical atrophy in multiple sclerosis. ○
- 131 Clinical and epidemiological correlates of treatment change in patients with NMOSD: insights from the CIRCLES cohort. ○
- 130 Obesity is associated with myelin oligodendrocyte glycoprotein antibody-associated disease in acute optic neuritis. **2022**, 12, ○
- 129 AQP4 as a vintage autoantigen: what do we know till now?. **2022**, 8, e12132 ○
- 128 Neuromyelitis optica spectrum disorders associated with AQP4-positive-cancer: A case series. 13, ○
- 127 Aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder with cholangiocarcinoma: Casual or causal association?. ○
- 126 Neuromyelitis optica spectrum disorders with and without associated autoimmune diseases. ○
- 125 Safety and efficacy of plasma exchange treatment in children with AQP4-IgG positive neuromyelitis optica spectrum disorder. 13, ○

- 124 The Characteristics of Cognitive Proficiency in Patients with Acute Neuromyelitis Optica Spectrum Disease and its Correlation with Serum Aquaporin-4 Antibody Titer. **2023**, 13, 90 ○
- 123 Long Term Misdiagnosis of Neuromyelitis Optica Spectrum Disorder Patients with Multiple Sclerosis. ○
- 122 The pathogenic role of lupus-specific autoantibodies and Interleukin-6 on demyelination of the brainstem and spinal cord in systemic lupus erythematosus. 096120332311516 ○
- 121 Clinical characteristics of late-onset neuromyelitis optica spectrum disorder. **2023**, 104517 ○
- 120 Therapeutic strategies in NMOSD and MOGAD patients: A multicenter cohort study in Latin America. **2023**, 104508 ○
- 119 T follicular helper cells contribute to pathophysiology in a model of neuromyelitis optica spectrum disorders. ○
- 118 Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results. **2023**, 8, ○
- 117 Paroxysmal painful tonic spasms in neuromyelitis optica spectrum disorder. **2023**, 100443 ○
- 116 B-cell proliferation characteristics and monitoring significance under the modified reduced-dose rituximab regimen for NMOSD: A real-world case series study. **2023**, 104524 ○
- 115 Transient organising pneumonia at the onset of AQP4-antibody neuromyelitis optica spectrum disorder: A case series and literature review. **2023**, 3, 100163 ○
- 114 Secreted aminoacyl-tRNA synthetase-interacting multifunctional protein-1 (AIMP1) is a promising predictor for the severity of acute AQP4-IgG positive neuromyelitis optica spectrum disorder. **2023**, 70, 104504 ○
- 113 Assessment of intelligence quotient in patients with neuromyelitis optica spectrum disease and multiple sclerosis. **2023**, 70, 104492 ○
- 112 Factors associated with the misdiagnosis of neuromyelitis optica spectrum disorder. **2023**, 70, 104498 ○
- 111 The epidemiology and burden of neuromyelitis optica spectrum disorder, multiple sclerosis, and MOG antibody-associated disease in a province in Thailand: A population-based study. **2023**, 70, 104511 ○
- 110 Utility of the tibial nerve somatosensory evoked potentials in differentiating between neuromyelitis optica spectrum disorders and multiple sclerosis. **2023**, 70, 104503 ○
- 109 AQP4 mitigates chronic neuropathic pain-induced cognitive impairment in mice. **2023**, 440, 114282 ○
- 108 Neuromyelitis optica spectrum disorders with an inverted V sign on spinal cord magnetic resonance imaging: antiaquaporin-4 antibody and functional vitamin B12 deficiency. **2022**, 19, 130-133 ○
- 107 Optic neuromyelitis after vaccination against SARS-CoV-2. **2022**, 15, e252309 ○

- 106 Ultrasound-guided pulsed radiofrequency for neuromyelitis optica spectrum disorder-associated neuropathic pain: A case report. **2022**, 101, e32417 ○
- 105 Optic neuritis: current challenges in diagnosis and management. **2023**, 36, 10-18 ○
- 104 Clinical analysis of neuromyelitis optica spectrum disease with area postrema syndrome as the initial symptom. **2022**, 27, ○
- 103 Predictors for Acute Respiratory Failure in AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorders Patients with Medullary Lesions. ○
- 102 Systemic lupus erythematosus with acute ischemic optic neuropathy complicated with neuromyelitis optica: a case report. **2023**, 17, ○
- 101 Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder. 10.1212/WNL.000000000206820 ○
- 100 Rituximab for Pediatric Central Nervous System Inflammatory Disorders in Alberta, Canada. 1-20 ○
- 99 Immunoabsorption as maintenance therapy for refractory neuromyelitis optica spectrum disorder. **2023**, 16, 175628642211503 ○
- 98 Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Diseases. **2023**, 10, e200082 ○
- 97 Neuromyelitis Optica Spectrum Disorder: Case Description and Information for Speech-Language Pathologists. 152574012211458 ○
- 96 Analysis of LAP+ and GARP+ Treg subsets in peripheral blood of patients with neuromyelitis optica spectrum disorders. ○
- 95 Retinal structural and microvascular changes in myelin oligodendrocyte glycoprotein antibody disease and neuromyelitis optica spectrum disorder: An OCT/OCTA study. 14, ○
- 94 Challenging Cases in Neuroimmunology. **2022**, 42, 695-707 ○
- 93 Correlation between cerebral cortex changes and clinical features in patients with neuromyelitis optica spectrum disorder with normal-appearing brain tissue: a case-control study. **2023**, 0 ○
- 92 Elevated serum levels of bone morphogenetic protein-9 are associated with better outcome in AQP4-IgG seropositive NMOSD. **2023**, 13, ○
- 91 Cognition in patients with neuromyelitis optica spectrum disorders: A prospective multicentre study of 217 patients (CogniNMO-Study). 135245852311512 ○
- 90 Clinical features and frequency of area postrema syndrome in neuromyelitis optica spectrum disorder: A single-center study in Mexico. **2023**, 9, 100068 ○
- 89 Clinical outcomes and prognostic factors in patients with optic neuritis related to NMOSD and MOGAD in distinct ethnic groups from Latin America. **2023**, 72, 104611 ○

- 88 Tumor or not a tumor: Pitfalls and differential diagnosis in neuro-oncology. **2023**, ○
- 87 Area postrema syndrome: Intractable hiccups and vomiting as a result of neuromyelitis Optica Spectrum disorder. **2023**, 14, 205427042311596 ○
- 86 Familial neuromyelitis optica spectrum disorders: Case series and systematic review. **2023**, 73, 104627 ○
- 85 Investigation on marital status of patients with neuromyelitis optica spectrum disorders in China. **2023**, 74, 104620 ○
- 84 Clinical and radiological profile of neuromyelitis optica spectrum disorders in a Pakistani cohort. **2023**, 74, 104656 ○
- 83 The prevalence and incidence of multiple sclerosis over the past 20 years in northern Japan. **2023**, 73, 104696 ○
- 82 Microorganisms in Pathogenesis and Management of Neuromyelitis Optica Spectrum Disorder. **2022**, 195-210 ○
- 81 Circumpapillary Retinal Nerve Fiber Layer, Optic Nerve Head, and Related Structural Abnormalities. **2022**, 241-304 ○
- 80 The case report of AQP4 and MOG IgG double positive NMOSD treated with subcutaneous Ofatumumab. **2023**, 376, 578035 ○
- 79 Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. **2023**, 22, 268-282 1
- 78 Decipher potential biomarkers of diagnosis and disease activity for NMOSD with AQP4 using LC-MS/MS and Simoa. **2023**, 116, 109761 ○
- 77 Paracentral Acute Middle Maculopathy Associated with Severe Anti-Mog (Myelin Oligodendrocyte Glycoprotein)-Positive Optic Neuritis. 1-8 ○
- 76 ACT001 Relieves NMOSD Symptoms by Reducing Astrocyte Damage with an Autoimmune Antibody. **2023**, 28, 1412 ○
- 75 Relapsing neuromyelitis optica spectrum disorder due to noncompliance to oral corticosteroid therapy. **2022**, 3, e0264 ○
- 74 Worldwide prevalence of neuromyelitis optica spectrum disorder (NMOSD) and neuromyelitis optica (NMO): a systematic review and meta-analysis. ○
- 73 Anti-AQP4IgG-positive Leigh syndrome: A case report and review of the literature. 11, ○
- 72 Humoral COVID-19 vaccine response in patients with NMOSD/MOGAD during anti-IL-6 receptor therapy compared to other immunotherapies. 135245852211511 ○
- 71 The Importance of Optical Coherence Tomography in the Diagnosis of Atypical or Subclinical Optic Neuritis: A Case Series Study. **2023**, 12, 1309 ○

- 70 The Neuroprotective Mechanism of IGF-2 in Neuromyelitis optica spectrum disorder. ○
- 69 Clinical and imagenologic significance of the neutrophil-to-lymphocyte ratio in neuromyelitis optica spectrum disorder: A systematic review with meta-analysis. **2023**, 18, e0281064 ○
- 68 Non-infectious meningitis and CNS demyelinating diseases: A conceptual review. **2023**, ○
- 67 Evaluation of the safety profile of COVID-19 vaccines in patients with MS, NMOSD, and MOGAD. ○
- 66 Unilateral Autoimmune Encephalitis: A Case Report on a Rare Manifestation of Myelin Oligodendrocyte Glycoprotein Antibody Disease. **2023**, ○
- 65 Imaging of Central Nervous System Demyelinating Disorders. **2023**, 29, 292-323 ○
- 64 CNS demyelinating events in primary Sjögren's syndrome: A single-center case series on the clinical phenotype. 14, ○
- 63 SAKuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab. 14, ○
- 62 Co-occurrence of Multiple Sclerosis and Severe Aplastic Anemia: A Report of Two Cases Successfully Treated with Allogeneic Hematopoietic Stem Cell Transplantation. ○
- 61 Comments on the article "Consensus opinion on the management of patients with neuromyelitis optica spectrum diseases: issues of terminology and therapy"**2023**, 15, 119-122 ○
- 60 A national case-control study investigating demographic and environmental factors associated with NMOSD. 135245852311519 ○
- 59 Diagnostic value of intereye difference metrics for optic neuritis in aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorders. jnnp-2022-330608 ○
- 58 Visual Outcomes Following Plasma Exchange for Optic Neuritis: An International Multicenter Retrospective Analysis of 395 Optic Neuritis Attacks. **2023**, ○
- 57 Comparison of clinico-radiological profile, optical coherence tomography parameters, and outcome in MOGAD and Neuromyelitis optica spectrum disorder subtypes: A prospective observational study. 1-13 ○
- 56 The Acute Optic Neuritis Network (ACON): Study protocol of a non-interventional prospective multicenter study on diagnosis and treatment of acute optic neuritis. 14, ○
- 55 Recent changes in the frequency of use of apheresis and biological drugs in the treatment of neuromyelitis optica spectrum disorders. ○
- 54 Characterization of Disease Severity and Stability in NMOSD: A Global Clinical Record Review with Patient Interviews. **2023**, 12, 635-650 ○
- 53 Aquaporin-4 Antibody Dynamics and Relapse Risk in Seropositive Neuromyelitis Optica Spectrum Disorder Treated with Immunosuppressants. ○

- 52 Orphan Drugs in Neurology Narrative Review. **2023**, 13, 420 ○
- 51 A 10-Year Single-Center Study of the Clinical Characteristics of Optic Neuritis-Related NMOSD, MS, and Double Seronegative Optic Neuritis, Together with Factors Predicting Visual Outcomes. **2023**, 7, 16 ○
- 50 Risk of fracture in neuromyelitis optica spectrum disorder and multiple sclerosis: a nationwide cohort study in South Korea. **2023**, 34, 925-933 ○
- 49 Complement biomarkers reflect the pathological status of neuromyelitis optica spectrum disorders. 14, ○
- 48 Ravulizumab in Aquaporin-4 Positive Neuromyelitis Optica Spectrum Disorder. ○
- 47 Neuromyelitis optica spectrum disorder and enterovirus-71 infection: A perplexing neurological constellations. **2023**, 3, 100168 ○
- 46 Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis. ○
- 45 B cell targeted therapies in inflammatory autoimmune disease of the central nervous system. 14, ○
- 44 Epidemiological and clinical characteristics of myelin oligodendrocyte glycoprotein antibody-associated disease in a nationwide survey. 135245852311567 ○
- 43 The neuro-ophthalmological manifestations of NMOSD and MOGAD comprehensive review. ○
- 42 Cases of aquaporin-4-positive neuromyelitis optica spectrum disorder with successful tapering of prednisolone to less than 3 mg/day after satralizumab administration. ○
- 41 Area postrema syndrome: An unusual presentation of neuromyelitis optica spectrum disorder. 1-2 ○
- 40 Impact of dysautonomic symptom burden on the quality of life in Neuromyelitis optica spectrum disorder patients. **2023**, 23, ○
- 39 Neuromyelitis optica spectrum disorders: a review with a focus on children and adolescents. **2023**, 81, 201-211 ○
- 38 Therapeutic efficacy and safety of plasmapheresis in elderly patients with neuromyelitis optica spectrum disorder: a single-center observational study. **2023**, 16, 175628642311624 ○
- 37 Comparison of OX40 expression in patients with multiple sclerosis and neuromyelitis optica as an approach to diagnosis. **2023**, 19, ○
- 36 Disease characteristics of idiopathic transverse myelitis with serum neuronal and astroglial damage biomarkers. **2023**, 13, ○
- 35 Factors influencing the cerebrospinal fluid antibodies to aquaporin-4: a study of 87 patients with neuromyelitis optica spectrum disorder. ○

- 34 Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder. ○
- 33 Comparison of IVIg and TPE efficacy in the treatment of neurological disorders: a systematic literature review. **2023**, 16, 175628642311543 ○
- 32 Attack phenotypes and disease course in pediatric MOGAD. ○
- 31 Guía de práctica clínica: tratamiento agudo de las enfermedades inflamatorio-desmielinizantes del sistema nervioso central: esclerosis múltiple, espectro de la neuromielitis óptica, encefalomiелitis diseminada aguda, enfermedades asociadas a anticuerpos antiglicoproteína de la membrana del oligodendrocito, miелitis aguda y neuritis óptica. Elaborada por el Grupo de Trabajo de Esclerosis Múltiple Desmielinizantes, Sociedad Neurológica Argentina. **2023**, ○
- 30 Artificial intelligence in healthcare: a mastery. 1-50 ○
- 29 Serum proteins for monitoring and predicting visual function in patients with recent optic neuritis. **2023**, 13, ○
- 28 Guidelines on the Use of Therapeutic Apheresis in Clinical Practice [Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. **2023**, 38, 77-278 ○
- 27 Therapeutic response to rituximab in seropositive neuromyelitis optica: Experience from a tertiary care center in South India. 1-6 ○
- 26 Patient Pathway to Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): Findings from a Multinational Survey of 204 Patients. ○
- 25 Immunologic Ocular Disease. **2023**, 943-958 ○
- 24 Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) [revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. ○
- 23 Predictive role of blood-based indicators in neuromyelitis optica spectrum disorders. 17, ○
- 22 Current perspectives on the diagnosis and management of acute transverse myelitis. **2023**, 23, 389-411 ○
- 21 C5a complement levels in clinical remission AQP4-IgG-positive NMO patients. ○
- 20 Microfibrillar-associated Protein 4 as Potential Marker of Acute Relapse in Inflammatory Demyelinating Diseases of the Central Nervous System: Pathological and Clinical Aspects. ○
- 19 High-efficacy therapies reduce clinical and radiological events more effectively than traditional treatments in neuromyelitis optica spectrum disorder. ○
- 18 Autoimmune encephalitis. **2023**, 445-467 ○
- 17 Myelin Oligodendrocyte Glycoprotein as an Autoantigen in Inflammatory Demyelinating Diseases of the Central Nervous System. **2023**, 88, 551-563 ○

- 16 Case Report: Severe rebound after withdrawal of fingolimod in a patient with neuromyelitis optica spectrum disorder. 14,
- 15 Effectiveness of rituximab versus oral immunosuppressive therapies in neuromyelitis optica spectrum disorder in a racially diverse cohort of subjects: A single-center retrospective study. **2023**, 74, 104718
- 14 Neuromyelitis Optica Spectrum Disorders: Clinical Perspectives, Molecular Mechanisms, and Treatments. **2023**, 13, 5029
- 13 Sleep in multiple sclerosis and neuromyelitis optica spectrum disorder—the SEMN study.
- 12 Granulocyte activation markers in cerebrospinal fluid differentiate acute neuromyelitis spectrum disorder from multiple sclerosis. jnnp-2022-330796
- 11 Central Nervous System Neuroimmunologic Complications of COVID-19.
- 10 Symptomatic trigeminal autonomic cephalalgias in neuromyelitis optica spectrum disorders. **2023**, 104722
- 9 Can volumetric analysis of the brain help diagnose isolated optic neuritis?.
- 8 White blood cell count profiles in anti-aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder and anti-myelin oligodendrocyte glycoprotein antibody-associated disease. **2023**, 13,
- 7 Clinical analysis of 173 pediatric patients with antibody-mediated autoimmune diseases of the central nervous system: a single-center cohort study. 14,
- 6 Macular vascular density alteration patterns in Pediatric optic neuritis patients with serum MOG antibody positivity detected by optic coherence tomography angiography.
- 5 It's not multiple sclerosis, what is it?!. pn-2022-003677
- 4 Pediatric Neuromyelitis Optica Spectrum Disorder. **2023**, 101051
- 3 New advancements in the management of Neuromyelitis Optica spectrum disease: literature review. 3,
- 2 Chronisch entzündliche ZNS-Erkrankungen. **2023**, 125-136
- 1 Central nervous system demyelinating diseases: glial cells at the hub of pathology. 14,